The Rationale, Design and Implementation of the African Cardiomyopathy and Myocarditis Registry by Kraus, Sarah
The Rationale, Design and 
Implementation of the African 
Cardiomyopathy and Myocarditis 
Registry 
 
Dr Sarah Kraus 
KRSSAR001 
 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
 
Doctor of Philosophy  
 
Department of Medicine 
Faculty of Health Sciences 










Date of Submission: 11 February 2019 
Supervisors: Professor Ntobeko Ntusi, Professor Bongani Mayosi, 



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 













I dedicate this work to my mentor and supervisor, the late Professor Bongani Mayosi (28th 
January 1967 – 27th July 2018).  
 
My mentorship journey with Professor Bongani Mayosi started 8 years ago at the bedside, as 
a second-year resident in internal medicine.  The patient I had presented to him had familial 
dilated cardiomyopathy. Professor Mayosi shared his passion for inherited cardiac conditions 
with me that day at the bedside and planted a seed that he nurtured over time, until it grew 
and became firmly rooted in me.  To many, Professor Mayosi was a beacon of hope, the gold 
standard to which to aspire to. He was a man who not only believed in transformation, but 
worked tirelessly to achieve it.  I am proof that his idea of transformation extended beyond 
political and social definitions – he believed in the transformation of individuals. He saw 
potential in me and willingly provided me with the platform on which to explore it.  In the book 
Outliers, the story of success, the author, Malcolm Gladwell, makes the argument that success 
is largely determined by a combination of unique opportunity and hard work. The discipline of 
hard work was instilled in me by my own father, but the privilege of rare opportunity was 
provided to me by this formidable man. One of the most fundamental lessons he taught me 
was that it takes a team to accomplish something of value in medical research. He entrusted 
me with this project and his team, and gave me the freedom and responsibility to build it in my 
own way.  It was an extraordinary challenge, with tremendous expectation, but it taught me 
the true extent of what I am capable of. He once told my co-supervisor that I challenged him 
– I can think of no greater compliment. He encouraged me to be self-sufficient and convinced 
both his mentor and his mentees to guide me when he was unable. He encouraged me to 
debate, to express my opinion, to disagree. I am deeply grateful for the experience of knowing 
him, for the confidence he bestowed and the time he gave me.  The imprint of his influence is 
something that I will carry with me for the rest of my life. Professor Mayosi taught me how to 
step into the arena and dare greatly. 
 ACKNOWLEDGEMENTS 
 
I would like to extend my deepest thanks to my academic supervisors, Professors Bongani 
Mayosi and Ntobeko Ntusi.  I am immensely grateful to Professor Mayosi for inspiring me to 
pursue a career in cardio genetics and cardiomyopathy, and for entrusting me with this project.  
I am grateful for the training opportunities provided that have equipped me for the job at hand, 
and the support given to me over the years by both Professors Mayosi and Ntusi, not only in 
this work but in the formation of my academic research career. I would like to acknowledge 
and thank Professor Ntusi for providing additional support and unwavering commitment to the 
completion of this work, in the wake of Professor Mayosi’s passing.      
 
I am very grateful to the Helen and Morris Mauerberger Foundation for the scholarship funding 
that I received during this time. Without their financial support, I would not have been able to 
dedicate myself to this project. I would also like to acknowledge the Newton Fund (MRC-SA 
and GSK) for supporting the IMHOTEP study since October 2016.    
 
I would like to acknowledge the efforts of my team, without them none of this work would have 
been possible; Unita September (research sister), Veronica Francis (project manager), Marnie 
van de Wall (echocardiographer), Nakita Laing (genetics counsellor), Amber Ross (genetics 
counsellor), Tessa Suttle (medical student), Emily Chedwin (medical student), Sinoxolo 
Bhuvula (research assistant), Shahiemah Pandie (data quality officer) and Lwazi Mhlanti (data 
manager).  I would like to specifically acknowledge the care and support provided to me by 
Veronica and Unita throughout this journey. I would also like to extend heartfelt thanks to 
genetics counsellor, Nakita Laing, for sharing her skill, enthusiasm, insight and experience 
with me over the years. I would like to acknowledge the collaborative efforts made in support 
of this work by Associate Professor Gasnat Shaboodien and the molecular laboratory team – 
Dr. Maryam Fish, Dr. Mzwandile Mbele, Ms Tafadzwa Machipisa, Mr Stephen Kamuli, Mr 
Timothy Spracklen, Dr Babu Muhamed, and Ms Lameez Pearce.  I appreciate the clinical 
support extended to me by Dr Shaheen Pandie, Associate Professor Ashley Chin, Professor 
Mipko Ntsekhe, Professor Karen Sliwa, Professor Ambroise Wonkam, Professor Helen 
Wainwright and Dr Sulaiman Moosa. I would like to extend my thanks to the radiographers at 
CUBIC and GSH, in particular Mrs Petronella Samuels, and bioengineer, Mr Stephen Jeremy, 
for their efforts.       
 
I am deeply grateful to the patients and families that I have worked with. I celebrate their 
courage in the face of adversity and thank them for allowing me the privilege of walking along-
side them through some of the most challenging moments in their lives. 
 
Most importantly, I would like to thank my parents, Elisabeth and Rodion Kraus, for their 
unconditional love and support in every endeavour I have pursued, and for teaching me the 
value of hard work and the importance of having passion for the work that I have chosen to 
do.  Thank you for the example you have set in leadership, humility, kindness, empathy and 
compassion. A special thanks to my mother for the time she spent reading my drafts. To my 
siblings and close friends: I salute your patience and resolve in supporting me through this 
process.    
DECLARATION 
I, Sarah Kraus, hereby declare that the work on which this dissertation/thesis is based is my 
original work (except where acknowledgements indicate otherwise) and that neither the whole 
work nor any part of it has been, is being, or is to be submitted for another degree in this or 
any other university. 
Signature: Date: 11 February 2019 
Updated: 18 October 2019 






Table of Contents .................................................................................................................. 7	
List of Tables ....................................................................................................................... 12	
List of Figures ...................................................................................................................... 14	
List of Abbreviations and Acronyms ................................................................................. 17	
Abstract ................................................................................................................................ 20	
CHAPTER 1:	 Introduction and study rationale ............................................................ 22	
1.1.	 The burden of heart failure in Africa .................................................................. 22	
1.2.	 Definition and classification of cardiomyopathies .............................................. 23	
1.3.	 Specific cardiomyopathy phenotypes ................................................................ 26	
1.3.1.	 Dilated cardiomyopathy (including peripartum cardiomyopathy) ........................... 26	
1.3.2.	 Hypertrophic cardiomyopathy ................................................................................ 30	
1.3.3.	 Restrictive cardiomyopathy .................................................................................... 34	
1.3.4.	 Arrhythmogenic right ventricular cardiomyopathy .................................................. 35	
1.3.5.	 Left ventricular noncompaction .............................................................................. 41	
1.3.6.	 Myocarditis ............................................................................................................. 43	
1.4.	 Role of cardiovascular magnetic resonance imaging in cardiomyopathies and 
myocarditis .................................................................................................................... 44	
1.5.	 Genetic cardiomyopathies ................................................................................. 46	
1.6.	 Rationale for this research ................................................................................. 48	
1.7.	 Study hypotheses .............................................................................................. 50	
1.8.	 Study aims ......................................................................................................... 50	
CHAPTER 2:	 Methods .................................................................................................... 52	
2.1.	 Study design ...................................................................................................... 52	
2.2.	 Study population ................................................................................................ 53	
2.3.	 Data collection and measurements ................................................................... 53	
2.4.	 Statistical analysis ............................................................................................. 54	
2.5.	 Ethical considerations ........................................................................................ 55	
2.5.1.	 Human Research Ethics Committee approval ....................................................... 55	
2.5.2.	 Informed consent ................................................................................................... 55	
2.5.3.	 Other ethical considerations ................................................................................... 56	
2.6.	 Safety ................................................................................................................. 57	
CHAPTER 3:	 Rationale and design of the African Cardiomyopathy and Myocarditis 
Registry Program: The IMHOTEP Study ........................................................................... 58	
3.1.	 Introduction ........................................................................................................ 58	
3.2.	 Rationale ............................................................................................................ 59	
3.3.	 Study design, materials and methods ................................................................ 61	
3.3.1.	 Study population .................................................................................................... 61	
3.3.2.	 Objectives .............................................................................................................. 61	
3.3.3.	 Study eligibility ....................................................................................................... 62	
3.3.4.	 Diagnostic approach .............................................................................................. 65	
3.3.5.	 Medical genetics, counselling and genetic testing ................................................. 68	
3.3.6.	 Data collection and management ........................................................................... 71	
3.3.7.	 Follow-up ................................................................................................................ 72	
3.3.8.	 Planned genotype analysis .................................................................................... 73	
3.3.9.	 Statistical analysis .................................................................................................. 74	
3.3.10.	 Study management ................................................................................................ 75	
3.3.11.	 Ethics ..................................................................................................................... 78	
3.4.	 Status of the study and study participants ......................................................... 78	
3.5.	 Discussion ......................................................................................................... 80	
3.6.	 Strengths and limitation ..................................................................................... 81	
3.7.	 Conclusion ......................................................................................................... 82	
3.8.	 Contributions and acknowledgements ............................................................... 82	
CHAPTER 4:	 Clinical features, genetics, and outcomes of the patients in the 
Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa ............. 83	
4.1.	 Introduction ........................................................................................................ 83	
4.2.	 Methods ............................................................................................................. 84	
4.2.1.	 Study population .................................................................................................... 84	
4.2.2.	 Study design and diagnostic evaluation ................................................................. 84	
4.2.3.	 Genotype analysis .................................................................................................. 85	
4.2.4.	 Statistical analysis .................................................................................................. 86	
4.3.	 Results ............................................................................................................... 87	
4.3.1.	 Clinical characteristics ............................................................................................ 87	
4.3.2.	 Investigations and diagnostic criteria ..................................................................... 91	
4.3.3.	 Outcomes ............................................................................................................... 96	
4.3.4.	 Genotypic information ............................................................................................ 99	
4.4.	 Discussion ....................................................................................................... 108	
4.5.	 Limitations ........................................................................................................ 115	
4.6.	 Conclusion ....................................................................................................... 115	
4.7.	 Contributions and acknowledgements ............................................................. 116	
CHAPTER 5:	 The baseline characteristics and vital status of prevalent cases of 
dilated cardiomyopathy from the Cape Town cohort .................................................... 117	
5.1.	 Introduction ...................................................................................................... 117	
5.2.	 Methods ........................................................................................................... 118	
5.2.1.	 Study design and population ................................................................................ 118	
5.2.2.	 Inclusion and exclusion criteria ............................................................................ 119	
5.2.3.	 Data collection and informed consent .................................................................. 119	
5.2.4.	 Statistical analysis ................................................................................................ 119	
5.3.	 Results ............................................................................................................. 120	
5.3.1.	 Enrolment and diagnosis ...................................................................................... 120	
5.3.2.	 Demographics and baseline clinical characteristics ............................................. 122	
5.3.3.	 Baseline investigations ......................................................................................... 124	
5.3.4.	 Drug and interventional therapy ........................................................................... 127	
5.3.5.	 Survival ................................................................................................................ 128	
5.4.	 Discussion ....................................................................................................... 130	
5.5.	 Limitations ........................................................................................................ 132	
5.6.	 Conclusion ....................................................................................................... 132	
5.7.	 Candidate contribution and acknowledgements .............................................. 133	
CHAPTER 6:	 Clinical and cardiovascular magnetic resonance (CMR) 
characteristics of incident cardiomyopathy patients from Cape Town: application of 
the 3-stage diagnostic approach ..................................................................................... 134	
6.1.	 Introduction ...................................................................................................... 134	
6.2.	 Methods ........................................................................................................... 135	
6.2.1.	 Study population .................................................................................................. 135	
6.2.2.	 Study design and diagnostic approach ................................................................ 135	
6.2.3.	 CMR analysis ....................................................................................................... 136	
6.2.4.	 Statistical analysis ................................................................................................ 136	
6.3.	 Results ............................................................................................................. 137	
6.3.1.	 Enrolment ............................................................................................................. 137	
6.3.2.	 Diagnosis ............................................................................................................. 141	
6.3.3.	 Demographics ...................................................................................................... 146	
6.3.4.	 Symptoms, treatment and events at the time of enrolment .................................. 147	
6.3.5.	 Baseline investigations ......................................................................................... 148	
6.3.6.	 CMR findings ........................................................................................................ 152	
6.4.	 Discussion ....................................................................................................... 158	
6.5.	 Limitations ........................................................................................................ 163	
6.6.	 Conclusion ....................................................................................................... 164	
6.7.	 Contributions and acknowledgements ............................................................. 164	
CHAPTER 7:	 A clinical genetics overview of families with different morpho-
functional types of cardiomyopathy in Africa ................................................................ 165	
7.1.	 Introduction ...................................................................................................... 165	
7.2.	 Methods ........................................................................................................... 167	
7.2.1.	 Study design ........................................................................................................ 167	
7.2.2.	 Study population .................................................................................................. 167	
7.2.3.	 Eligibility ............................................................................................................... 169	
7.2.4.	 Clinical genetics ................................................................................................... 169	
7.2.5.	 Molecular genetics ............................................................................................... 170	
7.2.6.	 Statistical analysis ................................................................................................ 170	
7.2.7.	 Ethical considerations .......................................................................................... 171	
7.3.	 Results ............................................................................................................. 171	
7.3.1.	 Clinical genetics ................................................................................................... 171	
7.3.2.	 Phenotypic description in selected families .......................................................... 177	
7.4.	 Discussion ....................................................................................................... 185	
7.5.	 Limitations ........................................................................................................ 191	
7.6.	 Conclusion ....................................................................................................... 191	
7.7.	 Contrabutions and Acknowledgements ........................................................... 192	
CHAPTER 8:	 The vision for IMHOTEP and future research ..................................... 193	
8.1.	 Research ......................................................................................................... 194	
8.1.1.	 Molecular genetics research ................................................................................ 194	
8.1.2.	 Clinical research ................................................................................................... 196	
8.1.3.	 Planned expansion of IMHOTEP ......................................................................... 196	
8.2.	 Clinical practice ................................................................................................ 196	
8.3.	 Education and training ..................................................................................... 198	
CHAPTER 9:	 Conclusion ............................................................................................. 200	
References ......................................................................................................................... 206	
Appendix ............................................................................................................................ 217	
 LIST OF TABLES 
 
Chapter 1: Introduction and study rationale 
 




Chapter 3: Rationale and design of the African Cardiomyopathy and myocarditis 
registry program: The IMHOTEP Study.  
 
Table 3.1. Cardiomyopathy phenotype definitions  
 
Table 3.2. IMHOTEP inclusion and exclusion criteria 
 
Table 3.3. Clinical classification for the diagnosis of myocarditis 
 
Table 3.4. Three stage investigative approach to cardiomyopathy and myocarditis  
 
Table 3.5. Primary and secondary outcome measures 
 




Chapter 4: Clinical features, genetics, and outcomes of the patients in the 
arrhythmogenic right ventricular cardiomyopathy registry of South Africa  
 
Table 4.1. Inclusion and exclusion criteria 
 
Table 4.2. Diagnoses of the 92 excluded cases 
 
Table 4.3. Investigations performed in excluded patients 
 
Table 4.4. Baseline characteristics of study participants compared to two large international 
cohorts 
 
Table 4.5. Investigations performed for patients with definite and borderline ARVC 
 
Table 4.6. 2010 task force criteria of study participants compared to two large international 
cohorts 
 
Table 4.7. CMR findings for 29 patients with definite and borderline ARVC 
 
Table 4.8. Disease-causing mutation in unrelated index cases in the ARVC Registry of South 
Africa 
 
Table 4.9. Variants of uncertain significance in unrelated index cases in the ARVC Registry 
of South Africa 
 
Table 4.10. Index cases from the 2009 report that were excluded according to 2010 TFC 
 
Chapter 5: The baseline characteristics and vital status of prevalent cases of dilated 
cardiomyopathy from the Cape Town cohort 
 
Table 5.1. Clinical characteristics of prevalent DCM cases recruited to IMHOTEP in 
comparison with the European Cardiomyopathy Pilot Registry 
 
Table 5.2. Investigations performed in prevalent cases in IMHOTEP compared to European 
Cardiomyopathy Pilot Registry 
 
Table 5.3. Electrocardiogram 
 
Table 5.4. Echocardiogram 
 
Table 5.5. Cardiovascular magnetic resonance characteristics in 18 patients 
 




Chapter 6: Clinical and cardiovascular magnetic resonance characteristics of incident 
cardiomyopathy patients from Cape Town: Application of the 3-stage diagnostic 
approach 
 
Table 6.1. Baseline Characteristics of 99 incident cases recruited 
 
Table 6.2. Final diagnosis of the first 99 incident cases recruited to IMHOTEP 
 
Table 6.3. Investigations done prior to or at the time of enrolment into IMHOTEP 
 
Table 6.4. Electrocardiogram 
 
Table 6.5. Echocardiogram 
 
Table 6.6. CMR findings in 67 incident cases 
 
Table 6.7. Specific cases demonstrating the diagnostic utility of CMR 
 
 
Chapter 7: A clinical genetics overview of families with different morpho-functional 
types of cardiomyopathy in Africa 
 
Table 7.1. Clinical genetics of 35 families with familial cardiomyopathy 
 
Table 7.2. Genotype positive families 
 
Table 7.3. Genotype unknown families
 LIST OF FIGURES 
 
Chapter 1: Introduction and study rationale 
 
Figure 1.1. Differences in the proportion of the causal factors for heart failure in sub-Saharan 
Africa during the periods 1957-2005 and 2007-2010.  
 
Figure 1.2. Classification of cardiomyopathies 
 
Figure 1.3. Adjusted Kaplan-Meier estimates of survival according to the underlying causes 
of cardiomyopathy 
 
Figure 1.4. A. CMR of a normal heart (4 chamber view), B. CMR of an adult patient with DCM 
(4 chamber view). 
 
Figure 1.5. Classification and aetiology of dilated cardiomyopathies (DCM) 
 
Figure 1.6. CMR of a patient with HCM with LV outflow tract obstruction due to septal 
hypertrophy and systolic anterior motion of the anterior mitral valve, and mid-cavity obliteration 
in systole.  
 
Figure 1.7. Classification and aetiology of hypertrophic cardiomyopathies (HCM) 
 
Figure 1.8. Example of isolated right ventricular endomyocardial fibrosis. 
 
Figure 1.9. Fibrofatty replacement of the myocardium in a IMHOTEP patient with ARVC 
 
Figure 1.10. Left ventricular non-compaction 
 
Figure 1.11. CMR of patient excluded from IMHOTEP with ischaemic LV dysfunction 
 





Chapter 3: Rationale and design of the African Cardiomyopathy and myocarditis 
registry program: The IMHOTEP Study.  
 
Figure 3.1. Three phase molecular genetics sub-study 
Figure 3.2. IMHOTEP clinical genetics sub-study 
Figure 3.3. IMHOTEP collaborating countries 
Figure 3.4. Organisational structure of IMHOTEP 




Chapter 4: Clinical features, genetics, and outcomes of the patients in the 
arrhythmogenic right ventricular cardiomyopathy registry of South Africa  
 
Figure 4.1. Referred cases of suspected ARVC  
 
Figure 4.2. Outcomes of patients with ARVC 
 
Figure 4.3.1. Kaplan-Meier survival analysis for overall transplant-free survival 
 
Figure 4.3.2. Kaplan-Meier survival analysis for transplant-free survival in ARVC patients with 
or without an ICD 
 
Figure 4.3.3. Kaplan-Meier survival analysis for transplant-free survival in genotype positive 
and genotype negative/unknown patients with ARVC 
 
Figure 4.4. ACM 39 family pedigree showing segregation of ARVC with PKP2 c.G1465A 
variant (+).  
 




Chapter 5: The baseline characteristics and vital status of prevalent cases of dilated 
cardiomyopathy from the Cape Town cohort 
 
Figure 5.1. Recruitment of existing prevalent DCM cases to IMHOTEP 
 
Figure 5.2. Aetiological diagnosis in patients with DCM 
Figure 5.3. Family pedigree for individual with HCM/DCM phenotype 




Chapter 6: Clinical and cardiovascular magnetic resonance characteristics of incident 
cardiomyopathy patients from Cape Town: Application of the 3-stage diagnostic 
approach 
 
Figure 6.1. Recruitment of incident cases to IMHOTEP 
 
Figure 6.2. Familial DCM (Family 35) 
 
Figure 6.3.  Familial cardiomyopathy characterised by LVNC and heart block (Family 28) 
 
Figure 6.4. Family pedigree for family with HCM and a previously identified sarcomeric 
mutation MYH7 c.2282C>A (p.T761N) (Family 16) 
 
Figure 6.5. Histogram showing distribution of age of presentation 
Figure 6.6. Diagnostic CMR images of patients with (A) Myocarditis; (B) Amyloidosis;  
(C) Sarcoidosis; and (D) Hypereosinophilic Myocarditis. 
 
 
Chapter 7: A clinical genetics overview of families with different morpho-functional 
types of cardiomyopathy in Africa 
 
Figure 7.1. Approach to the study of familial cardiomyopathies 
 
Figure 7.2. Family 29. Dilated cardiomyopathy with probable autosomal recessive inheritance 
 
Figure 7.3. Family 21. Dilated cardiomyopathy with left ventricular noncompaction overlap 
 
Figure 7.4. Family 18. Arrhythmogenic right ventricular cardiomyopathy 
 
Figure 7.5. Family 27. Dilated cardiomyopathy with associated muscular dystrophy 
 




Chapter 8: The vision for IMHOTEP and future research 
 
Figure 8.1. The IMHOTEP Study platform 
Figure 8.2. The IMHOTEP Study logo
17 
 LIST OF ABBREVIATIONS AND ACRONYMS 
 
ACE Angiotensin-converting enzyme 
AD Autosomal dominant 
AR Autosomal recessive  
ARB Angiotensin-receptor blockers 
ARVC Arrhythmogenic right ventricular cardiomyopathy 
BSA Body surface area 
CAD Coronary artery disease 
CDH2 Cadherin-2 
CI Confidence interval 
CMR Cardiovascular magnetic resonance  
CPR Cardiopulmonary resuscitation 
CRF Case report form 
CVD Cardiovascular disease 
CVG Cardiovascular Genetics  
DCM Dilated cardiomyopathy 





EMB Endomyocardial biopsy 
EMF Endomyocardial fibrosis 
EPS Electrophysiology studies 
ESC European Society of Cardiology 
EST Exercise stress test 
GSH Groote Schuur Hospital 
HCM  Hypertrophic cardiomyopathy 
HF Heart failure 
HFrEF Heart failure with reduced ejection fraction 
HIC High-income country 
HIV Human immunodeficiency virus 
HIVAC HIV-associated cardiomyopathy 
18 
HLA human leucocyte antigen 
HREC Human Research Ethics Committee 
IBM International Business Machines 
ICD Implantable cardioverter defibrillator 
IHD Ischaemic heart disease 
IMHOTEP African Cardiomyopathy and Myocarditis Registry Program 
IQR Interquartile range 
IVS Interventricular septum 
JUP Plakoglobin 
LBBB Left-bundle-branch block 
LGE Late gadolinium enhancement 
LMIC Low-to-middle-income country 
LMNA/C Lamin A/C 
LV Left ventricle (or left ventricular) 
LVEF Left ventricular ejection fraction 
LVH Left ventricular hypertrophy 
LVNC Left ventricular non-compaction 
LVOT Left ventricular outflow tract 
MBPC3 myosin-binding C 
MRA Mineralocorticoid receptor antagonists 
MRI Magnetic resonance imaging 
MYH7 ß-myosin heavy chain 
NCD Non-communicable disease 
NGS Next generation sequencing 
NYHA New York Heart Association 
OHT Orthotopic heart transplant 
PCO Project Coordinating Office  
PKP2 Plakophilin-2 
PLN Phospholamban 
PND Paroxysmal nocturnal dyspnoea 
PPCM Peripartum (or postpartum) cardiomyopathy 
RCM Restrictive cardiomyopathy 
RHD Rheumatic heart disease 
RV Right ventricle (or right ventricular) 
RVEF Right ventricular ejection fraction 
19 
SAECG Signal average electrocardiogram 
SCD Sudden cardiac death 
SD Standard deviation 
SOP Standard operating procedures 
SSA Sub-Saharan Africa 
TFC Task force criteria 
TTN Titin 
UCT University of Cape Town 
US/USA United States of America 
VT Ventricular tachycardia 
VUS Variant of unknown significance 





Background. Causes of heart failure in Africa are largely non-ischaemic: hypertension, 
rheumatic heart disease and cardiomyopathy. Cardiomyopathies pose a great challenge 
because of poor prognosis and high prevalence in low- and middle-income countries with 
limited access to specialised care. Little is known about aetiology or outcomes of 
cardiomyopathy in Africa. 
 
Method. The African Cardiomyopathy and Myocarditis Registry Program (IMHOTEP) is a 
pan-African multi-centre, hospital-based cohort study. It aims to describe the clinical 
characteristics, aetiology, genetics, management and outcome of cardiomyopathies in 
children and adults. Index patients were recruited as either incident (new) or prevalent 
(existing) cases, and family screening was conducted in selected cases. Several sub-studies 
were conducted at the initiating centre, including; outcome studies on prevalent cases 
incorporated into IMHOTEP, a cardiovascular magnetic resonance (CMR) study on incident 
cases, and a clinical genetics study on families.  
 
Results. The pilot phase was commenced in Cape Town (February 2015), followed by 
staggered initiation at 6 further sites. Over 600 index patients have been recruited to the 
registry to date. Preliminary data on the first 99 incident adult cases recruited at the initiating 
site, showed that dilated cardiomyopathy (DCM; n=67) was commonest, followed by 
hypertrophic (HCM; n=13), left ventricular noncompaction (LVNC; n=11), restrictive (RCM; 
n=4) and arrhythmogenic right ventricular (ARVC; n=4) cardiomyopathies. Cardiomyopathy 
occurred predominantly in mixed race (46%) and black (41%) Africans, and more frequently 
in females (54%). Mean age of presentation was 36.8 ±12.5 years. CMR performed in incident 
cases (67/99, 68%) proved diagnostically useful, however, acute myocarditis was only 
reported in one individual. In addition, prevalent cases with ARVC and DCM were enrolled 
from two existing studies at the initiating centre. Except for fewer (24%) genotype positive 
21 
(PKP2 20%, CDH2 4%) individuals with ARVC (n=70), the baseline characteristics and 
diagnostic criteria were similar to what has been reported internationally. Transplant-free 
survival probability at 1-year, 5-years and 10-years was 98.5%, 90.7%, and 80.8% 
respectively in ARVC (median survival time 9.0 years) and there were no significant 
differences in survival between those with and without implantable cardioverter defibrillators 
[p=0.27]. In the prevalent DCM cohort (n=133), transplant-free survival probability was 93.4%, 
82.2% and 73.1% at 1-year, 5-years and 10-years respectively, with a median survival time of 
5.3 years. The age of onset (34.8 ±11.0 years) and death (41.5 ±9.6 years) were significantly 
younger in our DCM patients compared to European cohorts. Thirty-five families were 
recruited (16 genotype positive, 19 genotype unknown) with autosomal dominant inheritance 
observed in 94.3% families.   
 
Conclusion. IMHOTEP is the first multi-centre registry for cardiomyopathy in Africa. 
Preliminary data suggests an earlier age of onset compared to European cohorts and that 
DCM is the most common form of cardiomyopathy in South Africa. Molecular genetic analysis 




CHAPTER 1: Introduction and study rationale 
1.1.  THE BURDEN OF HEART FAILURE IN AFRICA 
Heart failure (HF), the dominant form of cardiovascular disease (CVD) in hospitalised Africans, 
has great social and economic relevance owing to its high prevalence, mortality and impact 
on young, economically active individuals.
1,2
 According to data from the International 
Congestive Heart Failure (INTER-CHF) prospective cohort study, despite being the youngest 
cohort at baseline, African patients had the highest mortality.
3
 The younger age of onset of HF 
and high mortality rates in Africans mirror the findings of the THESIS-HF study.
2,4
 In contrast 
to high income countries, where ischaemic heart disease is predominant, the causes of HF in 
Africa remain largely non-ischaemic, with hypertension, rheumatic heart disease (RHD) and 
cardiomyopathy accounting for the majority of cases.
2,3,5
 Cardiomyopathy contributes to 20–
30% of HF in adults in the African population, and continues to be an important cause of HF 
in sub-Saharan Africa (SSA) (Figure 1.1.). 
2,6-8
 According to data from the Global Burden of 
Disease Study 2013, the number of deaths attributed to cardiomyopathy in SSA has risen, 
with a 14% change in age-standardised death rate (12.7 per 100 000 in 1990 versus to 14.5 




HF poses a major public health challenge globally, affecting 26 million people worldwide, and 
is associated with substantial healthcare expenditure.
10,11
  Development of health policies is 
reliant on sufficient epidemiological data on incidence, prevalence, determinants and 
outcomes. Adequate information on cardiomyopathies and myocarditis in the African 
population is lacking. There is a recognisable need for large, well-designed, epidemiological 
studies to evaluate the genetic and molecular epidemiology, as well as modifiable risk factors 







Figure 1.1.  Differences in the proportion of the causal factors for heart failure in sub-
Saharan Africa during the periods 1957-2005 and 2007-2010.  
From: Sliwa K, Mayosi BM. Recent advances in the epidemiology, pathogenesis and 
prognosis of acute heart failure and cardiomyopathy in Africa. Heart 2013;99(18):1317-226  
 
 
1.2.  DEFINITION AND CLASSIFICATION OF CARDIOMYOPATHIES 
Cardiomyopathies are a heterogeneous group of familial and acquired myocardial disorders 
in which the heart muscle is structurally and functionally abnormal, in the absence of coronary 
artery disease, hypertension, valvular disease, pericardial disease and congenital heart 
disease sufficient to cause the observed myocardial abnormality.
13
 While a number of different 
classification systems have been published, the European Society of Cardiology (ESC) 
approach is useful as it classifies cardiomyopathies into different morphological and functional 
phenotypes - dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive 
cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and 
unspecified cardiomyopathies, including isolated left ventricular non-compaction (LVNC) and 
Takotsubo cardiomyopathy. Once a morpho-functional diagnosis is made and alternative 
24 
conditions have been excluded, further elucidation is required to identify the specific cause 
and underlying disease mechanism.
14
 Each phenotype is sub-classified as either familial or 
non-familial (Figure 1.2.). The term ‘familial’ implies the presence of the same disorder, or a 
phenotype that is (or could be) caused by the same genetic mutation in at least one other 
family member. Non-familial cardiomyopathies, which are clinically defined by the presence 
of a cardiomyopathy in the index patient and the absence of disease in other family members, 
are subdivided into idiopathic and acquired cardiomyopathies.
13
 The relevance of aetiology 
was demonstrated by Felker et al. almost two decades ago, in a study showing that the 
underlying cause of HF was independently associated with survival among patients with 
different forms of cardiomyopathy and the differentiation beyond ischaemic versus non-
ischaemic causes of HF had prognostic importance (Figure 1.3.).
15
   
 
 
Figure 1.2.  Classification of cardiomyopathies 
Adapted from: Elliott P, et al. Classification of the cardiomyopathies: a position statement from the 




ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; RCM, restrictive cardiomyopathy. Unclassified includes left ventricular 
noncompaction (LVNC)  
Images: Cardiovascular magnetic resonance (CMR) images from IMHOTEP study participants with 
HCM, DCM, ARVC, RCM, and LVNC 
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Figure 1.3. Adjusted Kaplan-Meier estimates of survival according to the underlying 
causes of cardiomyopathy.  
From: Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival 
in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342(15):1077-84.15  
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1.3.  SPECIFIC CARDIOMYOPATHY PHENOTYPES 
1.3.1. Dilated cardiomyopathy (including peripartum cardiomyopathy) 
DCM – a primary disorder of the heart muscle that is characterised by left ventricular (LV) 
dilatation and systolic dysfunction
13
 (Figure 1.4.) – is one of the endemic cardiomyopathies in 
Africa, and accounts for 10–17% of all cardiac conditions at autopsy
16-18
 and for 17–48% of 
patients hospitalised for HF.
2,5,8,19-21
 DCM represents a significant health problem as it can 
lead to progressive refractory HF, requirement for cardiac transplantation and carries a high 
mortality. Prevalence of DCM in US populations is estimated to be 36.5/100 000,
22
 but there 
have been no population-based studies of the epidemiology of DCM in SSA. DCM can occur 
at any age, but patients typically present in the third and fourth decade of life and occurs more 
frequently in men.
8
   
 
 
Figure 1.4. A. CMR of a normal heart (4 chamber view), B. CMR of an adult patient with 
DCM (4 chamber view).  
 
Images: CMR of IMHOTEP study participants 
 
 
DCM is caused by both familial and non-familial aetiologies, and the exclusion of secondary 
treatable causes is key in the diagnostic workup (Figure 1.5.). These secondary causes 
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27 
include: myocarditis (infective, toxic, autoimmune); human immunodeficiency virus (HIV) 
infection; toxin exposure (chemotherapy, alcohol, illicit drugs such as methamphetamines, 
cocaine); endocrine conditions (thyrotoxicosis, phaeochromocytoma, acromegaly); nutritional 
deficiencies (thiamine, carnitine); and tachycardiomyopathy.
13,23
 Familial disease accounts for 
20–35% of patients with idiopathic DCM in high-income country (HIC) populations.
24,25
 In a 
retrospective hospital-based study conducted at Groote Schuur Hospital (GSH) in South 





Figure 1.5. Classification and aetiology of dilated cardiomyopathies (DCM) 
Adapted from: Elliott P, et al. Classification of the cardiomyopathies: a position statement from 
the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. 
Eur Heart J. 2007;29(2):270-276.13  
 
 
Diagnosing familial DCM can be challenging. There are few clinical characteristics that reliably 
distinguish familial from non-familial DCM,
27,28
 although familial disease has been associated 
with a younger age of onset and a male preponderance in some studies.
26,28
 Family history by 
patient report neither proves nor disproves familial disease. Michels et al. demonstrated in 
their original cohort that 20% of patients who had been unselected based on family history 
were found to have familial disease after investigation of their relatives.  Furthermore, in their 
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28 
follow-up study the index cases of familial disease had increased from 20% to 30% as 
additional relatives developed the disease.
24,27
 Familial DCM genetics are inherently complex.  
To date there are >30 genes associated with DCM and a genetic cause is identifiable in only 
30–35% of familial DCM cases. There is marked variation in age of onset, disease penetrance 
and clinical severity observed with a single mutation within an extended family or between 
families with the same variant.
29,30
  Very little is known about the genetics of DCM in the African 
population. 
 
HF is a preventable and treatable condition.  Therefore, early diagnosis and treatment of DCM 
can lead to dramatic decreases in morbidity and mortality. Many patients with DCM (familial 
or idiopathic) present with advanced disease, but early detection of asymptomatic patients 
through screening enables presymptomatic intervention that may prevent or ameliorate the 
progression of advanced disease.
28
 Response to medical therapy is variable in DCM. 
Apparent recovery can occur in a significant proportion (15%) of patients after an adequate 
period (9±4 months) on optimal medical therapy, and persistent apparent recovery has been 
demonstrated in approximately 10% of patients with DCM at 8 years.
31
 However, 33% of 
patients who achieved normalisation of their LV dimensions and function at ±19 months had 
deterioration of LV function subsequently,
31
 demonstrating the need for long-term follow-up. 
A study looking at the long-term progression of idiopathic DCM in paediatric patients 
suggested that despite having higher baseline LV ejection fractions and similar 
echocardiographic progression, children had a worse prognosis compared with adult DCM 
patients.
32
 Outcome data available for DCM from South Africa shows a 5-year mortality rate 
of 40%,
4
 but information on long-term outcomes in African patients with DCM, particularly in 
the paediatric population, is lacking. 
 
Peripartum cardiomyopathy (PPCM) is classified as a subtype of DCM. In order to address 
the considerable variability in PPCM case definition, in 2010 the Heart Failure Association of 
the ESC Working Group on PPCM, proposed defining PPCM as an idiopathic cardiomyopathy 
29 
presenting with HF secondary to LV systolic dysfunction towards the end of pregnancy or in 
the months following delivery, where no other cause of HF is found.  PPCM is a diagnosis of 
exclusion. The LV may, or may not, be dilated but the ejection fraction is nearly always 
reduced to below 45%.
33
 PPCM occurs globally and is likely under-reported as a cause of 
maternal death.
34
 Data regarding the incidence of PPCM is limited and highly variable, 
estimated at 1 in 2500–4000 in the US,
35,36
 1 in 1000 in South Africa,
37
 and 1 in 300 in Haiti.
38
 
The pathophysiology of PPCM has been well studied and a number of contributing factors 
have been implicated in initiation and propagation of disease.
33,39
 Recent experimental studies 
suggest that the breastfeeding hormone, prolactin, is a key contributor to the development of 
PPCM.  High levels of full-length prolactin have been shown to promote inflammation and the 
production of a cleaved 16kDa N-terminal fragment of prolactin is implicated in causing 
endothelial damage and cardiomyocyte dysfunction.
40-42
 Furthermore, recent clinical studies 
demonstrated that the inhibition of prolactin release using the dopamine-D2-receptor agonist, 
bromocriptine, in conjunction with conventional anti-failure therapy, was associated with 




Familial clustering of PPCM was first described in 1963 by Pierce et al.,44 and familial disease 
has been shown to occur in 5–10% of cases.
26,45
 However, up until recently, the genetic 
contribution to susceptibility to PPCM was largely unstudied. PPCM and DCM share a number 
of clinical characteristics, including impairment of systolic function, increased chamber 
dimensions and nonspecific histological findings. In a recent study, 172 women with PPCM 
were screened for variants in 43 genes previously associated with DCM. The burden of genetic 
variants was found to be similar to what has been previously reported in DCM, and 65% of 
these variants were found in Titin (TTN). The authors conclude that while many of these 
truncating variants lead to a strong predisposition to PPCM, the presence of more common 
variants is likely not a risk factor for penetrant PPCM and further study is required.
46
  It is 
important to note that these variants were not found in those women with preeclampsia and 
other forms of pregnancy-induced hypertension.
35
 When women present with HF during the 
30 
peripartum period, uncertainty often exists as to whether these women are affected with 
PPCM or have underlying familial DCM that has only become apparent consequent to the 
haemodynamic stress of pregnancy. There are currently no diagnostic criteria that separate 
these two entities, although a positive family history can be helpful.
47
 PPCM has a higher rate 
of spontaneous recovery of LV function and has better survival than idiopathic DCM,
15,48
 
therefore the distinction is important.  
 
1.3.2. Hypertrophic cardiomyopathy 
Historically, HCM has been defined by the presence of inappropriate myocardial hypertrophy 
in the absence of abnormal loading conditions (e.g. hypertension, aortic stenosis) or infiltration 
(e.g. amyloidosis, sarcoidosis). Traditionally, the term “hypertrophic cardiomyopathy (HCOM)” 
has been synonymous with the clinically heterogeneous but relatively common genetic form 
of cardiomyopathy characterised by LV hypertrophy (LVH), classically involving (although not 
limited to) the interventricular septum (IVS) which can result in LV outflow tract (LVOT) 
obstruction
13
 (Figure 1.6.). Histological findings in this condition include interstitial fibrosis, 
myocyte enlargement and myocyte disarray.
49,50
 It is important to distinguish myocyte 
hypertrophy, caused by a variety of sarcomeric mutations, from conditions with increased 
ventricular wall thickness due to interstitial infiltration (e.g. amyloidosis), intracellular 
accumulation of metabolic substances (e.g. glycogen storage diseases, lysosomal storage 
diseases, disorders of fatty acid metabolism), or the setting of syndromic conditions (e.g. 
Noonan syndrome, LEOPARD syndrome, Friedreich’s ataxia, Beckwith-Wiedermann 
syndrome, Swyer’s syndrome). In both the American and European classification systems, 
these non-sarcomeric genetic and acquired infiltrative conditions are classified as 
‘hypertrophic cardiomyopathy phenocopies’
13,51,52
 (Figure 1.7.). 
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Figure 1.6. CMR of a patient with HCM with LV outflow tract obstruction due to septal 
hypertrophy and systolic anterior motion of the anterior mitral valve, and mid-cavity 
obliteration in systole.  
 





Figure 1.7. Classification and aetiology of hypertrophic cardiomyopathies (HCM)  
Adapted from: Elliott P, et al. Classification of the cardiomyopathies: a position statement from 
the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. 
Eur Heart J. 2007;29(2):270-276.13  
 
A. Diastole B. Systole
Familial/Genetic Non-familial/Non-genetic (acquired)
Unidentified gene defect Disease sub-type Disease sub-typeIdiopathic
Sarcomeric protein mutations
Beta-myosin heavy chain




Essential myosin light chain






Glycogen storage disease 
Disorders of fatty acid metabolism 























Familial HCM is the most common form of genetic cardiomyopathy and has a prevalence of 1 
in 500. Prevalence estimates are based on data from the Coronary Artery Risk Development 
in Young Adults (CARDIA) cohort study published in 1995, and are supported by a number of 
other phenotype-based echocardiographic studies in different populations.
53,54
 While 
prevalence data in African populations is limited, echocardiographic studies from Ghana and 
Ethiopia have dispelled the myth that HCM is rare amongst Africans.
21,55
 Subsequent genetic 
population studies suggest that the prevalence of HCM gene carriers is estimated at 1 in 200 
or greater.
54
 Although all gene carriers may not manifest clinical HCM, these findings suggest 
that the prevalence of HCM may be higher than previously reported. Additionally, a number of 
comparative studies have demonstrated that cardiovascular magnetic resonance (CMR) is 
able to identify LV hypertrophy in regions not reliably visualised with standard 
echocardiography (namely apical, anterolateral or posterior inferior regions of the LV) and can 
assist in making the diagnosis of HCM in borderline or ambiguous cases.
56,57
 This provides 
additional support to the suggestion that the prevalence of HCM may have been 
underestimated by echocardiography-based studies.  
 
Familial HCM is recognised as an autosomal dominant disorder and is primarily a disease of 
the sarcomere. Numerous mutations encoding various contractile proteins of the cardiac 
sarcomere have been reported as disease-causing, most commonly in the ß-myosin heavy 
chain (MYH7) and myosin-binding C (MBPC3). The yield of screening for causal mutations 
ranges from 40–70%.
52,58
 There are no pre-existing national registries for HCM on the African 
continent; however, clinical and genetic studies have been conducted on a few single-centre 
cohorts of patients with HCM in South Africa. Moolman-Smook and colleagues have done 
pioneering work on the genetics of HCM in South African patients of mixed ancestry and white 
descent. In one study, 23 (58%) of the 40 unrelated patients’ studies were genotype positive, 
with three founder mutations (MYH7 Ala797Thr, TNNT2 Arg92Trp, MYH7 Arg403Trp) 
reported in 45% of genotyped patients in that cohort.
59
 Up until recently, black Africans were 
significantly under-represented in these studies. In a recent prospective study on HCM from 
33 
Cape Town (total n = 43; mixed ancestry 63%, black Africans 30%, Caucasian 5%, and Indian 
2%), comprehensive genetic screening was associated with a 29% yield of causal mutations, 
all in the MYH7 and MBPC3 genes. The authors note that, given the relatively low yield of 
screening in this study, routine molecular genetic testing in Africans with HCM should not be 
conducted until there is more data on the full spectrum of causal mutation, and the impact of 
genetic testing on outcomes is available.
60
 Genetic, epigenetic and environmental modifiers 
of the HCM phenotype are still not well understood, necessitating future research, especially 
among Africans. 
 
Longitudinal studies from the USA have demonstrated that with contemporary management 
strategies and interventional therapies, such as implantable cardioverter defibrillators (ICDs) 
and orthotopic heart transplantation (OHT), patients with HCM have a low disease-related 
mortality rate of 0.5–1.3% per year.
61
 In South Africa, a higher mortality rate of 2.9% per year 
has been reported.
60
 While the risk of SCD is well recognised in HCM, the incidence and 
mortality from disease progression to a HF syndrome are sometimes underappreciated. Up to 
a fifth of patients with HCM develop HF at a median age of 48±19 years,
62
 and chronic HF as 




Although the current clinical guidelines recommend family screening in children from age 10,
58
 
a recent study showed that a diagnosis in a child first degree relative was made in 8% of 
families screened, and while the HCM phenotype varies in childhood, severe disease is well 
described.
63
 There is currently no data on the incidence of childhood-onset HCM in the African 




1.3.3. Restrictive cardiomyopathy 
RCM is a rare cardiomyopathy characterised by impaired ventricular filling and diastolic 
dysfunction with relatively normal wall thickness and systolic function. It has a broad aetiology 
that includes genetic causes, infiltration, connective tissue disease, glycogen storage disease, 
drugs and radiation.
13
 The prognosis of RCM is poor, particularly in children, with transplant-




Endomyocardial fibrosis (EMF), the most common form of RCM, occurs primarily in tropical 
and sub-tropical regions worldwide, and is endemic in peri-equatorial regions of Africa. EMF 
is characterised by ventricular endomyocardial thickening with dense, white fibrous tissue that 
results in cavity obliteration and impaired ventricular filling
66,67
 (Figure 1.8.). The observed 
geographic restriction and regional variation in countries with high prevalence make accurate 
estimates of incidence and prevalence of EMF difficult to determine.
68
  Population screening 
for EMF in an endemic region of Mozambique, reported a prevalence of 19.8%, suggesting 
that it may be a dominant form of cardiomyopathy in that region.
69
 Apart from geography, a 
number of factors have been associated with EMF in Africa – including ethnicity, poverty, diet, 
age, sex, eosinophilia and infection – but their specific roles in the pathogenesis of EMF 
remain poorly understood.
67
 There is limited compelling evidence to support genetic 
susceptibility in EMF, although familial occurrence has been reported in case reports from 
different regions in Africa
70,71
 and certain HLA alleles have been associated with EMF in 2 
different populations in one study.
72
 EMF predominantly affects children and adolescents from 
poverty stricken communities, and usually presents in the advanced stages of disease. As a 
result, the early manifestations of this condition are poorly defined. EMF continues to be an 
important and debilitating condition with a poor prognosis, affecting young individuals from 






Figure 1.8. Example of isolated right ventricular endomyocardial fibrosis. 
Explanted heart of study participant. A. Cross-section of right and left ventricles. 
Endomyocardial fibrosis of right ventricle. B. Right atrium and ventricle. Right atrial thrombus, 
right ventricular endomyocardial fibrosis. 






1.3.4. Arrhythmogenic right ventricular cardiomyopathy 
ARVC is defined by the presence of right ventricular (RV) dysfunction (global or regional), with 
or without LV disease, in the presence of histological evidence of fibrofatty replacement 
(Figure 1.9.) and/or electrocardiographic abnormalities according to published criteria.
13,73
 
ARVC classically presents with malignant ventricular arrhythmias, which may lead to SCD, 
with HF occurring in 10–20% of patients. While ARVC is considered uncommon, with an 
estimated prevalence of 1 in 5000,
13
 it is a frequent cause of SCD in young people.
74
 The 





Figure 1.9. Fibrofatty replacement of the myocardium in an IMHOTEP patient with ARVC 
From: Mayosi BM, Fish M, Shaboodien G, et al. Identification of Cadherin 2 (CDH2) Mutations 





Images provided by H. Wainwright, Department of Pathology, University of Cape Town 
 
 
ARVC is considered a genetic (sporadic or inherited) form of cardiomyopathy and is familial 
in 50% of cases. It is usually transmitted as an autosomal dominant (AD) trait with variable 
penetrance, although autosomal recessive (AR) cardio-cutaneous forms of the condition are 
well described.
76,77
 The discovery of mutations in desmosomal genes in ARVC has been 
crucial in understanding the underlying mechanisms of disease as desmosomal proteins have 
an important role in myocyte cell-to-cell adhesion.
78,79
 Genetically altered function of cell-
adhesion proteins results in the disruption of intercellular junctions, myocyte uncoupling 
(aggravated by physical exercise)
80
 and myocyte death with subsequent fibrofatty tissue 
replacement. This leads to structural changes within the ventricular wall and electrical 
37 
instability with arrhythmias that are thought to occur through a scar-related macro-reentry 
mechanism.
81,82
 Pathogenic genetic variants associated with ARVC have been reported for 
desmosomal genes encoding plakophilin-2 (PKP2),83 desmoplakin (DSP),84 desmoglein-2 
(DSG2),85 desmocollin-2 (DSC2),86 and plakoglobin (JUP).78 In addition, non-desmosomal 
genes encoding cardiac ryanodine-2 receptor (RYR2),
87
 transforming growth factor beta-3 
(TGFß3),
88
 transmembrane protein 43 (TMEM43)
89
 and cadherin 2 (CDH2),75 have also been 




Following the call for unified international ARVC registries in 2000,
91
 a number of large 
collaborative registries were established. The largest of these are the ESC International 
Registry
92
 – combining cohorts from France, Germany, Italy, Greece, Poland, Cyprus and the 
United Kingdom – and a collaboration of the John Hopkins University and Dutch Interuniversity 
Medical Centre’s registries.
93
 With the knowledge generated from international registries over 
two decades, the original 1994 diagnostic task force criteria (TFC) were modified in 2010 
(Table 1.1.),
73,94
 highlighting the important role of collaborative registries for uncommon 
conditions. The diagnosis of ARVC is reliant on the demonstration of structural, functional and 
electrophysiological abnormalities that are associated with underlying histological changes. 
The TFC represent a working framework to improve diagnostic certainty. The diagnosis of 
ARVC requires a multidisciplinary approach that combines expertise from numerous 
disciplines including clinical cardiology, electrophysiology, imaging, pathology, and clinical 
and molecular genetics. By incorporating new knowledge, quantifiable variables, emerging 
diagnostic modalities such as cardiovascular magnetic resonance (CMR), and advances in 
the genetics of ARVC, the revised 2010 TFC have been shown to increase diagnostic value, 




The ARVC Registry of South Africa was established in 2003
95
 and our group published data 
on the first 50 participants classified according to the 1994 TFC in 2009. They reported that 
ARVC occurs in all ethnic groups in South Africa; patients usually presented with symptoms 
38 
by the third decade of life; and outcomes were worse than in other parts of the world, with an 
annual mortality of 2.8% and a 5-year cumulative mortality of 10%.
96
 While there are several 
explanations for the higher mortality, the most likely is that ICDs are underutilised in South 
Africa due to resource constraints in the public sector. Thirty percent of participants had a 
family member who was also affected, and genetic analysis revealed that 25% of cases were 
caused by PKP2 gene mutations.96 Additionally, a PKP2 founder mutation  was identified in 
four unrelated families, and more recently novel CDH2 mutations were reported in two 
unrelated families, from this cohort.
75,96
 The South African ARVC Registry has provided insight 
into ARVC in the South African context; however, there are no studies published on this 
condition from the rest of the African continent.  
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Table 1.1. Comparison of original and revised ARVC Task Force Criteria  
 
 
From: Marcus et al. Diagnosis of Arrhythmogenic Right Ventricular 




Figure 1.4. Comparison of Original and Revised Task Force Criteria.
Fro : Marcus et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: 
Proposed Modification of the Task Force Criteria. Circulation. 2010;121:1533-1541 (Table 1).
40 
Table 1.1. Comparison of original and revised ARVC Task Force Criteria (continued) 
  
 
From: Marcus et al. Diagnosis of Arrhythmogenic Right Ventricular 







1.3.5. Left ventricular noncompaction 
Isolated LVNC is a genetically heterogeneous disease characterised by prominent myocardial 
trabeculations and deep intertrabecular recesses
13
 (Figure 1.10.). The true prevalence of 
LVNC is unknown, and the reported prevalence in the literature varies considerably. Ritter et 
al. reported a prevalence of 0.05% of all adult echocardiographic examinations in a large 
institution in North America.
97
 Oechslin et al. reported a prevalence of 0.014% in patients 
referred for echocardiography in Switzerland.
98
 An epidemiological study of primary 
cardiomyopathy in Australian children revealed that LVNC accounted for 9.2% of all cases 
and was identified as the third most common cause of cardiomyopathy, after DCM and HCM.
99
 
The only prevalence data from Africa is from a single-centre prospective case-control study 
conducted in South Africa: Peters et al. found the prevalence of LVNC in to be 6.9% and 





Our understanding of genotype–phenotype correlations in LVNC is poor and the notion that 
LVNC is a distinct cardiomyopathy remains to be clarified. There is considerable genetic 
overlap of different morphological phenotypes of cardiomyopathy, and while a number of 
genetic mutations associated with LVNC have been reported, a true causal relationship 
between reported mutations and LVNC is yet to be established.
101
 Comprehensive diagnostic 
assessment – including multimodality imaging, systematic and comprehensive pedigree 
analysis, family screening and genetic testing – is required to further characterise the 
morphological expression and myocardial phenotype of genetic mutations. The common 
complications of LVNC are HF, arrhythmias, SCD, and systemic embolism. Currently there 
are no specific treatment guidelines for LVNC and further prospective studies are necessary 
to develop effective treatment strategies.
102




Figure 1.10. Left ventricular non-compaction 
A and B. Echocardiogram of an infant with LVNC (short axis view). Short axis view of the left 
ventricle with colour Doppler demonstrating flow within the intertrabecular recesses; C. CMR 
short axis view of a normal adult heart; D. CMR short axis view of a heart of an adult patient 
with LVNC. 
 
Images: CMR of IMHOTEP study participants; echocardiographic images of IMHOTEP 
participant provided by G. Comitis, Division of Paediatric Cardiology, Red Cross War Memorial 









The definition of myocarditis utilised in published studies is variable but the term ‘myocarditis’ 
applies to acute or chronic inflammatory disease of the myocardium due to environmental or 
endogenous triggers. The specific causes of myocarditis are diverse and both infectious 
(viruses, bacteria, fungi, parasites) and non-infectious (giant cell myocarditis, drug-induced 
hypersensitivity, organ/tissue/antigen-specific autoimmune conditions such as systemic lupus 
erythematosus and sarcoidosis) causes of myocarditis have been described.
103
 While the 
diagnosis of myocarditis has traditionally been based on established histological, 
immunological and immunohistochemical criteria, published CMR criteria for myocarditis are 
universally accepted,
104
 and newer more sensitive and specific CMR sequences have 
demonstrated improved diagnostic and prognostic value.
105
   
 
The burden of myocarditis as a contribution to prevalent HF varies by age and region and is 
estimated to range from 0.5% to 4%.
106
 Cooper et al. highlighted that the lack of substantial 
data worldwide has hindered epidemiological analysis.
 
The requirement of sophisticated tests, 
including endomyocardial biopsy (EMB) and CMR, restricts the ability to diagnose myocarditis, 
and identification of cases in cross-sectional studies is limited.
106
   
 
Myocarditis is an underdiagnosed cause of sudden death and DCM in both adults and 
children.
106
 Data from Western Europe and North America indicate that myocarditis presenting 
as acute DCM in adults has a high mortality and a low likelihood of complete LV recovery. The 
prospective US Myocarditis Treatment Trial reported a mortality rate of 20% at 1 year and 
56% at 4.3 years.
107
 A large single-centre registry of biopsy-proven myocarditis from Boston 
reported 1 and 5-year survival rates were 79% and 56%, respectively.
108
 In Italy, registry data 
showed that the risk of death or OHT was 27% with an average duration of follow-up of 23 
months.
109
 In Germany, a series of 203 patients with viral genome-positive cardiomyopathy 
and a mean follow-up of 4.7 years revealed a 19.2% all-cause mortality, 15% cardiac-related 
44 
mortality and 9.9% SCD rate.
110
 Myocarditis has been shown to be the most common cause 
of DCM in children in North America: The Paediatric Cardiomyopathy Registry found that 




Although DCM has been identified as a major cause of HF throughout Africa,
2
 there are only 
a few small single-centre studies looking at the prevalence of myocarditis in African patients. 
These studies suggest that myocarditis may play a significant role in the pathogenesis of HIV-
associated cardiomyopathy and idiopathic DCM in Africa.
112-114
 In a study conducted in South 
Africa, Shaboodien et al. reported that myocarditis was present in 44% of HIV-associated 
cardiomyopathy cases, 36% of heart transplant recipients, and 25% of participants with 
idiopathic DCM. While acute myocarditis was present in 50% of HIV- and heart transplant-
associated myocarditis cases, it was chronic in all those with idiopathic DCM.
114
 In a study 
looking at 103 HIV-infected individuals without known CVD, Ntusi et al. found CMR-detected 
evidence of subclinical myocardial oedema and an increased incidence of pericardial 
effusions, providing additional evidence for chronic myocardial inflammation in HIV infected 
patients.
115
 The true incidence of myocarditis in patients presenting with new onset DCM with 
HF in Africa is unknown.  
   
1.4.  ROLE OF CARDIOVASCULAR MAGNETIC RESONANCE IMAGING IN 
CARDIOMYOPATHIES AND MYOCARDITIS 
The fundamental aims of the diagnostic work-up of suspected cardiomyopathy are to 
accurately define the phenotypic characteristics, identify potentially treatable causes and risk 
stratification for prognostic purposes, so that directed medical and interventional therapy can 
be instituted timeously.
14,23
 CMR provides key information in a single non-invasive study that 
includes anatomical dimensions, ventricular function, tissue characterisation (particularly the 
presence of inflammation), and the presence, extent and location of fibrosis. Cine-CMR 
provides accurate and reproducible quantification of ventricular volumes, ejection fraction and 
45 
LV mass, making it the ideal imaging modality in both the clinical and research settings.
116,117
 
CMR has emerged as the gold standard for assessing RV volumes and function due to its 
complex geometry and the recognised limitations of other imaging techniques such as 
echocardiography and angiography.
118,119
 CMR has therefore become the imaging modality of 
choice in ARVC and is a crucial part of the diagnostic work-up in these patients.  
 
The relative safety of gadolinium agents and the lack of ionising radiation exposure allows for 
repeated imaging to review response to treatment, conduct periodic family screening and 
perform serial risk stratification. Additionally, by utilising different imaging techniques, CMR 
can be diagnostic for certain conditions such as myocarditis, Anderson-Fabry disease, 
amyloidosis and cardiac iron overload,
104,120-122
 and further invasive investigations such as 
EMB may be deferred. Non-contrast tissue characterisation with T2-weighted imaging can be 
used to detect acute myocyte oedema and interstitial fluid accumulation.
123
 Native T1 mapping 
has been shown to be significantly more sensitive than T2-weighted imaging and late 
gadolinium enhancement (LGE) in detecting acute myocarditis, identifying larger extent of 
myocardial involvement, and diagnosing additional cases with small focal areas of 
injury.
104,105,124,125
 Furthermore, myocardial inflammation can be detected using T2 mapping, 
as myocardial T2 increases in the presence of oedema, and myocardial extracellular volume 
(ECV), a surrogate marker of fibrosis (in the absent of confounders such as infiltration), can 
be calculated using T1 mapping tissue characterisation.
126
 LGE is able to detect focal 
myocardial fibrosis or infiltration, and is a powerful tool for distinguishing between ischaemic 
and non-ischaemic aetiologies of myocardial dysfunction
127
 (Figure 1.11.). Several studies 
have shown the prognostic significance of LGE in cardiomyopathy.
128
 The presence of LGE is 
an independent predictor for adverse outcomes, including SCD/ventricular tachycardia (VT), 
hospitalisations and all-cause mortality in DCM,
129
 and a 3.4-fold greater risk of major adverse 
events in HCM, with the risk being proportional with the amount of LGE-detected fibrosis 
present.
130




 Published data on CMR in African patients with cardiomyopathy 
is extremely limited. 
 
 
Figure 1.11. CMR of patient excluded from IMHOTEP with ischaemic LV dysfunction 
Images: CMR of IMHOTEP study participant 
 
1.5.  GENETIC CARDIOMYOPATHIES 
Genetic cardiomyopathies warrant close study because they are often present in younger 
individuals,
26,28
 and are an important cause of mortality and morbidity in the young.
27,64
 
Correctly identifying the definitive disease-causing mutation in an index case potentially 
affords a gold standard diagnostic marker for the presence or absence of the pathogenic 
substrate among relatives. If able to identify a pathogenic mutation in an affected individual, 
family screening provides a unique opportunity to offer early diagnosis, risk stratification and 
intervention preventatively or early on in the disease process.
58,64,132,133
 There is evidence that 
genotype has a role in risk stratification in both individual and families. For example, Lamin 
A/C mutation are associated with high penetrance in young asymptomatic genotype-positive 
relatives, frequent conduction abnormalities and ventricular arrhythmias, and a high (19%) 
likelihood of requiring cardiac transplantation.
134
 In many parts of the world, genetic testing in 
inherited heart disease has become standard of care,
58,135
 but it is not currently available 
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outside of the research setting on the African continent. The complexity of cardiomyopathy 
and genetic testing increasingly supports a model of clinical care involving a specialist unit 
with cardiologists, geneticists and genetic counsellors, able to collectively manage these 




The genetic complexity underpinning the cardiomyopathies remains a challenge in both 
research and clinical practice, and molecular genetic results often require nuanced 
interpretation, rather than definitive labelling of variants as pathogenic or benign.
133
 While the 
cardiomyopathies are classified into different morphological sub-types, there is significant 
genetic and phenotypic overlap between the different subtypes (Figure 1.12.).
29
 
Cardiomyopathy-associated mutations are notable for substantial variation in clinical 
expression. In addition to genetic heterogeneity and allelic variations contributing to variable 
clinical phenotypes and disease severity – background genomic variation, environmental 
exposures and lifestyle also account for variable clinical manifestations of disease even within 
families with identical mutations.
133
 Furthermore, next generation sequence analysis of 
disease and control cohorts have demonstrated that 60-90% of cardiomyopathy mutations are 
“private” – i.e. unique to a single family.
137,138
 These complexities pose significant challenges 
for clinicians when interpreting genetic results and their application into clinical practise, 
particularly with regards to risk stratification in family members. While the advancement of 
sequencing techniques, the development of pathogenicity prediction tools and the building of 
publicly available resources showing variant frequency in large populations (e.g. The Exome 
Aggregation Consortium – ExAC) has strengthened our ability to predict pathogenicity,
139,140
 it 
has also cast doubt on some cardiomyopathy-associated variants previously identified by 
candidate gene analysis.
141
 This has led to the reassessment of Mendelian gene pathogenicity 
showing that rare variation is not always clinically informative, and improved interpretation for 
specific genes and variant classes is necessary to increase the clinical utility of genetic testing 
in these conditions.
141
   Importantly, the frequency of specific variants appears to differ among 
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people of different ancestry.
140,142
 The interpretation of variants, therefore, relies on the 





Figure 1.12. Relationship between genes associated with cardiomyopathies and related 
phenotypes  
From: Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a 




1.6.  RATIONALE FOR THIS RESEARCH 
There is a need for large population-level studies of the incidence and prevalence of HF and 
cardiomyopathy in Africans, to influence decision-making for resource allocation for the 
prevention and treatment of CVD. Along with epidemiological surveys, molecular genetic 
studies of cardiomyopathy represent a new frontier for cardiovascular research in Africa. The 
advent of advanced methods of genotyping provide an opportunity for research in the field of 
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cardio-genetics and the determination of the cost-effectiveness of molecular testing in the 
diagnosis and management of patients with inherited cardiomyopathies in low-to-middle-
income countries (LMICs). We currently do not have sufficient information on the yield of 
genetic testing within the African population or the impact of genetic testing on outcomes in 
limited resource settings, to justify the cost of diagnostic genetic testing for cardiomyopathies 
on the continent. The core of human genetic studies is the careful and comprehensive 
phenotyping of patients and their family members, and the correlation of those phenotypes 
with genetic information. CMR provides an abundance of phenotypic information in a single 
study and is, therefore, the ideal imaging modality to facilitate genotype-phenotype 
correlations in cardiomyopathy. Furthermore, on a continent where infectious diseases are 
endemic, little is known about the contribution of infectious aetiologies to the burden of 
cardiomyopathies in Africans or the interplay between genetic and environmental factors in 
the natural history of disease in this context. The tissue characterisation capabilities of CMR 
provides a unique opportunity to study the contribution of inflammatory conditions to the 
burden of heart muscle disease in our population.      
 
This work represents the building of a clinical research platform that is able to provide 
information on epidemiology and clinical outcomes in patients with heart muscle disease from 
different regions of Africa, in addition to providing detailed phenotyping of individuals and 
families with inherited cardiomyopathies to facilitate molecular genetics research on the 
continent. The variable clinical expression and age of onset of cardiomyopathies challenges 
the traditional divide between paediatric and adult clinical care and research, and highlights 
the necessity for long term follow-up of individuals with cardiomyopathy, and their families. 
IMHOTEP has therefore been designed to address the deficiencies in our understanding of 
the epidemiology, aetiology, genetic predisposition and patient outcomes associated with 
heart muscle disease in both adults and children in Africa, and facilitate the study of families 
affected by these conditions. The rationale for the design of IMHOTEP is explored further in 
chapter 3. 
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1.7.  STUDY HYPOTHESES 
There are a number of research questions/hypotheses on which this work is based, and while 
they are not novel, our depth of understanding of these concepts in the African population is 
limited: 
1) Cardiomyopathy is caused by familial (genetic) and non-familial (secondary) factors; 
2) There is an overlap in the molecular genetic causes and phenotypic expression of 
different morpho-functional types of cardiomyopathy; 
3) Secondary factors (such as myocarditis, pregnancy, etc.) are present in a significant 
proportion of cases where they serve as triggering factors in familial cases and 
causative factors in non-familial cases; 
4) The outcome of cardiomyopathy in Africans is poor and is influenced by genetic and 
non-genetic factors. 
 
1.8.  STUDY AIMS 
The primary aim of this study was to develop a comprehensive and multi-centre clinical registry 
and database to systematically capture demographic, clinical, electrocardiographic, imaging, 
histological, genetic and outcome data on adults and children diagnosed with different 
morpho-functional types of cardiomyopathy and myocarditis in Africa (the African 
Cardiomyopathy and Myocarditis Registry Program – IMHOTEP) (Chapter 3). 
 
A number of sub-studies were designed to address the above-mentioned research 
hypotheses, and were implemented as part of the single-centre pilot phase of IMHOTEP. The 
aims of these sub-studies were as follows: 
  
1) to reclassify all patients referred to the Arrhythmogenic Right Ventricular 
Cardiomyopathy Registry of South Africa according to the updated 2010 task force 
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criteria, and report the demographics, clinical and genetic features, and the outcomes 
in ARVC in South Africa (Chapter 4); 
2) to describe the baseline characteristics and vital status of prevalent cases of familial 
and non-familial forms of DCM incorporated from existing studies into IMHOTEP 
(Chapter 5);  
3) to report preliminary data on the baseline clinical characteristics, CMR features and 
application of the 3-stage diagnostic approach in adult incident cases recruited to 
IMHOTEP from the initiating centre, Groote Schuur Hospital (Chapter 6); 
4) to describe the inheritance patterns and phenotypic expression in existing and new 
families with various forms of familial cardiomyopathy incorporated into IMHOTEP 




CHAPTER 2: Methods 
A detailed description of the methods for each study is included in the chapters that follow.  A 
brief overview of the thesis methodology is described below. 
 
2.1.  STUDY DESIGN 
The African Cardiomyopathy and Myocarditis Registry Program (IMHOTEP) is an on-going, 
multi-centre, hospital-based longitudinal observational study. The principal aim of IMHOTEP 
is to define the baseline characteristics and clinical course of the different morphological types 
of heart muscle disease, with particular focus on primary (genetic) and secondary 
cardiomyopathies, and myocarditis.  IMHOTEP has 2 different arms to facilitate the study of 
both retrospective and prospective patient cohorts: (1) a prevalent cases arm, based on the 
inclusion of existing cases of cardiomyopathy and the amalgamation of existing studies (A 
Clinical and Genetic Study of Familial Dilated Cardiomyopathy in South Africa HREC REC 
197/96; The Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa 
HREC 047/2003); and (2) an incident cases arm, which includes new cases of cardiomyopathy 
and myocarditis recruited based on a new phenotyping and investigative approach.  In 
addition, IMHOTEP has a third arm for ‘relatives’ to facilitate the study of families with inherited 
cardiomyopathies.  
 
It should be noted that some participants from existing studies (A Clinical and Genetic Study 
of Familial Dilated Cardiomyopathy in South Africa HREC REC 197/96; The Arrhythmogenic 
Right Ventricular Cardiomyopathy Registry of South Africa HREC 047/2003) and relatives 
enrolled in family studies were recruited retrospectively, therefore, the date of initial 
presentation and death may precede the date of study commencement. This accounts for 
longer follow-up periods in the outcomes studies presented in chapters 4 and 5.  
53 
2.2.  STUDY POPULATION 
For the purposes of this doctoral thesis, the study population is limited to prevalent cases 
recruited by the studies mentioned above, newly identified prevalent cases of cardiomyopathy 
attending follow-up in the Cardiac Clinic at Groote Schuur Hospital, newly diagnosed (incident) 
cases of cardiomyopathy referred to the Cardiomyopathy Clinic, and relatives of affected index 
patients. Patient eligibility is discussed in chapter 3. 
 
Additional note: Existing cases with HCM recently reported on by Ntusi et al.60 have been 
incorporated into IMHOTEP in order to facilitate long-term follow-up; however, this cohort of 
patients is not included in this thesis.  
 
2.3.  DATA COLLECTION AND MEASUREMENTS 
The development of the study protocol and data collection tools formed part of the mandate 
for this doctorate, and included the development of clinical algorithms to ensure precise 
diagnosis (Appendix G), standard operating procedure (SOP) algorithms (Appendix H), and 
study tools, including informed consent forms (Appendix B – E), information sheets for 
participants on genetics research and cardiomyopathies (Appendix F), and case report forms 
(CRFs) (Appendix I) for data acquisition. Consent forms and information sheets were 
translated into local languages, including English, Afrikaans, Xhosa, Sesotho, and 
Portuguese.  The development of these tools was conducted by the candidate in consultation 
with supervisors. 
 
In conjunction with the University of Cape Town (UCT) Clinical Research Centre, an electronic 
database for IMHOTEP has been developed on the OpenClinica platform 
(https://srvwinocs003.wf.uct.ac.za/OpenClinica/pages/login/login). Patient data (including 
patient demographics, medical history, co-morbidities, investigations, procedures, adverse 
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events, management and genetic information) has been collected using this newly developed 
database, designed to meet the following specifications, as outlined in the study protocol:  
• Advanced security features with regard to data storage protected by firewalls, user 
privileges and access procedures 
• Automatic backup systems 
• Built-in audit trails 
• Data filtering, sanitisation* and data type checking systems 
• Data import and export systems 
• The ability to hold multiple relational database tables within a single database 
The IMHOTEP database became fully operational in 2016 under the governance of the 
University of Cape Town. The design and content of the IMHOTEP database was led by the 
candidate. 
 
2.4.  STATISTICAL ANALYSIS 
International Business Machines (IBM) Statistical Package for Social Sciences (SPSS) 2017 
(Version 25.0, Chicago, USA) and Stata/IC (Version 15.1, StataCorp, USA) software were 
utilised to analyse data. Descriptive statistics were used to describe and draw inferences 
about the study population and the results have been reported in table format. Categorical 
data has been reported as number and proportion. Chi-squared test of equal proportions was 
utilised to determine differences between categorical data. Continuous variables were tested 
for distribution using a histogram for visualisation and Shapiro-Wilks for test of normality. 
Normally distributed data has been reported as mean and standard deviation (SD), and 
Student’s t-test (2 samples) and ANOVA (more than 2 samples) were used to determine 
statistically significant differences between groups. Non-normally distributed data has been 
                                                
*
 Data sanitisation is the process of deliberately and irreversibly removing or destroying data 
stored on a memory device to make it unrecoverable. 
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reported as median and interquartile range (IQR), and Wilcoxon sum rank (2 samples) and 
Kruskal-Wallis (more than 2 samples) were used to determine differences. Survival was 
determined using Kaplan-Meier survival analysis and Cox proportional hazards regression 
analysis was used to explore the risk factors for composite outcomes. All statistical tests were 
two-sided, at α = 0.05. Statistical analysis was performed by the candidate in consultation with 
a statistician. Survival analysis was conducted by a statistician.   
 
2.5.  ETHICAL CONSIDERATIONS 
All research has been conducted in accordance with the Helsinki declaration,
143
 with the 
primary purpose of understanding the causes, development and effects of disease and to 
improve preventive, diagnostic and therapeutic interventions, as stated in the declaration.    
2.5.1. Human Research Ethics Committee approval 
Approval from the UCT Human Research Ethics Committee (HREC) for the Rationale, Design 
and Implementation of the African Cardiomyopathy and Myocarditis Registry Program 
(IMHOTEP) was initially obtained on 21 October 2014 (HREC 766/2014), incorporating the 
previously approved studies: A Clinical and Genetic Study of Familial Dilated Cardiomyopathy 
in South Africa (HREC 197/96) and The Arrhythmogenic Right Ventricular Cardiomyopathy 
and Myocarditis Registry of South Africa (HREC 047/2003). Annual progress reports have 
been submitted in accordance with HREC requirements (Appendix A).  
2.5.2. Informed consent 
All subjects were required to give informed consent for their participation in this study, with the 
exception of deceased individuals where waver-of-consent has been approved by the UCT 
HREC. These exceptions primarily relate to the study of familial disease, where clinical 
information of deceased relatives is collected for the purposes of understanding disease within 
a family, whereby living affected individuals within the same family have consented to 
56 
participate in clinical research. For prospective (incident) participants, informed consent 
(Appendix B) was obtained at the time of recruitment. In accordance with current practises, a 
separate consent form was completed and signed prior to the drawing of blood for 
deoxyribonucleic acid (DNA) analysis and storage. While existing DNA consent forms were 
initially utilised, newly designed DNA consent forms (Appendix E) and information sheets for 
participants on cardiovascular genetics research (Appendix F[I]) were created through the 
course of the study and submitted to HREC for approval. For retrospective participants, 
informed consent was obtained at the time of recruitment into existing studies (mentioned 
above) or at the time of DNA specimen collection. Information sheets on the various types of 
cardiomyopathies have been provided to participants where possible (Appendix F[II-VI]).  With 
the inclusion of minors into IMHOTEP, assent forms for children over the age of 8 years 
(Appendix C), and illustrated consent forms for younger children were developed (Appendix 
D).     
2.5.3. Other ethical considerations 
All investigations and procedures recorded in this study were performed based on clinical 
indications and published guidelines that comply with current standard of care of 
cardiomyopathy and myocarditis. No additional costs were incurred by participants, as 
investigations, treatment and follow-up were conducted according to clinical indications. 
Although CMR is considered standard of care, it is not a universally available resource in our 
clinical setting, therefore a number of CMR studies were performed as research-funded 
studies. Routine informed consent for magnetic resonance imaging (MRI) was taken from all 
participants who had CMR imaging done as per clinical practice in our institution. In these 
instances, the results of CMR studies performed were shared with patients’ attending 
clinicians. Participant confidentiality has been maintained through the use of a unique 
identification number, and study procedures have been conducted in accordance with the 
Data Protection Act.     
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2.6.  SAFETY 
Due to the observational nature of this study, investigations performed were done as part of 
clinical care and according to clinical indications.  Blood specimen collection for DNA was 
done by a nursing sister (or doctor) trained in phlebotomy and standard safety precautions 
were adhered to. The Hatter Institute Cardiovascular Genetics Laboratory guidelines for the 
collection and transfer of blood specimens were followed. Resuscitation equipment was 
available in all facilities, including the UCT Clinical Research Unit and the Cape University 
Body Imaging Centre (CUBIC), where participants were seen or imaged.    
58 
CHAPTER 3: Rationale and design of the African 
Cardiomyopathy and Myocarditis Registry Program: The 
IMHOTEP Study 
3.1.  INTRODUCTION 
Akinkugbe and colleagues observed several decades ago that “the cardiomyopathies pose 
the greatest challenge of all the CVDs in Africa because of their greater prevalence in societies 
still plagued by diseases of famine and pestilence; the difficulty in diagnosis, which often 
requires specialised cardiological investigations that are lacking in resource-poor 
environments; the lack of access to effective interventions; and the high mortality associated 
with these often irreversible disorders of heart muscle”.
144
 Cardiomyopathy contributes 20–
30% of cases of HF in adults in Africa.
6
 There is, however, limited information on the aetiology, 
treatment, outcome and prevention of cardiomyopathy in African individuals.
145
 The relatively 
younger age of onset of HF in African patients
2
 and higher incidence of PPCM,
146
 affecting 
women of childbearing age, reported in LMICs compared with HICs countries has major 




Over the past 25 years, molecular genetic investigations conducted outside of Africa have 
identified specific genetic causes of cardiomyopathy, and this information has been applied 
increasingly in clinical practice to diagnose and manage these conditions.
148
 The Heart 
Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) have put forward 
expert consensus recommendations for genetic testing of specific CVDs, using diagnostic, 
prognostic and therapeutic impact as indicators or contra-indicators for genetic testing.
135
 
Molecular genetic studies of inherited cardiomyopathies have revealed genetic and allelic 
heterogeneity which renders the traditional molecular methodologies too labour-intensive and 
expensive for routine clinical practice.
149
 Recent advances in high throughput genotyping and 
sequencing technologies have facilitated the transition of genetic testing for many 
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cardiovascular disorders from specialised research to the diagnostic laboratories, as they offer 
a dramatic increase in the throughput of DNA sequencing, at a reasonable cost.
149-151
 
Diagnostic genetic screening is not widely available on the African continent, and our 





A recent review on myocarditis highlighted the lack of reliable epidemiological and clinical data 
worldwide. The burden of myocarditis as a percentage of prevalent HF varies from 
approximately 0.5% to 4%, although it is recognised that this figure is likely an underestimation 
due to diagnostic difficulty.
106
  DCM is a major cause of HF in Africa,
156
 but due to the lack of 
readily available diagnostic tools, myocarditis has rarely been identified and consequently data 
regarding the contribution of myocarditis to the pathogenesis of DCM are limited.
114
 Our 
understanding of the epidemiology, presentation and natural history of myocarditis comes 
from Western Europe and North America.
157
 A number of studies from different regions of the 
world report acute myocarditis as an important cause of SCD and chronic DCM in both adults 
and children.
51,106
 The dearth of information on the causes, outcome and treatment of 




3.2.  RATIONALE 
The paucity of data on aetiology, treatment and outcome of cardiomyopathy and myocarditis 
limits our ability to diagnose, manage and prevent these conditions at population and 
individual levels in Africa.
145
 The IMHOTEP registry has been designed to elucidate the 
aetiology, clinical features, outcome and management of all forms of cardiomyopathy and 
myocarditis in children and adults presenting to referral centres from all regions of Africa.  
 
The design of IMHOTEP as a single registry that includes all forms of cardiomyopathies is 
based on several observations: (1) It is well recognised that there is significant genetic and 
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phenotypic overlap between the different morphological and functional types of 
cardiomyopathy,
64
 thus raising the possibility that different morpho-functional types of 
cardiomyopathy may be on a phenotypic and genotypic continuum; (2) cardiomyopathies are 
caused by both familial (genetic) and non-familial (secondary) aetiologies,
13
 but the interplay 
between genetics and environment is not well understood; (3) myocarditis may be present in 
a significant proportion of cases where it serves as a causative factor in non-familial 
cardiomyopathy or a triggering factor for the symptomatic presentation of genetic disease, 
which may be expected to be more likely in Africa where there is a high prevalence of 
infectious disease with cardiac involvement, such as HIV infection; (4) EMF is endemic in 
certain peri-equatorial regions of Africa, including northern Mozambique, where the 
prevalence is as high as 19.8%, affecting young individuals between the ages of 10 and 19 
predominantly
69
 and carrying a case fatality rate of up to 75% at 2 years.
158
  Although the 
pathogenesis of EMF is not known, it has been postulated that the conditioning factors may 
be geography, poverty and diet, the triggering factor may be an unidentified infective agent, 
and the perpetuating factor is eosinophilia.
8,159,160
 Although there have been reports of familial 
aggregation and putative genetic association in the human leucocyte antigen (HLA) region in 





The IMHOTEP study includes adults and children because cardiomyopathies affect individuals 
of all ages.  Certain endemic conditions, such as EMF, affect children and adolescents 
predominantly.
69
 Patients presenting in childhood with severe disease provide a unique 
opportunity to study both genetic and environmental factors contributing to the development 
of cardiomyopathy, without the influence of co-morbidities and lifestyle confounders often 
present in adults.  
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3.3.  STUDY DESIGN, MATERIALS AND METHODS 
3.3.1. Study population  
IMHOTEP is a pan-African, multi-centre, hospital-based cohort study with two arms: (1) the 
‘incident cases’ arm involves the enrolment of new unrelated cases of cardiomyopathy and 
myocarditis; and (2) the ‘prevalent cases’ arm involves the enrolment of existing unrelated 
cases of cardiomyopathy and myocarditis.  The prevalent cases arm of the study includes the 
integration of existing studies from Cape Town - the Clinical and Genetic Study of Familial 
DCM in South Africa which was initiated in 1996,
4,26
 and the ARVC Registry of South Africa 
which was initiated in 2004.
95,96
 Furthermore, in cases of familial cardiomyopathies, both 
affected and unaffected relatives of incident and prevalent cases have been recruited.  
Incident cases, prevalent cases and relatives have been followed prospectively from the time 
of enrolment in IMHOTEP.  
 
3.3.2. Objectives  
The IMHOTEP study has been designed to address the following objectives: 
 
Primary objectives 
1. To describe the clinical, electrocardiographic, imaging, histological and genetic 
characteristics of cardiomyopathy and myocarditis in children and adults in Africa 
2. To describe the management of cardiomyopathy and myocarditis in children and adults 
in Africa 
3. To estimate the complications associated with cardiomyopathy and myocarditis in 
children and adults in Africa 
4. To determine the overall survival experience of children and adults diagnosed with 




1. To identify barriers to the use of evidence-based guidelines in the management of 
patients with cardiomyopathy and myocarditis in Africa 
2. To provide a platform for studies of the pathogenesis, trials of treatment and prevention 
of mortality and morbidity in patients with cardiomyopathy and myocarditis in Africa 
 
3.3.3. Study eligibility  
Patients with known (i.e. prevalent cases) or newly diagnosed (i.e. incident cases) 
cardiomyopathy or myocarditis who have undergone diagnostic evaluation at a participating 
centre are eligible for inclusion in IMHOTEP. The ESC definitions and classification of 
cardiomyopathy have been used as inclusion and exclusion criteria for IMHOTEP (Table 3.1 
and 3.2).
13
 The clinical definitions of hypertension and coronary artery disease have been 
adapted to accommodate low resource settings by expanding the clinical definitions of these 
conditions to guide clinicians in circumstances where sophisticated investigations are not 
accessible. In keeping with the ESC classification, secondary cardiomyopathies have been 
included. The diagnosis of myocarditis has been made according to the clinical classification 





Table 3.1. Cardiomyopathy phenotype definitions 
Phenotype  Description  
DCM Dilated cardiomyopathy is characterised by the presence of left ventricular dilatation 
and left ventricular systolic dysfunction in the absence of abnormal loading conditions 
(hypertension, valve disease) or coronary artery disease sufficient to cause global 
systolic impairment.* Right ventricular dilation and dysfunction may be present but are 
not necessary for the diagnosis. 
PPCM  Peripartum cardiomyopathy is classified as a subtype of dilated cardiomyopathy; 
defined as a cardiomyopathy presenting with heart failure secondary to left ventricular 
systolic dysfunction (LVEF < 45%), with or without LV dilatation, towards the end of 
pregnancy (last trimester) or in the months following delivery (usually within 5 months 
postpartum), where no other cause of heart failure is found.
33,162
  
HCM Hypertrophic cardiomyopathy is characterised by the presence of increased 
ventricular wall thickness or mass, in the absence of haemodynamic stresses 
sufficient to account for the degree of hypertrophy. This definition includes 
conditions in which there is myocyte hypertrophy and those in which left ventricular 
mass and wall thickness are increased by interstitial infiltration or intracellular 
accumulation of metabolic substrates. 
ARVC Arrhythmogenic right ventricular cardiomyopathy is characterised by presence of right 
ventricular dysfunction (global or regional), with or without left ventricular disease, in 
the presence of histological evidence for the disease and/or electrocardiographic 
abnormalities in accordance with published criteria.
73
 
RCM Restrictive cardiomyopathy is characterised by the presence of restrictive ventricular 
physiology in the presence of normal or reduced diastolic volumes (of one or both 
ventricles), normal or reduced systolic volumes, normal ventricular wall thickness, and 
normal or reduced systolic function. 
LVNC Left ventricular non-compaction is characterised by prominent left ventricular 
trabeculae and deep inter-trabecular recesses. The myocardial wall is often thickened 
with a thin, compacted epicardial layer and a thickened endocardial layer. In some 
patients, LVNC is associated with left ventricular dilatation and systolic dysfunction. 
Diagnosis should be confirmed by fulfilment of published imaging criteria.
163,164
   
* Parameter definitions may vary depending timing of assessment in the natural history of disease and 
the phenotypic expression. Strict echocardiographic criteria for left ventricular dilatation and systolic 
dysfunction are: LVEDD >117% of the predicted value corrected for age and BSA, and LVEF < 45% 




Definitions adapted from: Elliott P, et al. Classification of the cardiomyopathies: a position statement 
from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur 
Heart J. 2007;29(2):270-276. 
 
BSA, body surface area; FS, fractional shortening; LVEDD, left ventricular end-diastolic diameter; LVEF, 
left ventricular ejection fraction. 
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Table 3.2. IMHOTEP inclusion and exclusion criteria 
Inclusion criteria: Persons of all ages living in Africa with any of the following: 
Autopsy diagnosis Cardiomyopathy or myocarditis, based on currently accepted definitions 
Idiopathic cardiomyopathies  Aetiology unknown 
Familial cardiomyopathies Hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic 
right ventricular cardiomyopathy/dysplasia, restrictive cardiomyopathy, 
left ventricular noncompaction, mixed forms of cardiomyopathy 
Neuromuscular disorders 
with cardiac involvement 
Disorders that are atypical and/or are genotype negative for classical 
neuromuscular disorders on genetic screening 
Non-familial or secondary 
causes of cardiomyopathy 
Myocarditis (infective/toxin/immune), human immunodeficiency virus 
(HIV), drugs/toxins, peripartum, endocrine, nutritional, obesity, alcohol, 
tachycardiomyopathy, eosinophilic, Kawasaki disease, Takotsubo 
cardiomyopathy, amyloidosis, autoimmune, endomyocardial fibrosis, 
carcinoid heart disease, Radiation 
Myocarditis Acute or chronic myocarditis 
Exclusion criteria: Persons with any of the following 
Systemic arterial 
hypertension 
Blood pressure ≥160/100mmHg documented and confirmed at repeated 
measures 
Consider HHD in patients in patients with BP < 160/100:  
• History of longstanding hypertension with dilated LV and 
impaired systolic function  
• High normal (BP ≥ 130/85) or grade 1 hypertension (BP ≥ 
140/90) in patients with systolic dysfunction and concentric LVH, 
particularly if on blood pressure lowering medications 
• Evidence of hypertensive target organ damage – nephropathy, 
retinopathy, LVH, small vessel disease  
Coronary artery disease 
(ischaemic heart disease)  
Coronary artery obstruction >50% of the luminal diameter of a major 
branch on coronary CTA or coronary angiography 
Where coronary CTA or coronary angiography not available, consider 
CAD in patients with: 
• History of angina, ACS, or previous MI in a patient with risk 
factors for CAD, and/or evidence of previous infarction or 
ischaemia on ECG (Q waves, ST elevation or depression), 
echocardiogram (regional wall motion abnormalities) and/or 
CMR (subendocardial or transmural LGE) 
• Positive exercise stress test 
Pericardial diseases 
 
Primary pericardial disease, e.g. pericarditis, pericardial constriction, 
pericardial effusion (not associated with heart failure) 
Congenital heart disease Ventricular septal defect, atrial septal defect, patent ductus arteriosus, 
coarctation of the aorta, anomalous origin of the left coronary artery from 
pulmonary artery, Tetralogy of Fallot, pulmonary or aortic valve stenosis, 
transposition of the great vessels, hypoplastic right or left ventricle, 
Ebstein’s anomaly, other 
Cor pulmonale Primary pulmonary hypertension, pulmonary disease 
Valvular heart disease Rheumatic heart disease, degenerative valve disease, infective 
endocarditis, valve prolapse, congenital bicuspid valve, other 
LVH, left ventricular hypertrophy; ACS, acute coronary syndrome; HHD, hypertensive heart disease; CTA, 
computed tomography; CAD, coronary artery disease; ECG, electrocardiogram; CMR, cardiovascular 
magnetic resonance; LGE, late gadolinium enhancement 
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Table 3.3. Clinical classification for the diagnosis of myocarditis 
Diagnosis Criteria 
Probable acute myocarditis  In the clinical context of possible myocardial injury with 
cardiovascular symptoms and no evidence of coronary artery 
disease where the following criteria are met: 
 
1. Biomarkers of cardiac injury raised; and 
2. Either of the following: 
a. Wall motion abnormalities and/or left ventricular 
systolic dysfunction on echocardiography; or 
b. Abnormal left ventricular systolic function, left 
ventricular wall motion abnormalities, and abnormal 
tissue characteristics on CMR (increased signal 
intensity ratio on T2-weighted imaging; increased T1 
value and increased T2 value on parametric mapping; 
increased signal intensity on early gadolinium imaging; 
and/or typical pattern on enhancement on late 
gadolinium imaging) 
Definite myocarditis Histological or immune-histological evidence of myocarditis 
CMR, cardiovascular magnetic resonance 
 
3.3.4. Diagnostic approach  
Clinical algorithms, specifically adapted for the limited resource setting, were developed to 
guide clinicians in the appropriate work-up of patients with suspected cardiomyopathy and 
myocarditis. These algorithms illustrate a diagnostic approach that has been adopted in Cape 
Town, based on three stages of investigation: (1) non-invasive stage; (2) invasive stage; and 
(3) genetic stage (Table 3.4.). This approach was adapted from published standard of care 
guidelines,
14,52,161,166
 and highlights the use of core investigations for all patients and optional 
extended tests depending on clinical indication and the availability of resources.   
 
CMR was conducted in adult incident cases recruited in Cape Town, where possible. 
Standardised protocols were utilised to evaluate chamber size and ventricular function, LV 
mass, strain, haemodynamic assessment, tissue characteristics (including native and post-




Table 3.4. Three stage investigative approach to cardiomyopathy and myocarditis – Stage 1 
Stage 1: Non-invasive 
Confirm diagnosis of cardiomyopathy; morpho-functional phenotype and aetiology; exclude alternative causes (see table 3.2); SCD risk assessment 









Basic blood investigations:  
Hb, WCC, renal and liver function 





























Additional diagnostic investigations 
done at the physician’s discretion 
according to clinical indications and 



























free light chainse  
CMR CMR 




SCD risk assessment Holter and/or EST according to published guidelines 
Exclusion of CAD EST, and/or MIBI, and/or coronary CTA according to published guidelines 
aSarcoidosis suspected; bAutoimmune conditions such as systemic lupus erythmatosus or rheumatoid arthritis suspected; c Mitochondrial disorder suspected; 
dHypereosinophilic syndrome suspected; eAmyloidosis suspected; fAnderson-Fabry disease suspected,  
*Viral screen includes coxsackie A/B, parvovirus B19, mumps, rubella, cytomegalovirus, Ebstein Barr virus, echovirus, respiratory viruses, **Metabolic screen 
includes plasma acylcarnitine, urine reducing substances, urine organic acid, urine ketone 
ARVC, arrhythmogenic right ventricular cardiomyopathy; CAD, coronary artery disease; CK, creatinine kinase; CMP, calcium magnesium phosphate; CMR, 
cardiovascular magnetic resonance; CRP, C-reactive protein; CTA, computerized tomography angiography; DCM, dilated cardiomyopathy; Eos, eosinophil; ESR, 
erythrocyte sedimentation rate; EST, exercise stress test; HbA1C, glycosylated haemoglobin; Hb, haemoglobin; HCM, hypertrophic cardiomyopathy; HIV, human 
immunodeficiency virus; LV, left ventricle; LVNC, left ventricular non-compaction; MIBI, myocardial perfusion imaging; RCM, restrictive cardiomyopathy; SACE, 




Table 3.4. Three stage investigative approach to cardiomyopathy and myocarditis – Stages 2 and 3 (continued) 
Stage 2: Invasive – Only undertaken at institutions that have the facilities and expertise, in the following circumstances: 
Diagnostic or etiologic uncertainty, exclusion of CAD, transplantation assessment, SCD risk assessment, arrhythmias 
Not routinely 
undertaken 
 All cardiomyopathies (as per clinical indications) Children 
Extended 
investigations  
TOE: Exclusion of left atrial thrombus prior to cardioversion/EPS, or poor transthoracic views where CMR is not available    
Cardiac catheterization: Exclusion of coronary artery disease OR haemodynamic assessment (diagnostic, transplantation) 
EMB: Indications according to published guidelines173 including:  
• New onset heart failure of < 2 weeks’ duration, a normal sized or dilated LV, and haemodynamic compromise  
• New onset HF with a dilated ventricle, 2 weeks - 3 months of symptoms, new ventricular arrhythmias or Mobitz type 2 
second-degree HB or third-degree HB, or who fail to respond to usual care within 1-2 weeks  
• Diagnostic purposes that will alter management (e.g. giant cell myocarditis, amyloidosis, cardiac sarcoidosis, ARVC) or 
post-transplantation (organ rejection) 
EPS: For assessment of arrhythmias or ablation procedure where required 
SMB: If myopathy or muscular dystrophy suspected 
Indications must 
be individualized 








Stage 3: Genetics (screening for familial/genetic cardiomyopathy) 
All patients Family history and basic pedigree As for adults 
Extended 
investigations 
Extended family pedigree (≥ 3 generation) 
Family screening – indicated in ARVC and HCM, and in DCM and RCM cases with positive family histories 
Molecular genetic testing 
As for adults 
Screen parents 
 
ARVC, arrhythmogenic right ventricular cardiomyopathy; CAD, coronary artery disease; CMR, cardiovascular magnetic resonance; DCM, dilated cardiomyopathy; 
EMB, endomyocardial biopsy; EPS, electrophysiology study; HB, heart block; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left ventricle; LVNC, left 
ventricular cardiomyopathy; SCD, sudden cardiac death; SMB, skeletal muscle biopsy; TOE, transoesophageal echocardiogram;  
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EMB has been recommended in patients with suspected myocarditis based on clinical 
suspicion, or CMR findings, at centres with appropriate facilities and expertise to conduct EMB 
safely and pathologists with the requisite experience. 
 
3.3.5. Medical genetics, counselling and genetic testing  
Blood samples for DNA analysis were collected and processed using standard protocols from 
prevalent and incident cases. Patients received basic genetic counselling and were required 
to sign consent for DNA analysis prior to sample collection. Specimens were transferred to 
the Cardiovascular Genetics (CVG) Laboratory, Hatter Institute of Cardiovascular Research 
in Africa, UCT, for DNA extraction, storage and analysis. The molecular genetic approach (not 
included in this thesis) has been designed to follow three phases (Figure 3.1.). First, all index 
cases will be screened for known molecular genetic causes of cardiomyopathy using targeted 
Next Generation Sequencing (NGS). Basic family pedigrees have been constructed at the 
time of sample collection, and family screening has been conducted in selected cases of 
unexplained and familial cardiomyopathy, with an emphasis on identifying large multiplex 
families (>5 affected members) and family trios in children under the age of 12 years (clinical 
genetics sub-study, Figure 3.2.).  Second, genotype-negative probands from multiplex 
families, and children with severe early-onset cardiomyopathy (in parent-offspring trios), will 
be subjected to whole exome sequencing (WES) to identify novel genetic causes of 
cardiomyopathy. We aim to apply this approach to approximately ±10 multiplex families and 
±40 parent-offspring trios. Finally, the genotype-negative cases not included in stage two will 
be screened for the novel genetic mutations that are identified in this and other studies. This 
approach will provide a comprehensive analysis of established and new genetic causes of 




Figure 3.1. Three phase molecular genetics sub-study 
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Incident or prevalent cases 
recruited to IMHOTEP 
AGE 
≤ 12 years > 12 years 
Parents will be invited for: 
• Genetics counselling 
• Family Pedigree 
• Clinical screening  
o History 
o Physical examination 
o ECG 
o Echocardiogram 
• DNA sample collection from both parents 
Parent(s) clinically affected 
OR 





No further family screening 
required unless disease-






No further family screening 
required unless disease-
causing mutation identified   
Invitation to all first-degree relatives for: 
• Genetics counselling 
• Extension of family pedigree 
• Clinical screening  
o History 
o Physical examination 
o ECG 
o Echocardiogram 
• DNA sample collection from relatives 
 
Further investigations of affected individuals 




Extended family screening may 
be required 
Family history of cardiomyopathy 
 
Familial disease is defined as the 
presence of an affected proband and 
at least one first-degree* relative with 
cardiomyopathy 
 




3.3.6. Data collection and management 
All clinical and demographic information has been captured on a secure database, on the 
OpenClinica platform, accessible to all participating centres via the Internet. Entered data has 
been stored on a secure server governed by UCT. Access to the database has been controlled 
by a username and password system. Baseline data has been collected using paper or 
electronic CRFs at the time of recruitment. Data captured on paper CRFs, has been entered 
onto the database by a trained data-capturer. Patients have been asked to complete a 
personal information sheet containing contact details at the time of recruitment.  All patient 
identifiers have been anonymised and recorded separately from clinical and demographic data 
to ensure the confidentiality of participants.  Each participant was assigned a unique 
identification number at the time of recruitment.  
 
As this is an ongoing longitudinal study of both prevalent and incident patients with 
cardiomyopathy or myocarditis, managed according to standard of care guidelines at multiple 
centres with different resource availability, the amount of data recorded varied considerably.  
Mandatory data required at recruitment includes demographics, medical history and 
presenting symptoms, physical examination findings, drug therapy, and basic investigations 
including electrocardiography (ECG) and echocardiography. To accommodate facilities with 
extended expertise, CRFs for all additional specialised investigations (including signal 
average electrocardiogram [SAECG], 24-hour ambulatory ECG, exercise stress tests [EST], 
CMR) and procedures (angiography, EMB, device insertion, electrophysiology studies) have 
been developed and made available on the database. 
 
Data entry was via voluntary submission by participating centres under the guidance of the 
local site coordinator. Incentives to clinicians include the use of an established data collection 
tool for collecting patient information and access to data for their site for purposes of audit and 
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publication. An active system of data collection instituted by an outreach team has been 
implemented with the initiation of additional sites.   
 
Source documents have been stored according to the hospital record-keeping protocols at 
each centre. Informed consent forms, contact information, copied source documents and 
paper CRFs have been stored in a securely locked area on site. Auditing of randomly selected 
sample of cases have been conducted to look for data discrepancies and to ensure data 
quality.  
  
3.3.7. Follow-up  
Follow-up clinic visits have been scheduled according to clinical necessity in accordance with 
standard practice guidelines. Follow-up has been arranged by the attending physician based 
on the patients’ clinical condition. If additional events, investigations or procedures occurred, 
the attending clinician recorded the data using the relevant CRF(s). IMHOTEP requires an 
annual follow-up CRF to be completed that can be done at the time of a follow-up visit or by 
means of a hospital folder and telephonic review to ensure that all symptoms, events, 
investigations and procedures are recorded, thus enabling review of primary and secondary 
outcomes on an annual basis (Table 3.5.). A random sample of 10% of the locally adjudicated 











Table 3.5. Primary and secondary outcome measures 
Primary endpoint/outcome measures Secondary endpoints/outcome measures 
 Death from all causes 
 Hospitalization for heart failurea 
 Embolic stroke/transient ischaemic attack  
 Heart failure (new or decompensated) 
 Resuscitated cardiac arrestb 
 New onset atrial fibrillation 
Death from cardiovascular disease 
Pulmonary embolism 
 Systemic embolism (other than stroke) 
aHeart failure (HF) is defined as a clinical syndrome characterized by typical symptoms (e.g. 
breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated 
jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural 
and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated 
intracardiac pressures at rest or during stress.174 
bCardiac arrest is defined as the cessation of cardiac mechanical activity as confirmed by the 
absence of signs of circulation. Resuscitated cardiac arrest is defined by the restoration of life 
by establishing or maintaining airway (or both), breathing, and circulation through 




3.3.8. Planned genotype analysis  
Extracted DNA samples from all index cases have been batched and transferred to Oxford 
Medical Genetics Laboratory for targeted NGS analysis of the cardiomyopathy related genes 
(Table 3.6.). Selected genotype-negative probands of multiplex families and children with 
severe early-onset cardiomyopathy in family trios will be subjected to WES to identify novel 
genetic causes of cardiomyopathy. The WES analysis will be carried out as previously 
described by our group176 and will also be based on the recent guidelines for assigning 
causality177,178 and will rely on familial transmission over biological plausibility. We note that 
for detection of causative mutations in Mendelian disorders, formal statistical testing is often 
not required; nevertheless, Fisher’s exact test will be used to determine the level of 
significance for mutations detected in any of our 750 cases and not present (or present at 
much lower frequencies) in ethically matched controls using population data from the genome 




Table 3.6. Targeted Next Generation Sequencing for cardiomyopathy related 
genes* 






































α-actinin 2  
ankyrin repeat domain-containing protein 1  
BCL2-associated athanogene 3  
α-crystallin B chain  
cysteine and glycine-rich protein 3  
desmin  
dystrophin  
desmocollin 2  
desmoglein 2  
desmoplakin  
four-and-a-half LIM domains 1  
four-and-a-half LIM domains 2  
filamin C  
α-galactosidase  
junction plakoglobin  
lysosome-associated membrane protein 2  
lamin A/C  
myosin-binding protein C  
β-myosin heavy chain  
regulatory light chain of myosin  
essential light chain of myosin  
plakophilin 2  
phospholamban  
AMP-activated protein kinase  
RNA-binding motif protein 20  
sodium channel protein type 5 subunit alpha  
tafazzin  
transmembrane protein 43  
troponin C   
troponin I type 3  
troponin T type 2  




*including, but not limited to 
 
3.3.9. Statistical analysis 
Descriptive statistics were used to describe the study population; all continuous variables were 
tested for distribution using a histogram for visualisation and Shapiro-Wilks for test of 
normality. Normally distributed data has been reported as mean and standard deviation. Non-
normally distributed data has been reported as median and interquartile range. Categorical 
data has been summarised in tables and reported as number and proportion. Chi-squared test 
of equal proportions has been used to determine differences between categorical data. 
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Wilcoxon sum-rank (2 samples) and Kruskal-Wallis (more than 2 samples) have been used to 
determine differences between non-normally distributed continuous data. Students’ t-test (2 
samples) and ANOVA (more than 2 samples) have been used for normally distributed data. 
Kaplan-Meier survival analysis has been used to explore the survival of cardiomyopathy and 
myocarditis patients in relation to different treatments. All statistical tests were two-sided, at α 
= 0.05. International Business Machines (IBM) SPSS Statistics 2017 (Version 25.0, Chicago, 
USA) and Stata/IC (Version 15.1, StataCorp, USA) software was utilised to analyse data. 
 
We aimed to recruit 750 unrelated probands with cardiomyopathy in this pilot study, conducted 
over a five-year period (2015–2019), involving sites in South Africa and Mozambique. This 
sample size will be adequate for testing the genetic hypothesis and will provide preliminary 
data on outcomes. These data will be used to estimate the minimum sample size for future 
expansion of IMHOTEP to include all the participating centres in IMHOTEP. 
 
3.3.10. Study management  
The Project Coordinating Office (PCO) for IMHOTEP is based in the Department of Medicine 
at UCT. The PCO has been responsible for the management of the registry, the coordination 
of the different centres, overseeing data collection and quality assurance. A project manager 
has been appointed to co-ordinate study procedures. The PCO has overseen the development 
of the CRFs, consent forms, patient information sheets, and management algorithms 
(Appendix B-I), in addition to the development and maintenance of the web-based database. 
A data management plan outlining standard operating procedure has been developed, and a 
data manager and quality assurance officer have been appointed at the PCO to oversee data 
collection. Additionally, the PCO is the statistical consulting site responsible for analysis of 
data. Local site investigators have been appointed at each participating site (List of 
Collaborators – Appendix J). A steering committee (decision-making body) – comprised of the 
principal and co-investigators – and a scientific panel – comprised of experts in the fields of 
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cardiomyopathy, cardiovascular imaging, cardiac electrophysiology, histopathology and 
molecular genetics – has been established.  Support from the Pan-African Society of 
Cardiology (PASCAR), as well as proposed collaborators from other centres was obtained 
prior to the establishment of this registry (Figures 3.3 and 3.4)  
 
 
Figure 3.3. IMHOTEP collaborating countries  
The pilot phase of the IMHOTEP study will be conducted in (1) South Africa and (2) Mozambique 
(green). Recruitment sites for the pilot phase include Cape Town (3 sites), Bloemfontein, Port Elizabeth, 
and Mthatha in (1) South Africa, and Maputo in (2) Mozambique. Following the pilot phase, participating 
sites from countries 4-12 (blue) will initiate recruitment. Additional collaborating institutions not 
represented here include Oxford University (United Kingdom), Mayo Clinic (United States) and King 
Saud Bin Abdalaziz University for Health Sciences (Saudi Arabia).     
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Figure 3.4. Organisational structure of IMHOTEP  
Adult sites (dark blue), paediatric sites (pale blue) 
 
CMR, cardiovascular magnetic resonance; NHLS, National Health Laboratory Service, PI, 




Founding PI: Bongani Mayosi (1 February 2015 – 27 July 2018)
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The study has been approved by the UCT Faculty of Health Sciences Human Research Ethics 
Committee (HREC REF: 766/2014). Participating centres required institutional ethics 
committee approval prior to being established as part of the registry.  For the incident cases, 
informed consent for inclusion into the registry was obtained from participants prior to 
enrolment. In the case of minors (under the age of 18 years), the participant’s parent/guardian 
was required to sign consent.  Additionally, children aged eight and above could sign an assent 
form. In accordance with current practices, a separate consent form was required for DNA 
specimen collection, storage and analysis. Regarding the prevalent case cohort, informed 
consent for participation in research and DNA analysis was obtained from participants when 
they were recruited into the previous studies. Detailed information sheets have been 
developed and were provided to participants.  
 
All invasive investigations have been performed according to prevailing standard of care 
guidelines for cardiomyopathy and myocarditis,14,23,52,161,166 or as part of an approved research 
protocol. There were no additional costs incurred by the participants, as treatment, 
investigations and follow-up have been conducted according to clinical indications.   
  
3.4.  STATUS OF THE STUDY AND STUDY PARTICIPANTS  
The pilot phase of the study commenced at Groote Schuur Hospital in Cape Town on February 
1, 2015, followed by staggered initiation of additional recruitment sites in Cape Town (Red 
Cross War Memorial Children’s Hospital, Tygerberg Hospital - 2016), Mthatha (2017), Port 
Elizabeth (2018) and Bloemfontein (2018). Training was conducted at the Mozambican site in 
November 2018 and recruitment will commence in 2019. A total of 600 index patients have 
been enrolled into IMHOTEP thus far (20 November 2018) from 6 recruitment sites (Figure 
3.5.). We expect that the enrolment of the first 750 participants in the pilot phase of the study 
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will be complete by 30 September 2019, and 18 months (average) follow-up data will be 
available by this time. The first phase of the molecular genetics sub-study has been initiated 
– the first batch of 250 samples have been transferred to Oxford University for targeted NGS 
and analysis. Preliminary clinical data collected at the initiating centre, Groote Schuur Hospital 




Figure 3.5. IMHOTEP recruitment  
Total number of adult and children incident and prevalent cases recruited (above). 
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Cape Town - GSH Cape Town - RXH Cape Town - TBH Port Elisabeth Mthatha Bloemfontein
Incident 204 40 15 11 24 13
Prevalent 248 0 0 5 7 33
Incident Prevalent 
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3.5.  DISCUSSION 
Cardiomyopathy is an endemic non-communicable disease (NCD) of high importance to the 
poor majority in Africa, and is a locally relevant unmet need for research.8,145,159 The IMHOTEP 
study aims to fill knowledge gaps in our understanding of cardiomyopathy and myocarditis, 
specifically related to the African population, by delineating clinical features and molecular 
genetics of the different morpho-functional forms of cardiomyopathy, and obtaining important 
outcome data. As access to healthcare and the availability of sophisticated investigations and 
interventions vary considerably across the African continent, IMHOTEP has been designed to 
record core information required to make a diagnosis of cardiomyopathy or myocarditis and 
key outcome events over a minimum follow-up period of two years in the pilot phase.  
Additionally, IMHOTEP has the facility to record detailed reports of specialised investigations 
and procedures, which can be utilised by those facilities that have the equipment and 
expertise. We have proposed a standardised three-stage investigative approach to the work-
up of cardiomyopathy and myocarditis that can be easily adapted according to resource 
availability (Table 3.4.). 
 
We postulate that myocarditis is underdiagnosed in Africa, due to the requirement of 
sophisticated imaging (like CMR) or invasive investigations (specifically EMB) to confirm the 
diagnosis; by utilising a tailored clinical classification system, we hope to not only improve 
diagnostic yield, but also facilitate better use of available resources. Infectious diseases 
contribute significantly to the burden of disease in African countries,179 highlighting the 
importance of establishing the role of myocarditis in the aetiology, pathophysiology and 
outcomes of cardiomyopathies in Africans. IMHOTEP aims to establish the prevalence of 
myocarditis in patients presenting with new-onset heart failure in Africa, and contribute to the 
development of innovative diagnostic strategies more suitable for resource-limited settings.   
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Internationally, there is a recognised need to conduct more extensive genomic studies in much 
larger cohorts of rigorously phenotyped probands and family members to improve our 
understanding of the genomic basis of inherited cardiomyopathies.29,64 By incorporating the 
prevalent cases that include the amalgamation of several existing studies in which phenotypic 
information and DNA have been collected over the last 20 years, in addition to the collection 
of DNA samples in incident cases, IMHOTEP seeks to assemble one of the largest cohorts of 
cardiomyopathies in African individuals, whereby the genetic origin of disease can be studied. 
The variable expressivity and penetrance seen in genetic cardiomyopathies suggest that 
genetic, epigenetic and environmental modifiers influence disease manifestation, in addition 
to single pathogenic mutations.64 IMHOTEP will provide the platform to address the 
environmental modifying factors that alter the natural history of genetic cardiomyopathy. 
Importantly, IMHOTEP will stimulate the establishment of cardio genetics clinical services in 
Africa and facilitate the development of cost-effective diagnostic strategies to diagnose genetic 
cardiomyopathy in a LMIC setting.  
 
3.6.  STRENGTHS AND LIMITATION 
IMHOTEP is a hospital-based registry and will therefore not address disease burden at the 
population level.  Participating centres will be selected based on the availability of expertise 
required to diagnose cardiomyopathy and myocarditis and exclude alternative cardiac 
conditions such as ischaemic heart disease, hypertension, valvular heart disease, congenital 
heart disease and pericardial disease. This will likely result in an overrepresentation of 
advanced disease and disease-related adverse events, as patients will be recruited from 
tertiary centres (selection bias). The pilot phase will provide an opportunity to address 
operational problems prior to scaling up the study to multiple sites in all regions of Africa (List 
of collaborators in Appendix J).  
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3.7.  CONCLUSION 
Cardiomyopathy and myocarditis contribute significantly to the burden of cardiovascular 
disease in Africa and result in considerable morbidity and mortality.2,60,114 Sufficient information 
on cardiomyopathies and myocarditis in the African population is currently lacking. There is a 
need for large, well-designed, prospective studies to evaluate the clinical, genetic and 
molecular epidemiology, as well as modifiable risk factors for cardiomyopathy, and the impact 
cardiomyopathy and myocarditis have on the burden of heart failure in the population.3,5 To 
the best of our knowledge, this is the first multi-national study to record clinical characteristics, 
adverse events and long-term outcomes of children and adults with heart muscle disease in 
Africa, with the aim of addressing diagnostic and management deficiencies.  The ultimate goal 
of IMHOTEP is to improve the quality of life and prognosis in affected individuals living in 
Africa. 
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CHAPTER 4: Clinical features, genetics, and outcomes of 
the patients in the Arrhythmogenic Right Ventricular 
Cardiomyopathy Registry of South Africa 
4.1.  INTRODUCTION 
ARVC is a genetically determined myocardial disorder characterised pathologically by 
fibrofatty replacement of the myocardium with myocyte loss and fibrosis, resulting in electrical 
instability with ventricular arrhythmias and HF, with predominantly RV dysfunction.73  ARVC is 
associated with increased risk of premature SCD particularly in athletes, frequently occurring 
in the early ‘concealed’ phase of the disease.74 Disease expression is variable, and the clinical 
manifestations vary with age and stage of disease.180 Considerable progress has been made 
in the understanding of the pathogenesis, clinical manifestations and genetic aetiology of 
ARVC over the past four decades.   
 
The hereditary nature of ARVC has been  well recognised since the time of the first description 
by Giovanni Maria Lancisi in 1736,181 with autosomal dominant, and less commonly autosomal 
recessive inheritance.76,77,182 A number of ARVC disease-causing mutations in desmosomal 
and non-desmosomal genes have been identified,75,78,83-86,89,183,184 and successful genotyping 
among patients meeting diagnostic criteria is approximately 50% (range 30 – 70%).93,185-187  
 
The original 1994 TFC for the diagnosis of ARVC were based on structural, histological, 
electrophysiological and familial features, and although highly specific, they lacked sensitivity 
for the detection of early disease.73,94  Application of the modified international TFC, published 
in 2010, has been shown to improve diagnostic sensitivity without loss of specificity by 
providing quantitative criteria, and includes CMR criteria and the presence of disease-causing 
mutations.73    
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The ARVC Registry of South Africa, established in 2003 by the Cardiac Arrhythmia Society of 
Southern Africa (CASSA), is the only ARVC registry on the African continent.95 This report 
serves as an update on the status of the registry. With the incorporation of the ARVC Registry 
of South Africa into IMHOTEP, we analysed the entire series of index cases referred with 
suspected ARVC to the registry since its establishment in 2003.  The main aims of the study 
were: (1) to review the diagnosis of ARVC in all cases referred with suspected ARVC 
according to the modified 2010 TFC; (2) to describe the clinical characteristics of affected 
individuals; (3) to report the pathological mutation rate in desmosomal and selected non-
desmosomal genes; and (4) to report the outcomes of ARVC in South Africa. 
 
4.2.  METHODS 
4.2.1. Study population 
The study population comprised of 162 unrelated cases that were referred to the ARVC 
registry of South Africa for evaluation from all regions of South Africa between May 2003 and 
May 2018. It should be noted that some patients were recruited to the ARVC registry as 
retrospective cases, therefore the date of initial presentation (ranging from June 1978 to May 
2018) and death may precede the date of study commencement. Informed consent for 
participation in the registry was obtained from participants at the time of referral.  Blood 
samples for DNA were collected and stored in the Cardiovascular Genetics Laboratory at the 
Hatter Institute for Cardiovascular Research in Africa, UCT. The incorporation of the ARVC 
Registry of South Africa (HREC: 047/2003) into IMHOTEP (HREC: 767/2014) was approved 
by the Human Research Ethics Committee of UCT.  
 
4.2.2. Study design and diagnostic evaluation 
Following the modification of the TFC, all index cases were reviewed and reclassified 
according to the 2010 TFC, including those previously reported cases that had been 
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diagnosed according to the 1994 TFC.96 The referred cases were reviewed by a diagnostic 
panel consisting of experts in clinical cardiology, electrophysiology, imaging 
(echocardiography, angiography and CMR), histopathology, clinical genetics and molecular 
genetics. The panel reviewed all standard ECG, SAECG, 24-hour ambulatory ECG, EST, 
electrophysiology studies (EPS) and invasive angiographic images. Echocardiographic 
images were not available for re-evaluation; however, a standardised protocol for the 
assessment of the RV was performed on the majority of cases with the establishment of the 
registry, and the required variables were extracted from those reports. CMR images were 
reviewed and reported by two trained readers. Morphometric analysis was not routinely 
performed on EMB specimens prior to the publication of the updated criteria.  Histopathology 
slides were only reviewed for quantification of fibrosis in cases where an additional major or 
minor criterion for tissue characteristics would alter the 2010 TFC classification, either from 
borderline to definite, or from possible to borderline or definite. Inclusion and exclusion criteria 
are outlined in Table 4.1. 
 
Table 4.1. Inclusion and exclusion criteria 
Inclusion criteria 
A diagnosis of definite or borderline ARVC according to the 2010 TFC,73 where an alternative 
pathology could not explain the clinical findings, or pathological confirmation of a diagnosis of 
ARVC at autopsy or transplant 
Exclusion criteria 
Either:  
I. Insufficient criteria to make a diagnosis of definite or borderline ARVC (i.e. possible ARVC 
or no criteria for ARVC according to the 2010 TFC); or 
II. Alternative diagnosis to explain clinical findings 
ARVC, arrhythmogenic right ventricular cardiomyopathy; TFC, task force criteria 
 
4.2.3. Genotype analysis 
Genotyping was performed for index cases where DNA was available for analysis.  Mutation 
analysis for desmosomal genes encoding plakophilin-2 (PKP2), desmoplakin (DSP), 
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desmoglein-2 (DSG2), desmocollin-2 (DSC2), plakoglobin (JUP), and non-desmosomal 
genes encoding phospholamban (PLN) and cadherin 2 (CDH2) was done for index patients 
using methods previously reported75,96,155 at the cardiovascular molecular genetics laboratory, 
Hatter Institute, UCT (Mbele, M. 2014. Ph.D. Thesis, UCT; Fish, M. 2016. Ph.D. Thesis, UCT; 
Machipisa, T. 2016. M.Phil. Thesis, UCT, Kamuli, S. 2016. M.Phil. Thesis, UCT). In addition, 
two participants had genetic screening done at international diagnostic laboratories for the 
listed mutations (Invitae [https://www.invitae.com/en/licensing/]; Oxford University Hospitals, 
Genetic Laboratories, National Health Service, Accredited Medical Laboratory Reference No. 
0745 [https://www.ouh.nhs.uk/geneticslab]). Classification of variants as disease-causing was 
re-evaluated according to definitions outlined by the 2010 TFC, recent guidelines for assigning 
causality177,178 and public archive, ClinVar (https://www.ncbi.nlm.nih.gov/clinvar). 
 
4.2.4. Statistical analysis 
Continuous variables were tested for distribution using a histogram for visualisation and 
Shapiro-Wilks for test of normality, and were summarised as mean and SD or median and 
IQR depending on distribution. Categorical variables were summarised in tables and reported 
as number and proportion (%). Median survival from presentation to the time of death was 
determined by the Kaplan–Meier method, and differences in survival between groups (with 
and without an ICD, and genotype positive and negative/unknown) were evaluated using the 
log-rank test. Comparisons between mutation carriers and non-carriers for death or 
transplantation were performed using Chi-squared test, Fisher exact test, or Student’s t-test, 
and adjusted using post-hoc Bonferroni correction. A value of P < 0.05 was considered 
significant.  Statistical analysis was performed using statistical software, IBM SPSS Statistics 
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(Version 25). Survival analysis was done using Stata/IC (Version 15.1, StataCorp, USA) 
software2. 
 
4.3.  RESULTS 
4.3.1. Clinical characteristics 
Of the 162 unrelated individuals referred to the ARVC registry of South Africa with suspected 
ARVC, 153 were evaluated by the diagnostic panel and classified according to the 2010 TFC 
(Figure 4.1.). Nine patients were not classified due to a lack of sufficient clinical data available 
for evaluation.  
 
Excluded cases. Eighty-three of the 153 patients evaluated by the diagnostic panel were 
excluded, in addition to the 9 cases not evaluated (total number of cases excluded, n=92; 
Table 4.2.). Seven of the excluded patients met definite or borderline TFC; however, there 
was compelling evidence supporting alternative diagnoses, including one case of isolated RV 
endomyocardial fibrosis diagnosed on histology following transplantation, two cases of HCM 
confirmed on CMR, one case of Brugada syndrome, two cases of cardiac sarcoidosis and one 
asymptomatic individual with athlete’s heart. Twenty-five patients were classified as possible 
ARVC and 51 patients had no criteria for ARVC. In the vast majority of cases, an alternative 
diagnosis was made; 19 individuals were considered to be at risk for ARVC, however there 
was insufficient clinical evidence to confidently confirm a diagnosis of ARVC at the time of 
initial evaluation or at follow-up.  In addition to standard investigations, CMR was performed 
in 54/83 (65.1%) of the patients excluded and proved useful in establishing alternative 
diagnoses outlined in Table 4.2. Table 4.3 outlines investigations performed in excluded 
patients. 
                                                
2 The statistical software varied according to preference of the statistician and doctoral 
student, and the software resources available through the University of Cape Town  
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Figure 4.1. Referred cases of suspected ARVC  
 
ARVC, arrhythmogenic right ventricular cardiomyopathy; EMF, endomyocardial fibrosis; HCM, 




9 index cases excluded (Table 4.2)
- Incorrectly classified/no clinical data
7 index cases excluded (Table 4.2)
Alternative diagnoses
- 1 Isolated RV EMF
- 2 HCM 
- 1 Brugada 
- 1 Athletes heart 
- 2 Cardiac sarcoidosis
TFC diagnosis of definite ARVC
n = 52
TFC diagnosis of borderline ARVC
n = 16
153 index cases reviewed by ARVC Diagnostic Panel
2010 Task Force Criteria
76 index cases excluded (Table 4.2)
162 index cases referred with suspected ARVC
70 index cases included
77 index cases with definite and borderline criteria
PM/explant diagnosis of ARVC
n = 2
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At risk for ARVC 
Possible early ARVC but insufficient criteria 
















Idiopathic RVOT VT  12 (13.0) - - - 12 (23.5) 
Idiopathic VT/VF/PVC  9 (9.8) - - 1 (4.0) 8 (15.7) 
Supraventricular tachycardia 5 (5.4) - - - 5 (9.8) 
Alternative type of cardiomyopathy (total)  
Dilated cardiomyopathy  
Hypertrophic cardiomyopathy 
Endomyocardial fibrosis 
Left ventricular noncompaction 
Myocarditis 




































Alternative diagnosis (total) 
Brugada syndrome 
Athlete’s heart 



























Symptoms only (no cardiac disease) 13 (14.1) -  4 (16.0) 9 (17.6) 
Not classified – no clinical data 9 (9.8) - - - - 
*DNA was available for 83 of the excluded cases. All excluded patients with DNA were genotype negative for known disease causing mutations; **Includes 
congenital heart disease, chronic lung disease, ischaemic heart disease, TB pericarditis, hypertensive heart disease. 
ARVC, Arrhythmogenic right ventricular cardiomyopathy; RVOT, right ventricular outflow tract; VT, ventricular tachycardia; VF, ventricular fibrillation; PVC, 
premature ventricular complexes.  
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Table 4.3. Investigations performed in excluded patients* 
Investigation EXCLUDED 




Signal average electrocardiogram 
24-hour Holter 
Echocardiogram 








Right ventriculogram   




* Cases not included in this table: 9 patients not classified due to lack of clinical information, 1 infant that 
could not be assessed using TFC 
 
 
Included cases. Seventy of the 153 cases reviewed by the diagnostic panel were considered 
to have a diagnosis of ARVC; 52 patients met definite criteria, 16 patients met borderline 
criteria and 2 patients had a pathological diagnosis (1 post-mortem, 1 after transplantation) 
where preceding clinical investigations were not available. The baseline clinical characteristics 
including age of onset, gender, race and symptoms at presentation of the 70 affected 
individuals are summarised and compared with two international series
93,186
 in Table 4.4.  Of 
the patients considered to have definite or borderline ARVC, the mean age of onset was 35.4 
± 14.0 years with male predominance (67.1%). Sixty percent of patients were Caucasian, 
27.1% were mixed-race, 7.1% were black African, and 5.7% were Indian (South Asian 
ancestry). The vast majority of patients (95.7%) were symptomatic at presentation. The most 
common symptoms reported were palpitations (75.7%), followed by presyncope/dizziness 
(55.7%), chest discomfort (35.7%), syncope (34.3%) and dyspnoea (25.7%). More than half 
of the cases (54.3%) had documented ventricular tachycardia at the time of presentation. 
Seven patients (10.0%) presented with cardiac arrest; 6 (8.6%) were resuscitated and 
survived, and 1 (1.4%) died out-of-hospital and was recruited post-mortem.  
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Table 4.4. Baseline characteristics of study participants compared to two large 
international cohorts 














n = 129 
Age at presentation, years ± SD 35.4 ± 14.0 36±14 46±17.4 
Male gender, n (%) 47 (67.1) 282 (64.0) 75 (58.0) 
Ethnicity, n (%)  
Black African  
Caucasian  

























































VT at presentation, n (%)  38 (54.3) 220 (50.0) - 
Cardiac arrest at presentation, n (%) 











SA, South African; SD, standard deviation; VT, ventricular tachycardia 
 
 
4.3.2. Investigations and diagnostic criteria  
Investigations were performed according to clinical indications and the availability of resources 
at referring centres. Table 4.5. outlines the investigations performed on study participants. 
Table 4.6. compares the 2010 TFC in the 70 affected study participants with those of two 
international series.
93,186







Table 4.5. Investigations performed for patients with definite and borderline ARVC 
Investigation ALL 
n = 70 
n (%) 
Definite 
n = 54 
n (%) 
Borderline 




Signal average electrocardiogram 
24-hour Holter 
Echocardiogram 





















Right ventriculogram   













Genetic screening 58 (82.9) 46 (85.2) 12 (75.0) 
 
 
Table 4.6. 2010 task force criteria of study participants compared to two large international cohorts  
2010 Task Force Criteria SA Registry   International Registries 
South African  
cohort 










n = 129 
(%)  
Structural abnormalities  
Major criteria (echocardiogram, CMR, and/or RVA) 

















Major criteria  
Minor criteria  




















TWI V1-3 (major) 














 (27)*  
Depolarization abnormalities 
Epsilon wave (major) 

















VT with LBBB morphology and superior axis (major)
§ 
VT with LBBB morphology and inferior axis (minor)
§ 
> 500 PVC/24 hours (minor) 

























Investigations not performed; *TWI in V2 only, 
§
7 cases had both superior and inferior axes 
ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiovascular magnetic resonance; LBBB, 
left bundle branch block; PM, post-mortem; PVC, premature ventricular complexes; RBBB, right bundle 
branch block; SA, South African; TWI, T-wave inversion; VT, ventricular tachycardia 
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Major and minor structural abnormalities were found in 50.0% and 1.4% cases, respectively. 
Echocardiograms were performed on the majority (84.3%) of patients; however, diagnostically 
significant structural changes were only found in 15.3% (9/59) of the studies performed. CMR 
was performed on 29 (41.4%) of the 70 study participants included (Table 4.7.). Major CMR 
criteria for ARVC were met in 48.3% of the patients imaged. Mild structural and/or functional 
abnormalities (not meeting CMR TFC) and/or LGE was observed in a further 41.4% of 
patients, and only 10.3% of patients were considered to have completely normal studies.  
Significant differences between patients with definite versus borderline TFC diagnoses were 





, p=0.016), RV ejection fraction (RVEF) (36.8% versus 57.4%, 
p=0.003), LV ejection fraction (LVEF) (51.4% versus 61.8%, p=0.041), tricuspid regurgitation 
(70.0% versus 11.1%, p=0.003) and LGE of RV septum and/or walls (60.0% versus 14.3%, p 
0.045). Evidence of LV involvement on CMR was seen in 75.0% of patients imaged.  RV 
angiograms were performed in 44 (62.9%) of the index cases included, with major diagnostic 
criteria being met in 52.3% of those imaged.   
 
Major and minor criteria for tissue characterisation were only met in 10.0% and 7.1% of the 
cohort, respectively. Fibrofatty infiltration on EMB was reported but not quantified in a further 
11.4% of cases. EMB was performed in half (51.4%) of patients included with a diagnostic 
yield of 33.3% (12/36), however, these findings only contributed to changing the TFC 
diagnosis in 6 (16.7%) of the patients biopsied (possible to borderline/definite ARVC in 2 
patients, borderline to definite ARVC in 4 patients). 
 
Electrocardiograms were performed on all patients except 2 cases: one recruited after 
transplant and one recruited post-mortem. Repolarisation abnormalities were noted in 84% of 
cases, with 71.4% and 12.9% fulfilling major and minor criteria, respectively. Epsilon waves 
were only observed in 5.7% of the cohort; however, late potentials on SAECG (or terminal 
activation of the QRS on standard ECG) were present in 51.4% of patients. Seventy-four 
94 
percent of cases had a documented left-bundle-branch-block (LBBB) morphology ventricular 
tachycardia (VT) with superior (45.7%) and/or inferior (38.6%) axes. Unclassified VT, where 
the morphology and axis could not be determined, was present in an additional 7.1% of cases. 
Only one proband met major criteria for family history in the absence of a disease-causing 
mutation. Two probands that met minor criteria for family history were subsequently found to 
have disease-causing mutations on genotyping.    
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Table 4.7. CMR findings for 29 patients with definite and borderline ARVC  










Normal CMR 3 (10.3) 1 (5.0) 2 (22.2) 0.159 















In those that did not meet task force criteria (n = 15) 
RV RWMA only  
Increased right ventricular volumes without RWMA 





















RA area (cm2)c 




































RV aneurysm(s) 5 (17.2) 4 (20.0) 1 (11.1) 0.558 
RVOT dimensions 27.6 ±6.4 28.9 ±6.9 24.4 ±3.5 0.122 
Tricuspid regurgitation 15 (51.7) 14 (70.0) 1 (11.1) 0.003 
Presence of LGE  
LGE of the RV septum and/or walls 













Thrombus 1 (3.4) 1 (5.0) 0 (0.0) 0.495 
*Unable to access LV in one case  
BSA, body surface area; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, 
left ventricular ejection fraction; RA, right atrium; RV, right ventricle; RVOT, right ventricular outflow tract; RWMA, regional wall motion abnormalities; 
RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction 
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4.3.3. Outcomes 
Outcome data (as of 1 May 2018) is represented in Figure 4.2.  Seven cases were lost to 
follow-up, 12 (17.1%) patients died, and 4 (5.7%) patients were transplanted over a median 
follow-up period of 9.0 years [IQR 6.1 – 14.4]. The median age of death was 37.9 years [IQR 
22.2 – 55.2]. Thirty-six patients had implantable cardioverter defibrillators (ICD) inserted for 
prevention of SCD. Of those with an ICD, 1 patient was transplanted and 4 died: 1 patient died 
while swimming, 2 died of HF, and 1 died suddenly after the ICD was turned off at the patient’s 
request. Of those without an ICD, 3 patients were transplanted and 8 patients died: 2 patients 
died of HF, 4 died suddenly, and 2 died of RV failure following RV disconnection surgery (in 
1986 and 1997, respectively). The indication for transplantation was biventricular failure in all 
cases. Radiofrequency ablation was performed in 15 cases (9 without ICDs, 6 with ICDs), and 
4 individuals underwent RV disconnection surgery.  
 
 
Figure 4.2. Outcomes of patients with ARVC 
 
ICD, implantable cardioverter defibrillator; SCD, sudden cardiac death; VT, ventricular 
tachycardia 
Index patients





































Overall transplant-free survival probability at 1-year, 5-years and 10-years was 99% 
(confidence interval [CI] 90 – 99.8), 91% (CI 80 – 96), and 81% (CI 68 – 89), respectively, with 
median survival time of 9.0 years [IQR 6.1 – 14.4]. While SCD was more frequent in patients 
without an ICD (4/34, 12% versus 2/36, 6%), there were no significant difference in overall 
transplant-free survival between those with and without devices (p=0.27). Furthermore, there 
was no significant differences in outcomes between genotype positive and genotype 
negative/unknown individuals. Figure 4.3. shows the results of the Kaplan–Meier transplant-
free survival analysis overall, and comparisons in transplant-free survival in patients with and 






















Figure 4.3.2. Kaplan-Meier survival analysis for transplant-free survival in ARVC 




Figure 4.3.3. Kaplan-Meier survival analysis for transplant-free survival in genotype 




































Log-rank test = p 0.27 
Log-rank test = p 0.16 
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4.3.4. Genotypic information  
DNA was available for 58 (82.9%) of the 70 unrelated index cases with definite or borderline 
criteria. Twelve patients were not genotyped; blood specimens were not available in 7 cases 
(loss to follow-up, n=4; death, n=3) and molecular genetic analysis was incomplete for the 
remaining 5 cases at the time of writing.  Fourteen (24.1%) of the 58 index cases genotyped 
were found to have disease-causing mutations based on the fulfilment of the following criteria 
outlined by the 2010 TFC: (1) associated with ARVC, (2) unobserved or rare in large non-
ARVC control populations, and (3) alters, or is predicted to alter, the structure or function of 
the protein, or has demonstrated linkage to the disease phenotype in a conclusive pedigree.73  
 
The pathogenic mutations described were previously identified by CVG laboratory-based 
masters and doctoral students and are referenced and summarised in Table 4.8. All variants 
described in tables below have been found to be rare in local population controls as described 
in the referenced work (Mbele, M. 2014. Ph.D. Thesis, UCT; Fish, M. 2016. Ph.D. Thesis, 
UCT; Machipisa, T. 2016. M.Phil. Thesis, UCT; Kamuli, S. 2016. M.Phil. Thesis, UCT). The 
PKP2 c.G1465A variant, classified as a ‘variant of uncertain significance’ (VUS) by ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), was considered ‘likely pathogenic’ as segregation with 
disease has been demonstrated in Family 10 - ACM 39 (Figure 4.4.). In addition, a further 4 
variants of uncertain significance were observed in this cohort, where only 2/3 of the above 
criteria were met (Table 4.9.). Although likely pathogenic, further work demonstrating 
segregation with disease in families or functional studies will be required before these variants 
can be considered causal. The presence of a disease-causing mutation did not change the 
diagnostic classification in any of the 14 genotype positive patients as all had a definite 
diagnosis of ARVC based on other clinical criteria.
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Table 4.8. Disease-causing mutation in unrelated index cases in the ARVC Registry of South Africa 




Type  Reported  ClinVar Criteria for pathogenicity according to 
TFC∑ 







Splice site Watkins et al., 2009* 
Gerull et al., 2004;  
Syrris et al., 2006;  
Dalal et al., 2006;  
den Haan et al., 2009; 
Fressart et al., 2010;  
Kant et al., 2016; 
Svensson et al., 2016 
Pathogenic 
 
(1) Reported in multiple individuals with 
ARVC  
(2) Conserved. Not observed with any 
significant frequency in large population 
cohorts (Lek et al., 2016; 1000 
Genomes Consortium et al., 2015; 
EVS). 
(3) Supported by functional studies 
(Groeneweg et al., 2014). Segregation 
with ARVC in multiple affected relatives 
in multiple families (Dalal et al., 2006; 
Svensson et al., 2016). 




Watkins et al., 2009* 
Syrris et al., 2006;  
Dalal et al., 2006;  
den Haan et al., 2009;  
Fressart et al., 2010; 
Tan et al., 2010;  
Xu et al., 2010; 
Rajkumar et al., 2012; 
Baskin et al., 2013; 
Phillips et al., 2014; 
Groeneweg et al., 2015 
Pathogenic 
 
(1) Reported in multiple individuals with 
ARVC  
(2) Conserved. Not observed in ±6,500 
individuals of European and African 
American ancestry in the NHLBI Exome 
Sequencing Project, nor was it 
observed in ExAC 
(3) Predicted to lead to a truncated or 
absent protein. Segregate with ARVC 
in six relatives from two different 
families (Syrris et al., 2006). 
ACM 1.2 PKP2 4 c.C1132T Q378X Nonsense Watkins et al., 2009* 
Fressart et al., 2010; 
Bhonsale et al., 2013; 
Ohno et al., 2013; 
Philips et al., 2014; 
Groeneweg et al., 2015; 
Torkamani et al., 2016; 
Walsh et al., 2017; 
Sonoda et al., 2017; 




(1) Reported in multiple individuals with 
ARVC 
(2) Conserved. Not observed at a 
significant frequency in large population 
cohorts (Lek et al., 2016) 
(3) Predicted to cause loss of normal 
protein function either by protein 
truncation or nonsense-mediated 
mRNA decay 




Table 4.8. Disease-causing mutation in unrelated index cases in the ARVC Registry of South Africa (continued) 













PKP2 4 c.C1162T R388W Missense Watkins et al., 2009* 
 
The results for 
individuals, ACM 8.3, 
ACM 57.1 and ACM 
71.1, were reported by 
Machipisa, T. 2016. 
M.Phil. Thesis. UCT; 
Kamuli, S. 2016. 
M.Phil. Thesis, UCT*  
Pathogenic (1) Reported in multiple individuals and 
families, founder mutation 
(2) Conserved. Allele frequency ExAC 
0.00001. The NHLBI ESP Exome 
Variant Server reports Arg388Trp was 
not observed in approximately 6,400 
samples from individuals of European 
and African American backgrounds 
(3) Segregates with ARVC in multiple 
families (Watkins et al., 2009) 





(1) Reported in one individual with ARVC 
(2) Conserved. Allele frequency ExAC 
0.00009  
(3) Functional studies not done. 
Note: Segregation with ARVC 
demonstrated in ACM 39 family (see 
pedigree)  
ACM 51.1 PKP2 13 c.2509delA S837fs Deletion  Watkins et al., 2009* 
Gerull et al., 2004,  
Dalal et al., 2006,  
Dalal et al., 2006, 
Dalal et al., 2009,  
Xu et al., 2010, 
Antoniades et al., 2006, 
Fressart et al., 2009, 
Barahona-Dussault et 
al., 2010,  
Den Haan et al., 2009, 
Tan et al., 2010,  
Cox et al., 2011,  




(1) Reported in multiple unrelated 
individuals diagnosed with ARVC  
(2) Conserved. Not detected in more than 
1,500 control alleles. ExAC - no 
frequency reported 
(3) Predicted to alter PKP2 protein. 
Reported to segregate with ARVC in a 
family (PMID: 17010805) 
 
 
*Cardiovascular Genetics Laboratory, Hatter Institute of Cardiovascular Research in Africa, University of Cape Town 
† homozygous, ∆ compound heterozygous  
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Table 4.8. Disease-causing mutation in unrelated index cases in the ARVC Registry of South Africa (continued) 




Type  Reported  ClinVar Criteria for pathogenicity according to 
TFC 
ACM 136.1 PKP2 5 c.C1237T R413X Nonsense Syrris et al., 2006;  
den Haan et al., 2009; 
Unsoeld et al., 2009; 
Tan et al., 2010; 
Fressart et al., 2010; 
Quarta et al., 2011; 
Philips et al., 2014; 
Alcalde et al., 2014 
 
Unpublished result - 
provided by 




(1) Reported multiple times in association 
with ARVC, with observation in more 
than ten individuals with ARVC  
(2) Conserved. Not observed at a 
significant frequency in large population 
cohorts (Lek et al., 2016; 1000 
Genomes Consortium et al., 2015; 
EVS). Allele frequency GO-ESP 
0.00008, ExAC 0.00002 
(3) Predicted to cause loss of normal 
protein function either by protein 
truncation or nonsense-mediated 
mRNA decay. Observed segregation 
with ARVC in families (Unsoeld et al., 
2009, Alcade et al., 2014)  
ACM 2.4 CDH2 5 c.A686C Q229P Missense Mayosi et al., 2017* Not 
reported  
(1) Reported in one family with ARVC 
(2) Conserved. Not observed in local 
population controls 
(3) Segregation with ARVC demonstrated 
(Mayosi et al., 2017) 
ACM 11.2 CDH2 9 c.G1219A D407N Missense Mayosi et al., 2017* Not 
reported 
(1) Reported in one individual with ARVC 
(2) Conserved. Not observed in local 
population controls 
(3) De Novo mutation (trio study) described 
in chapter 7 
*Cardiovascular Genetics Laboratory, Hatter Institute of Cardiovascular Research in Africa, University of Cape Town 





Figure 4.4. Family 10 (ACM 39) pedigree showing segregation of ARVC with PKP2 c.G1465A variant (+).  





Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Sept. 19, 2018, 11:17 a.m. GMT
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Table 4.9. Variants of uncertain significance in unrelated index cases in the ARVC Registry of South Africa 




Type  Reported  ClinVar Criteria for pathogenicity according 
to TFC 




(1) Reported in one individual with 
ARVC  
(2) Conserved. Not observed in large 
population cohorts (Lek et al., 2016; 
1000 Genomes Consortium et al., 
2015; EVS). 
(3) Functional effects unknown (Al-
Jassar et al.). Silico analysis 
predicts this variant is probably 
damaging to the protein structure or 
function. Linkage analysis not done. 
ACM 7.1 DSG2 11 c.A1435G K479E Missense The result for this 
individual was 
reported by Mbele, M. 




(1) Not previously reported (novel) 
(2) Conserved. Not observed in ARVC 
database, 1000 genomes, NCBI 
dbSNPs and 232 local population 
controls* 
(3) Functional studies and linage 
analysis not done 
ACM 48.1 DSG2 11 c.A1478G N493S Missense Quarta et al., 2011 
 
This result for this 
individual was 
reported by Mbele, M. 







(1) Reported as a possible disease-
causing mutation in association 
ARVC (Quarta G et al., 2011) and 
as an unclassified variant (Van der 
Zwaag P et al., 2009). 
(2) Conserved. Not found in ARVC 
database, 1000 genomes, NCBI 
dbSNPs and 232 local population 
controls*, ExAC 0.00004 
(3) No functional studies, but predicted 
as disruptive. Computational 
prediction tools and conservation 
analysis do not provide strong 
support for or against an impact to 
the protein. No linkage analysis 
available. 
*Cardiovascular Genetics Laboratory, Hatter Institute of Cardiovascular Research in Africa, University of Cape Town 
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Table 4.9. Variants of uncertain significance in unrelated index cases in the ARVC Registry of South Africa (continued) 




Type  Reported  ClinVar Criteria for pathogenicity according 
to TFC 
ACM 53.1 DSC2 6 c.G2587A G863R Missense Cox et al., 2011 
Kapplinger et al., 2011; 
Bhonsale et al. 2013; 
Proost et al., 2017 
Elliott et al., 2010 (DCM) 
 
This result for this 
individual was 
reported by Mbele, M. 






(1) Reported VUS in ARVC and DCM. 
Previously reported in at least three 
individuals in association with ARVC 
however, these individuals all 
harboured an additional cardio-
genetic variant, including two 
individuals who each harboured a 
different pathogenic frameshift 
variant in the PKP2 gene. 
(2) Not found in 232 population local 
controls*, G863R variant has been 
observed in 0.03% alleles from 
individuals of Non-Finnish European 
ancestry in large population cohorts 
(Lek et al., 2016; 1000 Genomes 
Consortium et al., 2015; Exome 
Variant Server). Its frequency 
suggests that it is more likely to be 
benign and is classified as a variant 
of uncertain significance by multiple 
other clinical laboratories  
(3) Silico analysis predicts this variant is 
probably damaging to the protein. 
Computational prediction tools and 
conservation analysis suggest that it 
may impact the protein, though this 
information is not predictive enough 
to determine pathogenicity. Lacks 
large segregation studies and 
functional evidence 
*Cardiovascular Genetics Laboratory, Hatter Institute of Cardiovascular Research in Africa, University of Cape Town 
PKP2, plakophilin-2; DSG2, desmoglein-2; DSC2, desmocollin-2 
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Following the 2009 report of the PKP2 C1162T founder mutation present in 4 unrelated 
individuals (ACM 5.1, ACM 12.1, ACM 19.2, ACM 38.3) in this cohort,96 3 additional probands 
(ACM 8.1, ACM 57.1, ACM 71.1) were found to carry the same founder mutation (Machipisa, 
T. 2016. M.Phil. Thesis, UCT; Kamuli, S. 2016. M.Phil. Thesis, UCT). Cascade genetic and 
clinical screening was performed for available members of the founder families. A variation in 
age of onset and severity of clinical phenotype was observed amongst PKP2 C1162T mutation 
carriers within these families. The majority of non-proband carriers screened were 
asymptomatic with minimal clinical manifestations of disease. The index cases (probands) in 
4 families (ACM 5, ACM 12, ACM 57, ACM 71) presented with VT in the third and fourth 
decades of life (ages 38–45 years). Three of these four index cases were competitive 
marathon runners (ACM 5.1, ACM 12.1, ACM 57.1) and one (ACM 71.1) had additional co-
morbidities (hypertension and recreational drug use).  
 
In contrast, probands ACM 8.1, ACM 19.2 and ACM 38.3 presented in childhood or early 
adolescence with severe disease (Figure 4.5.), all requiring transplantation in the first, second 
or third decade of life. Homozygosity and compound heterozygosity was associated with 
severe phenotypes in families ACM 8 (Figure 4.5.A) and ACM 19 (Figure 4.5.B), respectively 
(Machipisa, T. 2016. M.Phil. Thesis. UCT; Kamuli, S. 2016. M.Phil. Thesis, UCT).96 The severe 
phenotype observed in ACM 38 family is unaccounted for; no additional known disease-
causing variants have been identified, nor were there any specific environmental cofactors 
observed. The proband (ACM 38.3) presented at age 9 and required transplantation at age 
16.  In this family, a female sibling of the proband suffered a sudden death at age 8 with 
probable ARVC, and a male sibling also diagnosed with ARVC required transplantation at age 
8. This observation is important as ARVC is exceptionally rare in children particularly under 
the age of 10.93 The most likely explanation for the manifestation of severe disease in these 3 




Figure 4.5. Founder families with severe phenotypes 
A. Family ACM 8 (Appendix K - Family 4); B. Family ACM 19 (Appendix K – Family 7); C. 
Family ACM 38 (Appendix K – Family 9).
Patient Name: ACM 8.3 MRN: ML DOB: 30 yrs Created By: s.kraus@uct.ac.za Last Updated: Sept. 24, 2018, 2:01 p.m. GMT
Patient Name: ACM 19.2 MRN: CMG DOB: 33 yrs Created By: s.kraus@uct.ac.za Last Updated: Sept. 24, 2018, 2:04 p.m. GMT





4.4.  DISCUSSION 
In this study, we report the classification of patients referred to the ARVC Registry of South 
Africa according to the 2010 TFC, and the clinical manifestations, survival and mutation status 
of patients with ARVC in South Africa. The age of onset (35.4 ± 14.0 years), male 
predominance (67.1%), and frequency of symptoms (95.7%), VT (54.3%) and cardiac arrest 
(10.0%) at presentation were similar to what has been reported in international series.93,186  
Although ARVC is seen in all race groups in the South African population, there was a 
predominance of Caucasian (60.0%) and mixed race (27.1%) participants – likely the result of 
referral bias and historical racial inequalities in access to tertiary health care services required 
to make a diagnosis of ARVC, as previously described in this cohort.96 Similar racial disparities 
have been described in other areas of health care in South Africa.188 The true incidence of 
ARVC in Africa is not known, and African-Americans/Europeans are unrepresented in 
international cohorts. The role of genetics factors in the underrepresentation of black African 
individuals in this ARVC cohort remains unclear.  
 
The combined presence of VT (LBBB morphology) and repolarisation changes in the 
precordial leads on ECG was highly suggestive of the disease (present in 71.2% of cases). 
Significant structural abnormalities were reported in 51.4% of cases and LV involvement was 
observed in 75.0% of cases where CMR was performed. Disease-causing mutations were 
found in 24.1% of patients genotyped. Overall transplant-free survival probability at 1-year, 5-
years and 10-years was 99% (CI 90 – 99.8), 91% (CI 80 – 96), and 81% (CI 68 – 89), 
respectively. While there was a significant difference in age of presentation between genotype 
positive and genotype negative/unknown individuals (median 25.0 years versus 38.0 years; 
mean, 27.6 ±13.7 years versus 37.4 ±13.5 years; p 0.018), there was no significant difference 
in survival between these groups. Although, there was no significant difference in overall 
transplant-free survival between those with and without ICDs, inferences relating to the clinical 
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utility of devices in patients with ARVC in SA cannot be made due to the small sample size in 
this study. 
 
The first objective of this study was to review the diagnosis of all patients referred to the 
registry; this included those patients diagnosed according to the 1994 TFC and reported on 
by Watkins and colleagues in 2009 (total number of referred cases, n = 70; cases included in 
the report with ARVC according to 1994 TFC, n = 50; excluded cases, n = 20).96  Six patients 
(6/20, 30%) previously referred but not included in the 2009 report were found to have definite 
or borderline ARVC using the modified 2010 criteria. The subsequent inclusion of these cases 
reflects the improved sensitivity of the repolarisation and arrhythmia criteria. Thirteen cases 
(13/50, 26%) included in the 2009 report were excluded from this study (Table 4.10.); 1 case 
had a diagnosis of sarcoidosis made on biopsy at follow-up and 12 cases did not have 
sufficient criteria for inclusion. We were unable to exclude ARVC with absolute certainty in 
many of these patients, as they were not available for re-evaluation due to loss to follow-up 
(n=11) or death (n=2). The changes in diagnosis reflect the advancements in TFC definitions 
with the inclusion of quantifiable variables for structural abnormalities and histological tissue 
characterisation, and the utility of modified definitions in the interpretation of the epsilon wave.  
 
Although the impact of the epsilon wave on ARVC diagnosis in large registries has been 
shown to be low, it can have considerable influence as a major diagnostic criterion and has 
been identified as a caveat leading to over-diagnosis in patients that do not meet other criteria 
for ARVC.189 Inter-observer variability in the interpretation of the epsilon wave has been shown 
to be high due to the qualitative nature of the original definition, leaving room for subjective 
interpretation.189 By utilising the modified definition of an epsilon wave, which quantifies the 
end of the QRS complex as the latest end of the QRS complex seen in any of the leads V1, 
V2 or V3,189 we found that only 5.7% of cases had epsilon waves – a much lower frequency 
than previously reported in this cohort (56%)96 and other registries (average 13%, range 1-
25%) using conventional methods of interpretation.96,189 The presence of an epsilon wave did 
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not influence the diagnosis of ARVC in the four individuals in which it was observed, as they 
all met sufficient criteria without it, demonstrating once again the association of the epsilon 
wave with advanced disease.189 The incorrect interpretation of the epsilon wave has been 
identified as a major pitfall in over-diagnosing ARVC in our cohort in the past, and largely 
accounts for the exclusion of cases that may previously have been thought to have the 
condition.  
 
CMR is regarded as the standard reference for the evaluation of RV function and morphology, 
and has become the imaging modality of choice in ARVC.118 While quantification of RV 
volumes and function has improved the diagnostic sensitivity of this imaging modality, the 
correct interpretation of images remains subject to the experience and expertise of the 
reader.118,190  Although magnetic resonance imaging (MRI) is available in most centres in 
South Africa, expertise in CMR interpretation is limited to a few select centres. Both the 
subjective nature of the 1994 TFC for structural abnormalities and the misinterpretation of 
CMR findings have previously led to over-diagnosis of ARVC in this cohort. Re-evaluation of 
CMR images by 2 trained readers, without prior knowledge of other clinical criteria, proved 
useful in both including and excluding referred patients in this study.  More than half of the 
patients with a TFC diagnosis of ARVC did not undergo CMR as part of their work-up; notably, 
the majority of these patients were referred prior to 2009. This reflects the limited availability 
of CMR in South Africa, the use of the 1994 TFC in the diagnosis of ARVC prior to 2010 where 
CMR was not specifically indicated, contraindications to CMR in patients with older devices 
where MRI was not performed, and lost CMR images.  Despite the exclusion of these 13 
patients, an additional 33 cases have been recruited into the ARVC Registry of South Africa 





Table 4.10. Index cases from the 2009 report that were excluded according to 2010 TFC  
Index 
case 2009 report - 1994 TFC 
Updated  
2010 TFC 
















- Late potentials  
Insufficient criteria 
Minor 
- Late potentials  
 
 
Undefined 19 Chest pain None Very mildly dilated 




















Possible ARVC 16 Syncope None Not performed 
(ICD incompatible) 










FFR not quantifiable  






Suboptimal scan -  




LV apex. LGE not 
done. 









- Mild RV dilatation 
- Late potentials 
Insufficient criteria 
Minor 
- Late potentials 
 
 
Probable DCM 49 Palpitations RBBB 
morphology 
Normal LV volume 
with impaired LV 
function.  Normal 
RV volume and 
function. No LGE.   
























Suboptimal scan - 
normal chamber 
sizes and normal 
function.  No 
aneurysm. LGE 
not performed.  




Table 4.10. Index cases from the 2009 report that were excluded according to 2010 TFC (continued) 
Index 
case 2009 report - 1994 TFC 
Updated  
2010 TFC 













- FFR on histology 
- Depolarization/epsilon 
Minor 
- Late potentials 
Insufficient criteria 
Minor 




Idiopathic PVC 55 Palpitations 
and dizziness 
None Not performed (not 
available at the 
time) 







- FFR on histology 
Minor 
- Mild dilatation of RV 
Insufficient criteria 
Minor 
- Late potentials 
 








function. No RV 
RWMA. No LGE 






- FFR on histology 
- Depolarization/epsilon 
Minor 
- Mild RV dilatation 



















Not performed (not 
available at the 
time) 











FFR not quantifiable 





None Not performed (not 
available at the 
time) 
No Unknown Died 
1997 
113 
Table 4.10. Index cases from the 2009 report that were excluded according to 2010 TFC (continued) 
Index 
case 2009 report - 1994 TFC 
Updated  
2010 TFC 
classification Diagnosis Age  
Symptoms at 

































Not performed (not 
available at the 
time) 






- Severe RV dilatation 
- Depolarization/epsilon 





43 Syncope while 
running 
Polymorphic 








































dilated LA, dilated 
RV, moderately 
impaired RVEF. 





























RWMA. LGE not 
performed 
No Unknown LTFU 
2009 
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; CMR, cardiovascular magnetic resonance; DCM, dilated cardiomyopathy; DNA, 
deoxyribonucleic acid; EPS, electrophysiology study; EST, exercise stress test; FFR, Fibrofatty replacement (on histology); FU, follow-up, HHD, hypertensive heart disease; 
ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LTFU, lost to follow-up; LV, left ventricle; PVC, premature 
ventricular contractions; RBBB, right bundle branch block; RV, right ventricle; RVA, right ventriculogram; RVEF, right ventricular ejection fraction; RVOT, right ventricular 
outflow tract; RWMA, regional wall motion abnormality; TFC, task force criteria; VT, ventricular tachycardia 
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Despite expanding the genetic screening profile to include 5 desmosomal genes (PKP2, 
DSG2, DSC2, DSP, JUP) and selected non-desmosomal genes (CDH2 and PLN), the 
proportion of genotype positive individuals within this South African cohort is still relatively low 
(24.1%). Since the 2009 report, we have identified 3 additional unrelated individuals with PKP2 
c.C1162T founder mutations. Cascade genetic screening and clinical correlation of available 
family members has allowed us to make some key observations regarding variable phenotype 
expression in patients carrying this mutation. As would be expected with a mutation conserved 
over many generations, the clinical phenotype associated with the PKP2 c.C1162T founder 
mutation is relatively mild – most carriers express minimal clinical signs of disease. 
Environmental factors, particularly endurance sport, appear to be correlated with the 
development of symptomatic disease in heterozygous individuals. Severe phenotypes have 
been associated with compound heterozygosity96 and homozygosity (Machipisa, T. 2016. 
M.Phil. Thesis, UCT; Kamuli, S. 2016. M.Phil. Thesis, UCT) in 2 of the founder families, 
however, the PKP2 c.C1162T founder mutation alone does not explain the severe phenotype 
in 3 affected siblings in the ACM 38 family, and further molecular genetic analysis is indicated 
in this family. Further work, including functional studies and/or family screening to demonstrate 
segregation with disease, will be required to determine the clinical relevance of the variants of 
unknown significance that have been identified in our cohort.    
 
Routine diagnostic genetic testing is not readily available in South Africa. The relatively low 
genetic diagnostic yield (24.1%) demonstrated in this cohort indicates that further research is 
required to better elucidate the genetic causes of ARVC in our population. Although 
genotyping has not been shown to contribute significantly to confirming the diagnosis of ARVC 
in index patients in our cohort, identifying a disease-causing mutation has provided an 
effective screening tool in relatives. Importantly, genetic testing should only be undertaken in 
index patients where there is sufficient clinical evidence to support the diagnosis of ARVC, or 
in family members where a genetic diagnosis has been confirmed in the proband. 
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4.5.  LIMITATIONS 
Due to the observational nature of this study, the amount of clinical data available for each 
participant varied considerably, depending on the resource capacity at referral centres and 
the time period in which the patient was recruited. Participants were therefore not all 
investigated to the same degree, and thus the prevalence of certain characteristics cannot be 
determined accurately. Standardised approaches to investigations applied by sufficiently 
trained individuals appointed to the diagnostic panel were instituted to reduce inter-observer 
variability in the interpretation of investigative data. Due to social inequalities in access to 
healthcare that are still present in South Africa, referral bias is likely responsible for the 
underrepresentation of black African individuals in this cohort. Loss of follow-up, particularly 
in patients without ICDs may reflect undocumented deaths, therefore, the outcomes data in 
patients with and without ICDs should be considered with caution. Despite these limitations 
and the relatively small size of the cohort when compared to international series, this study 
does contribute to our understanding of ARVC in the South Africa context.  
 
4.6.  CONCLUSION 
With the exception of the lower mutation rate (24.1%), the clinical presentation and diagnostic 
criteria correlate with the findings in North American and European studies. While outcomes 
were poorer than reported in other cohorts, survival was not significantly altered by device 
therapy or mutation status. The diagnosis of ARVC remains a major challenge, particularly in 
countries with limited resources and expertise. Reclassification according to updated criteria 
by a panel of experts in all patients referred, improved the accuracy of clinical diagnosis in 
those with ARVC, as well as those excluded with other cardiac conditions. The requirement 
for specialised investigations and multidisciplinary expertise highlights the need for a unified 
registry, not just in South Africa, but throughout the African continent. The incorporation of the 
ARVC Registry of South Africa into the newly established African Cardiomyopathy and 
116 
Myocarditis Registry Program (IMHOTEP) is an attempt to extend established expertise in the 
field to other countries lacking in the capacity to support a registry of this nature, and to provide 
the opportunity for continued research across the continent, whereby the genetic causes of 
ARVC in African patients can be determined.  
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(in consultation with statistician, K. Manning and W. Basera).       
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CHAPTER 5: The baseline characteristics and vital status 
of prevalent cases of dilated cardiomyopathy from the 
Cape Town cohort 
5.1.  INTRODUCTION 
Dilated cardiomyopathy, associated with LV chamber dilatation and dysfunction, is the 
dominant form of cardiomyopathy causing heart failure in SSA.2 It has been shown, that 
despite guideline-mandated medical therapy, both familial and idiopathic DCM have been 
associated with a high mortality in the South African population.4 Most of the information 
available on the presentation and natural history of cardiomyopathies in Africa has been 
derived from single-centre cohort studies,4,37,191,192 and there is limited data describing 
contemporary management of DCM within a LMIC setting over an extended period of time.   
In 2011, Ntusi and colleagues reported the clinical characteristics and outcomes of a cohort 
of 120 patients with idiopathic and familial DCM from Cape Town.4 Several important 
observations emerged from that study related to mortality. The presence of symptoms of heart 
failure was the most important clinical predictor of mortality. Furthermore, digoxin appeared to 
be a significant predictor of mortality in idiopathic DCM. While this study had important findings 
for clinical practice and is the largest study to date on DCM in the African population, 
generalisation of the findings is limited by the relatively small sample size and the retrospective 
design.4  
 
While IMHOTEP is a prospective registry, the inclusion of prevalent cases affords us the 
opportunity of incorporating retrospective cohorts that have been compiled over decades at 
our institution to maximise our sample size, improve the statistical power and draw more 
meaningful conclusions about long-term management and clinical outcomes within our DCM 
population. In addition, the Cape Town cohort is unique in that DNA was collected and stored 
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for patients presenting with DCM as part of a previous study, providing an opportunity to 
examine the genetic contribution to this condition in our population.   
 
The principal aims of the study were to (1) recruit existing cases of DCM where DNA had been 
collected and sufficient clinical information was available to confirm a diagnosis of DCM, (2) 
describe the baseline characteristics of prevalent DCM patients and (3) review the long-term 
overall survival of patients with DCM in the Cape Town cohort.   
 
5.2.  METHODS 
5.2.1. Study design and population 
The prevalent cases arm of the IMHOTEP study involves the recruitment of existing unrelated 
individuals with a diagnosis of cardiomyopathy at recruiting centres.  A Clinical and Genetic 
Study of Familial Dilated Cardiomyopathy in South Africa (HREC 197/96) was an existing 
study initiated in Cape Town in 1996, in which DNA specimens were collected from patients 
and relatives with dilated cardiomyopathy, and stored at the Cardiovascular Molecular 
Genetics Laboratory at the Hatter Institute, University of Cape Town. With the inclusion of 
prevalent cases into IMHOTEP, patients from this cohort were reviewed and included if they 
had a valid consent for collection of medical information and molecular genetic analysis, and 
sufficient clinical information was available to confirm a diagnosis of cardiomyopathy 
(Appendix H).  In addition, existing patients with DCM being followed-up in the Cardiac Clinic 
at Groote Schuur Hospital, that had not previously been included into the above-mentioned 
study, were consented and recruited as prevalent cases. 
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5.2.2. Inclusion and exclusion criteria  
Inclusion criteria  
I. Informed consent for participation in genetics research.  
II. Adults and adolescent minors.  
III. A confirmed diagnosis of dilated cardiomyopathy (or postpartum cardiomyopathy) as 
describe in Table 3.1. (Chapter 3).  
Exclusion criteria 
I. Consent form not signed/invalid. 
II. Insufficient clinical information available.  
III. IMHOTEP exclusion criteria as listed in Table 3.2 (Chapter 3). 
 
5.2.3. Data collection and informed consent 
Due to the retrospective nature of the study, data was collected by reviewing hospital records, 
research folders and datasets compiled for by previous investigators (HREC 197/96), and 
entered into the IMHOTEP OpenClinica registry database. As one of the principal aims of 
IMHOTEP is to conduct molecular genetic analysis on patients recruited, patients were 
included if they had a valid consent form for DNA collection, storage and analysis, except in 
specific circumstances where waver of consent was approved by HREC.  The original consent 
forms included permission from participants to collect clinical information from medical 
records. 
 
5.2.4. Statistical analysis 
Descriptive statistics were used to describe the study population. Continuous variables were 
tested for distribution using the Shapiro Wilks test for normal data and using a histogram for 
visualisation. Normally distributed data was summarised as mean and standard deviation. 
Non-normally distributed data was reported as median and interquartile range.  Wilcoxon sum 
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rank and Kruskal-Wallis were used to determine differences between non-normally distributed 
data. Categorical variables were summarised in tables and reported as number and 
proportion, and Chi-squared tests of equal proportions were used to determine differences in 
categorical data. Statistical analysis was performed using SPSS statistical software (SPSS 
Statistics 25.0). Median survival from presentation to the time of death was determined by the 
Kaplan–Meier method, and differences in survival between groups were evaluated using the 
log-rank test, using STATA statistical software (Version 15.1. StataCorp. USA). 
 
5.3.  RESULTS 
5.3.1. Enrolment and diagnosis 
A total of 133 patients with DCM were recruited to IMHOTEP from existing studies conducted 
at UCT and the Cardiac Clinic at Groote Schuur Hospital over a period of 19 years (1 February 
1996 - 1 February 2015) (Figure 5.1). Due to the nature of retrospective recruitment, the timing 
of initial presentation and diagnosis of DCM varied across the cohort, with onset of disease 
dating as far back as 1981.  
 
 
Figure 5.1. Recruitment of existing prevalent DCM cases to IMHOTEP 
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Idiopathic DCM (33.1%) was the most frequent diagnosis, followed by PPCM (29.3%) and 
suspected familial DCM (19.5%) (Figure 5.2.). DCM-LVNC overlapping phenotype was noted 
on CMR in 7.5% of cases. This is, however, not a true reflection of LVNC prevalence in this 
population as CMR was only performed in 12.8% of cases recruited. Although 16.5% of 
recruits had co-existing HIV, only 6% were considered to have an HIV-associated 
cardiomyopathy (HIVAC). Other secondary causes included tachycardia-related 
cardiomyopathy (n=3), anthracycline-related cardiomyopathy (n=2) and alcohol-related 
cardiomyopathy (n=1).    
 
  
Figure 5.2. Aetiological diagnosis in patients with DCM 
DCM – Secondary (other) included tachycardia-related cardiomyopathy, anthracycline-related 
cardiomyopathy and alcohol-related cardiomyopathy.    
 




5.3.2. Demographics and baseline clinical characteristics  
Table 5.1. represents the baseline characteristics of 133 prevalent DCM cases recruited to 
IMHOTEP, in comparison to DCM patients recruited to the European Cardiomyopathy Pilot 
Registry.193 The vast majority of patients recruited were black African (50.4%) and mixed race 
(36.1%), with slight female predominance (54.9%).  Fifty-nine percent of women presented in 
the peripartum period. The mean age of presentation was 34.8 ± 11.0 years. Ninety-seven 
percent of patients were symptomatic at presentation, with 91.0% reporting impaired effort 
tolerance (NYHA Class II, 44.4%; NYHA Class III, 32.3%; NYHA Class IV, 14.3%). In addition 
to reduced effort tolerance, the most common symptoms noted at presentation were body 
swelling/oedema (49.6%), orthopnoea (42.9%), chest discomfort (24.8%) and paroxysmal 
nocturnal dyspnoea (21.1%). Forty-two percent of patients had clinical signs of congestive 
heart failure at the time of first enrolment as a research participant. Syncope was infrequently 
reported (1.5%). Co-morbid chronic illnesses were noted in a third of patients, with HIV 
(16.5%) being the most frequently encountered co-existing medical condition. Mild 
hypertension was reported as a co-morbidity in 6.8% of cases but was not considered to be a 
significant contributor in these cases.  A history of atrial fibrillation and embolic stroke/TIA were 
reported in 9.0% and 4.6% of cases, respectively. Ventricular tachycardia and previous 
cardiac arrest were reported in 3.0% and 0.8% of cases, respectively. 
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Table 5.1. Clinical characteristics of prevalent DCM cases recruited to IMHOTEP in 
comparison with the European Cardiomyopathy Pilot Registry 

















Age at presentation, years  
Mean age ±SD 







Type of presentation, n(%) 
Cardiac symptoms  
SCD/cardiac arrest 
Embolic event 











NYHA Class, n(%) 
NYHA Class I 
NYHA Class II 
NYHA Class III 



































Onset of symptoms peripartum (females), n(%) 43/73 (58.9) - 
Chemotherapy exposure 3 (2.3) - 
Reported lifestyle-social exposures, n(%) 
Alcohol (>30 drinks/month or binge use) 





Family history, n(%) 
Heart failure  
Cardiomyopathy 









Co-morbidities present, n(%) 
HIV positive 
Hypertension (not considered causal) 
Diabetes 
Chronic pulmonary disease 
Thyroid disease 









History of arrhythmia or stroke reported 
Atrial fibrillation 
SVT (other than AF) 
Resuscitated cardiac arrest  
Ventricular tachycardia 
Stroke 















Examination at time of enrolment 
Heart rate (beats/minute), mean ±SD 
Systolic blood pressure (mmHg), mean ±SD 
Diastolic blood pressure (mmHg), mean ±SD 








5.3.3. Baseline investigations  
The investigative approach varied according to existing guidelines and available investigations 
at the time of presentation. While the vast majority of cases had diagnostic confirmation on 
echocardiography, a few of patients were recruited based on histopathology (post-transplant) 
and/or angiographic findings. Table 5.2. outlines the clinical investigations performed. 
Electrocardiograms were done in 97.7% of cases (Table 5.3.); 91.5% of patients were in sinus 
rhythm.  Various conduction abnormalities were noted; the most common of which were left 
bundle branch block (14.6%) and first-degree heart block (13.8%).  T-wave inversion was 
noted in 69.2% of patients. Echocardiograms were available for 98.5% of cases (Table 5.4.). 
Left ventricular dimensions were increased in the vast majority (90.8%) of patients (mean LV 
end-diastolic dimension 64 ± 9 mm), with the exception of 12 (9.2%) cases with reduced 
ejection fraction only (PPCM, n=3; familial DCM, n=2; DCM/LVNC overlap, n=1; HIVAC, n=2; 
anthracycline-related cardiomyopathy, n=2, idiopathic DCM, n=2). The mean LVEF and 
fractional shortening were 28 ± 10.9% and 13.4 ± 5.9% respectively. Moderate or severe mitral 
regurgitation was reported in 45.0% of cases and the mean RV systolic pressure was elevated 
(40.0 ± 13.0 mmHg).  
 
Table 5.2. Investigations performed in prevalent cases in IMHOTEP 
compared to European Cardiomyopathy Pilot Registry 































Table 5.3. Electrocardiogram 
 Patients with DCM (n = 130) 
Rate (beats per minute), mean±SD 92 ±22.5 
Rhythm 
Sinus rhythm (normal PR interval), n(%) 
Sinus rhythm with 1st degree heart block, n(%)  
Atrial fibrillation, n(%) 






PR interval (ms), mean±SD 165 ±29.6 
QRS duration (ms), mean±SD 106 ±31.1 
QRS morphology 
Normal, n(%) 
Incomplete left bundle-branch-block, n(%) 
Left anterior bi-fascicular block, n(%) 
Left posterior bi-fascicular block, n(%) 
Left bundle-branch-block, n(%) 
Right bundle-branch-block, n(%) 









T-wave inversion, n(%) 90 (69.2) 
QTc (ms), mean±SD 451 ±41.8 
Chamber hypertrophy 
Left atrial hypertrophy, n(%) 





Table 5.4. Echocardiogram 
 Patients with DCM (n = 131) 
Left heart study 
Left ventricular dimensions 
LV non-dilated, n(%) 
LV dilated, n(%) 





LV fractional shortening (%), mean±SD (n=119) 
LV ejection fraction (%), mean±SD (n=127) 
13.4 ±5.9 
28.0 ±10.9 
Septal thickness (mm), mean±SD (n=115) 
LV posterior wall thickness (mm), mean±SD (n=117) 
9 ±2.2 
10 ±2.5 
LA dilatation reported, n(%) 
LA dimension (mm), mean±SD (n=124) 
92 (70.2) 
44 ±7.7 
Moderate to severe mitral regurgitation, n(%)  59 (45.0) 
Right heart study 
Right ventricular dimensions (not routinely measured) 
RV dilatation reported, n(%) 




RA dilatation reported (not routinely measured) 
RA not assessed, n(%) 
24 (18.3) 
78 (59.5) 
Moderate to severe tricuspid regurgitation, n (%)  35 (26.7) 
RV systolic pressure (mmHg), mean±SD (n=74) 40.0 ±13.0 
Intra-cardiac thrombus reported, n(%) 6 (4.6) 
Pericardial effusion (≤15mm), n (%) 28 (21.4) 
LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic dimension; RA, right 
atrium; RV, right ventricle
126 
 
CMR was performed on 18 patients (Table 5.5.). It should be noted that CMR was only 
performed in selected patients; those with poor recovery of LV function on treatment, PPCM 
in a subsequent pregnancy after initial recovery, familial DCM, chronic inflammatory conditions 
(e.g. RA, HIV), tachymyopathies or where there were diagnostic queries.  Our findings, 
therefore, likely reflect the more severe spectrum of disease which may account for the 
prominence of LGE. Although the numbers were small, CMR proved useful in refining the 
clinical phenotype, particularly in defining overlapping morphologies (DCM-LVNC overlap, 
n=8; DCM-HCM overlap, n=1). Subtle differences were noted when comparing those patients 
with a ‘classical DCM phenotype’ to those with ‘DCM-LVNC overlap’; however statistically 
significant differences were only noted in LVEF (19.0% versus 27.4%, p 0.04) and minimum 
wall thickness (6.3±1.1mm versus 4.9±1.3mm, p=0.03) between these two groups. One 
individual (III.2 - Figure 5.3.) presented with a DCM-HCM overlapping phenotype.  It was noted 
that he had a severely affected sibling (III:5 - Figure 5.3.) with a predominantly dilated 
phenotype who had presented in childhood and died in adolescence.  Although pedigree 
information was limited, matrilineal inheritance was considered in this family. A skeletal muscle 
biopsy showed non-specific mitochondrial abnormalities, but the findings were not sufficiently 
conclusive of a mitochondrial cytopathy.    
 
 
Figure 5.3. Family pedigree for individual with HCM/DCM phenotype (Family 23)



















Left heart study 
LVEF, mean±SD 
LVEDV (ml), mean±SD 
LVESV (ml), mean±SD 
LV mass (g), mean±SD 
LV mass/BSA (g/m2), mean±SD 
LV minimum wall thickness (mm), mean±SD 
LV maximum wall thickness (mm), mean±SD 
LV trabeculation (NC/C ratio), mean±SD 
LA dimension (mm), mean±SD 













































Right heart study  
RVEF (%), mean±SD 
RVEDV (ml), mean±SD 
RVESV (ml), mean±SD 





















Pericardial effusion <20mm, n (%) 8 (44.4%) 3 (33.3) 5 (62.5) 0 (0.0) 
Presence of late gadolinium 









Pattern of LGE, n (%) 
Sub-epicardial 




























*in keeping with an embolic infarct 
All scans were performed on the 1.5T Siemens MRI scanner with the exception of one case (done on 3.0 
Tesla Siemens MRI Scanner). In all cases, T2-weighted imaging was normal (no myocardial oedema), and 
T1 mapping was not performed as not available. LGE was not available for 3 patients (inadequate for 
analysis, n=2; contraindicated, n=1). 
Post-hoc tests were not performed as 1 group had fewer than 2 cases.   
 
 
5.3.4. Drug and interventional therapy  
Diuretics were prescribed in 89.8% of participants, with beta-blockers, angiotensin-converting 
enzyme (ACE) inhibitors (or angiotensin-II receptor blocker - ARB) and spironolactone 
prescribed in 58.3%, 87.4% and 48.8% of participants.  Forty-four percent of patients were 
prescribed digoxin. Thirteen percent of patients were on anticoagulant therapy. Thirteen 
percent of patients had devices inserted; cardiac resynchronisation therapy (CRT) 
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pacemakers (8.3%) for patients with LBBB and poor ventricular function, and ICDs (4.5%) for 
secondary prevention of SCD.  It should be noted that ICDs are not routinely available for 
primary prevention of SCD in the state health sector in South Africa (Table 5.6.). 
 
 
Table 5.6. Medical and interventional therapy  
 IMHOTEP (n=133) 
n (%) 
EURO193 (DCM, n=1260) 
(%) 
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5.3.5. Survival  
Follow-up data was available on 93 (70%) patients; 64 patients were alive at follow-up, 21 
patients died, and 8 patients underwent cardiac transplant (7/8 alive; 1/8 died following 
transplant). Forty (30%) patients were lost to follow-up. The overall transplant-free survival 
probability at 1-year, 5-years and 10-years was 93.4% (95% confidence interval [CI] 87.3 – 
96.7), 82.2% (95% CI 73.3 – 88.3) and 73.1% (95% CI 62.2 – 81.4) respectively. Median 
survival time was 5.3 years (IQR 2.3 – 8.4) and mean age of death was 41.5 ±9.6 years. 
Patients with PPCM had better outcomes compared to other forms of DCM 
(death/transplantation; 26 versus 3, p=0.02) and although not statistically significant, patients 
on digoxin had higher rates of adverse outcomes (death/transplantation) than those not on 






Figure 5.4. Kaplan-Meier survival analysis. A. Transplant-free survival overall. B. 
Transplant free survival in PPCM compared to DCM (excluding PPCM). C. Transplant-free 














5.4.  DISCUSSION 
In this study, we describe the baseline characteristics of patients with DCM seen at tertiary 
institution in South Africa over a period of 2 decades.  While the numbers do not reflect the 
full spectrum of patients seen at our institution, they represent a useful resource for genetics 
research in patients with diverse ethnic backgrounds (black African 50.4%, mixed race 36.1%, 
Caucasian 12.8% and Indian 0.8%).  Due to the retrospective nature of the study, selection of 
cases was based on the quality of clinical data available to confirm a diagnosis of DCM in 
patients where DNA has previously been collected and stored at our institution.   
 
Several important observations have emerged; the age of presentation is much younger than 
has been observed in European cohorts193 (median IQR of 28.0-40.5 years versus 40.0-58.0 
years). With the exception of secondary causes of DCM including tachycardia-related 
cardiomyopathy, anthracycline-related cardiomyopathy and alcohol-related cardiomyopathy, 
where the mean age of presentation was 47 ±11.4 years, all other forms of DCM had a much 
younger age of onset (idiopathic, 37.0 ±12.6 years; familial DCM, 35.8 ±11.2 years; PPCM, 
30.9 ±7.5 years; HIVAC, 35.0 ±8.0 years; DCM/LVNC overlap, 30.4 ±9.8 years). With a 
younger age of onset and a median survival time of 5.3 years, we also observe a younger age 
of death (41.5 ±9.6 years). These findings have significant social and economic implications 
for families and communities. Furthermore, in contrast to European cohorts where DCM is 
predominantly seen in men (74.2%), we have a much more equally weighted cohort with a 
slight female predominance, which raises concern about the potential impact these conditions 
have on both maternal health care and child welfare. Majority of patients presented with 
reduced effort tolerance (NYHA Class II-IV, 91.0%), signs and symptoms of congestive heart 
failure, dilated LV (90.8%; mean LVEDD 64 ± 9.0mm) and severely impaired systolic function 
(mean LVEF 28.0 ± 10.9%). As would be expected in a younger cohort of patients, co-
morbidities such as diabetes, hypertension and chronic lung disease were infrequent. At 
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baseline, atrial and ventricular arrhythmias were reported less frequently than in European 
cohorts.  
 
In comparison to a previous study on idiopathic and familial DCM at our institution where a 
mortality was reported as 40% at a median follow-up of 5 years,4 transplant-free survival at 5 
years appeared to be better in our cohort (82.2%). This may, in part, reflect the variation in 
prognosis associated with different aetiologies, and the inclusion of secondary causes of DCM 
in our cohort, particularly patients with PPCM (29.3%). It is well recognised that PPCM patients 
have greater rates of recovery and better survival than patients with other forms of DCM,15 
and our findings further support this observation (Figure 5.3. B.). Digoxin has been associated 
with worse outcomes in HF194 and has been reported as a significant predictor of mortality in 
patients with idiopathic DCM.4 Although not statistically significant, digoxin was associated 
with reduced survival in our cohort, however, due to the nature of the retrospective 
observational design of this study, it is not possible to make definitive conclusions related to 
this observation.  On review of the clinical characteristics of those on digoxin compared to 
those not on digoxin at baseline, we found that there were no significant differences in age, 
sex, ethnicity, NYHA Class III-IV symptoms, heart rate, blood pressure, QTc, LV dimensions, 
LV systolic function, or RV pressures. There were, however, significant differences in 
prescribed medications, with higher numbers of patients on ACE-inhibitors/ARB, MRA and 
diuretic therapy in the group on digoxin at baseline. The observation likely reflects guideline-
based HF management where digoxin is indicated in symptomatic patients already on 
maximal tolerated doses of ACE-inhibitors, beta-blockers and MRA therapy.174 While this may 
suggest more advanced disease, we have not been able to demonstrate any significant 
differences in any other baseline parameters to support the presence of more severe disease 
in those on digoxin.  Unfortunately, we do not have sufficient data on the clinical management 
of patients over time to appreciate the relevance of this observation. Our study does, however, 
show a decline in the percentage of patients on digoxin at our institution, compared to what 
was reported previously by Ntusi et al. The lower rates of beta-blocker therapy overall may be 
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related to the presence of congestive heart failure, however, when analysed there were no 
statistically significant differences in NYHA class, diuretic use or the presence of clinical signs 
of CCF between those on beta-blockers and those not on beta-blockers at baseline. It should 
be noted that 59% of patients presented prior to the inclusion of MRA therapy into the HF 
guidelines (Class Ia) in 2012.195  These observations, while interesting, merely highlight the 
limitations of retrospective observational studies in making clinically useful inferences.    
 
5.5.  LIMITATIONS 
This study has all the limitations of a retrospective observational design, including incomplete 
data, non-uniform assessments, variable degrees of investigation and inclusion bias. The 
younger age of onset and more severe disease noted in this cohort may be a reflection of 
selection bias, as patients were enrolled from a previous study that specifically recruited 
patients with idiopathic and familial DCM at a tertiary centre. Thirty percent of patients were 
lost to follow-up, and may reflect undocumented deaths. Despite these limitations, inclusion 
of these patients affords us the opportunity to review outcomes in the context of standard of 
care within our institution over a prolonged time period and provides important insights into 
the impact these conditions have on health care and social stability within communities.   
 
5.6.  CONCLUSION   
While there are a number of clinical questions that remain unanswered, the relative 
improvement in survival compared to a previous study conducted in our institution is 
encouraging and may simply reflect the advancements in heart failure over the last 20 years. 
The age of onset of DCM and age of death are significantly younger in our population 
compared to European cohorts, with potential health care, social and economic implications. 
In addition to looking at outcomes, the primary aim of recruiting prevalent cases to IMHOTEP 
was to increase the number of cases of dilated cardiomyopathy on which to conduct genetic 
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research. The work done in delineating the underlying cause of dilated cardiomyopathy in our 
population and refining the phenotypic variation in expression of disease will hopefully prove 
useful in interpretation of genetic variants that may be identified in this cohort in the future.   
 
5.7.  CANDIDATE CONTRIBUTION AND ACKNOWLEDGEMENTS  
All patients were retrospectively recruited by S. Kraus. Over 450 unrelated cases of DCM were 
screened according to the SOP in Appendix H. All clinical data was reviewed by S. Kraus.  
Data collection was done by S. Kraus with assistance from medical students, T. Suttle and E. 
Chetwin. Data analysis was done by S. Kraus in consultation with statistician, K. Manning. 
Vital status follow-up was done by U. September (research nurse) and S. Kraus.    
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CHAPTER 6: Clinical and cardiovascular magnetic 
resonance (CMR) characteristics of incident 
cardiomyopathy patients from Cape Town: application of 
the 3-stage diagnostic approach 
6.1.  INTRODUCTION 
International registries have played a fundamental role in refining diagnostic criteria and 
improving clinical care and long-term survival in cardiomyopathy patients, particularly HCM 
and ARVC.61,93 While there are a number of single centre studies on the various forms of 
cardiomyopathy from Africa,4,60,96,100 there is a paucity of large registry data from the continent. 
Heart failure studies have identified notable differences in the causes of heart failure in African 
patients compared to those from high income countries, and have shown that African patients 
present at a younger age and have a higher mortality.2,5 While these data are broadly 
informative on heart failure in Africans, they do not provide sufficient information on the 
causes, manifestation or outcomes specific to heart muscle disease.  
 
Numerous diagnostic approaches and clinical guidelines for cardiomyopathies and 
myocarditis have been published, highlighting the degree of complexity underpinning heart 
muscle disease.14,23,33,58,73,103,165,196-198 A multidisciplinary approach is recommended with 
deliberate analysis of every aspect of the clinical phenotype in individuals with cardiomyopathy 
(and their families), with careful integrated interpretation of cardiac investigations and 
reanalysis of clinical data throughout the diagnostic, treatment and follow-up process.14 CMR 
is recognised as an integral part of the diagnostic work-up of patients with cardiomyopathy, 
providing reliable and reproducible data pertaining to functional and morphological 
characteristics of the myocardium.116,199 Tissue characterisation techniques can be particularly 
useful in non-invasively determining specific aetiologies. The availability of sophisticated 
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investigations, specialised management interventions, and clinical expertise remains a 
challenge in LMICs, and the utility of scarce resources is highly relevant. More information on 
the manifestation of these conditions in local populations would be highly informative for health 
care system development and optimisation.   
 
In this chapter, we present pilot phase data on adult patients recruited prospectively to 
IMHOTEP at the initiating centre, Groote Schuur Hospital, in Cape Town. A primary focus of 
this study was detailed phenotyping of new cases of cardiomyopathy in order to identify 
specific aetiologies of heart muscle disease presenting to our tertiary centre. The specific aims 
of this study were to (1) describe the baseline clinical characteristics of patients with newly 
diagnosed cardiomyopathy (incident cases) recruited into the IMHOTEP study over a 30-
month period; (2) describe the CMR features of patients with newly diagnosed cardiomyopathy 
and examine the role of CMR in identifying specific aetiologies; and (3) to review the 
usefulness of the 3-stage diagnostic approach to cardiomyopathy adopted by IMHOTEP and 
discuss its application in resource restricted environments. 
 
6.2.  METHODS 
6.2.1. Study population 
The study population comprised of unrelated adult patients referred to the Cardiomyopathy 
Clinic at Groote Schuur Hospital in Cape Town (or directly to the IMHOTEP study) between 1 
February 2015 and 31 July 2017. 
 
6.2.2. Study design and diagnostic approach 
This sub-study primarily focused on the incident cases arm of IMHOTEP, where patients with 
newly diagnosed cardiomyopathy were recruited and followed up prospectively. The rational 
and design of IMHOTEP, and eligibility criteria for inclusion into the study (Chapter 3 – Table 
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3.2.) have been described in Chapter 3.   All patients were evaluated according to the 3-stage 
diagnostic approach (Chapter 3 – Tables 3.4.1. and 3.4.2.) and the diagnosis of 
cardiomyopathy was based on published criteria. Core investigations including ECG and 
echocardiography were required for enrolment. All extended diagnostic investigations and 
management procedures were done according to the discretion of the attending clinician, 
however, CMR studies that were not performed as part of the clinical evaluation of the patient, 
were conducted by the study investigators where possible.  Informed consent was obtained 
prior to recruitment into the registry.     
 
6.2.3. CMR analysis 
CMR studies were performed on both 1.5 Tesla and 3.0 Tesla Siemens MRI scanners. 
Standardised CMR protocols were used to evaluated chamber dimensions, ventricular 
function, LV mass, haemodynamic assessment, and tissue characteristics (including native 
and post-contrast T1 and T2 mapping techniques where available) and late gadolinium 
enhancement (LGE).  CMR studies done as part of the clinical evaluation from referral centres 
were accepted if standardised protocols were followed for image acquisition and image quality 
was adequate for comprehensive evaluation. All images were reviewed by 2 trained readers 
and post processing analysis was done using Argus software (Siemens Health Systems, 
Version VE 11).   
 
6.2.4. Statistical analysis  
Descriptive statistics were used to describe the study population. Continuous variables were 
tested for distribution using the Shapiro-Wilks test for normal data and using a histogram for 
visualisation.  Normally distributed data were summarized as mean and standard deviation. 
Non-normally distributed data were reported as median and interquartile range.  Wilcoxon-
sum rank and Kruskal-Wallis tests were used to determine differences between non-normally 
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distributed data. Categorical variables were summarised in tables and reported as number 
and proportion and Chi-squared tests of equal proportions were used to determine differences 
in categorical data.  Statistical analysis was performed using IBM SPSS Statistics 2017 
(Version 25.0). 
 
6.3.  RESULTS 
6.3.1. Enrolment 
A total number of 314 unrelated patients were reviewed between 1 February 2015 and 31 July 
2018. Of the patients seen, 103 patients were newly diagnosed with cardiomyopathy and were 
enrolled into the incident cases arm of IMHOTEP after initial evaluation (history, examination, 
electrocardiogram and echocardiography) as per the first stage of the 3-stage diagnostic 
approach (Chapter 3 – Table 3.4.). Subsequent to enrolment and after further clinical 
evaluation (including CMR), 4 cases were excluded with alternative diagnoses (Figure 6.1.). 
Three of the 4 cases excluded had hypertensive heart disease, diagnosed according to the 
exclusion criteria described in chapter 3 (Table 3.2.). Although these patients had blood 
pressures <160/100 at enrolment, on further evaluation we found significant hypertensive 
target organ damage in two of these cases. The third case presented with heart failure and 
normal blood pressure in the postpartum period. At follow-up, with recovery of her LV function, 
she was noted to be hypertensive on more than one occasion, requiring multiple anti-
hypertensive agents. The fourth patient was diagnosed with LV dysfunction secondary to a 
left anterior descending artery territory myocardial infarction noted on CMR. The baseline 
characteristics of the 99 cases of cardiomyopathy included into IMHOTEP are represented in 




Figure 6.1. Recruitment of incident cases to IMHOTEP 
*Cases of cardiomyopathy that had recovered with incomplete baseline data, diagnostic 
uncertainty, or recruitment not feasible. **CMR was not performed in 32 cases.  
ARVC; arrhythmogenic right ventricular cardiomyopathy, CAD; coronary artery disease, CMR; 
cardiovascular magnetic resonance, DCM; dilated cardiomyopathy, DM; diabetes mellitus, 
GSH; Groote Schuur Hospital, HHD; hypertensive heart disease, HCM; hypertrophic 
cardiomyopathy, IHD; ischaemic heart disease, LVNC; left ventricular noncompaction, RCM; 
restrictive cardiomyopathy, TOD; target organ damage,  




15 Other genetic conditions
30 Other
26 Cardiomyopathy*
Incident (new) cases enrolled into IMHOTEP
n = 103
EXCLUDED, n = 4
1 HHD   
1 IHD (CMR diagnosis)
1 HHD with TOD, and CAD 
1 HHD/DM
Final diagnosis of cardiomyopathy
n = 99 
DCM










Medical history and examination
Electrocardiogram
Echocardiogram
Blood investigations (depending on phenotype)
Family history and basic pedigree
Extended investigations
CMR performed in 71/103**
Other non-invasive and invasive investigations 
performed according to clinical indications
IMHOTEP PREVALENT 
CASES, n = 47
Reported separately
Adult patients attending the 
cardiomyopathy clinic at GSH 
n = 284 





Table 6.1. Baseline Characteristics of 99 incident cases recruited 
 DCM (n = 67) HCM (n = 13) ARVC (n = 4) RCM (n = 4) LVNC (n=11) P value 
Female, n (%) 36 (53.7) 5 (38.5) 1 (25.0) 3 (75.0) 8 (72.7) 0.301 
Ethnicity, n (%) 
Black 
Caucasian 























Age at presentation, years  
Mean age ±SD 
Median age (IQR) 




















25 - 52 
 
0.002 
Type of presentation, n (%) 
Symptomatic and living 
Resuscitated (survived cardiac arrest) 
Embolic event 




























NYHA Class, n (%) 
NYHA Class I 
NYHA Class II 
NYHA Class III 




















































































Onset of symptoms peripartum (females), n (%) 21/36 (58.3) 0/5 (0.0) 0/1 (0.0) 1/3 (33.3) 3/8 (37.5) 0.104 
Viral illness preceding presentation, n (%) 17 (40.3) 0 (0.0) 0 (0.0) 1 (25.0) 1 (9.1) 0.416 
Previous chemotherapy for cancer, n (%) 6 (9.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.007 
Lifestyle/substance exposure, n (%) 
Alcohol (>30 drinks/month or binge use) 





















Table 6.1. Baseline Characteristics of 99 incident cases recruited (continued) 
 DCM (n = 67) HCM (n = 13) ARVC (n = 4) RCM (n = 4) LVNC (n=11) P value 
Family history, n (%) 
Heart failure  
Cardiomyopathy 
SCD < 35y 































Co-morbidities, n (%) 
HIV (ART naive) 
HIV (on ART) 
Hypertension (not considered causal) 
Diabetes 
Chronic pulmonary disease 
Chronic renal disease 
























































Events prior to or at the time of recruitment, n (%) 
Embolic stroke/loss of limb 
Atrial arrhythmia 
Ventricular tachyarrhythmia 
Second or third degree heart block 





































Examination at time of enrolment  
Heart rate (beats/minute), mean ±SD 
Systolic blood pressure (mmHg), mean ±SD 







































































































6.3.2. Diagnosis   
The commonest diagnosis was DCM (n=67, 67.7%), followed by HCM (n=13, 13.1%), LVNC 
(n=11, 11.1%), ARVC (n=4, 4.0%) and RCM (n=4, 4,0%) (Table 6.2.). All patients with ARVC 
fulfilled definite (n=3) or borderline (n=1) ARVC task force criteria.73 A diagnosis of LVNC was 
made if CMR criteria were fulfilled.164  Ten of the 11 cases (90.1%) with LVNC had overlapping 
DCM phenotypes with dilatation of the LV chamber and systolic dysfunction.  Of the 67 
patients with DCM, idiopathic (22.1%) and peripartum cardiomyopathy (18.1%) accounted for 
the vast majority of cases. Other secondary causes included anthracycline-related 
cardiomyopathy (6.1%), illicit drug use (methamphetamines and cocaine) (4.0%), HIV-
associated cardiomyopathy (4.0%), alcohol (3.0%), thyrotoxicosis (1.0%), tachycardia- or 
PVC-related cardiomyopathies (2.0%) and rheumatoid arthritis (1.0%). Alcohol was only 
considered causal where there was significant alcohol intake and other target organ damage 
was evident (e.g. peripheral neuropathy). Inflammatory causes of cardiomyopathy diagnosed 
on CMR included 1 case of acute myocarditis (presumed viral, no EMB), 1 case of 
endomyocarditis associated with hypereosinophilia (EMB non-diagnostic) and 1 case of 
sarcoidosis (confirmed on EMB). Two male patients (1 Caucasian, 1 black African) presented 
with a clinical-triad of cardiomyopathy, conduction abnormalities and elevated creatinine 
kinase levels in the absence of neuromuscular abnormalities. Neither patient had a family 
history of cardiomyopathy or SCD, however the Caucasian patient presented with a cardiac 






Table 6.2. Final diagnosis of the first 99 incident cases recruited to IMHOTEP 
Final diagnosis Patients n=99 
n (%) 
Dilated cardiomyopathy 
Idiopathic dilated cardiomyopathy 
Familial dilated cardiomyopathy 
Cardiomyopathy with conduction abnormalities and CK elevation 
Secondary 





Cardiomyopathy secondary to CTD 
HIV 
Thyrotoxicosis 



















Hypertrophic cardiomyopathy 13 (13.1) 

















CK, creatinine kinase; CTD, connective tissue disease; HIV, human immunodeficiency virus; PVC, 
premature ventricular contractions; LVNC, left ventricular non-compaction. 
 
 
A positive family history of heart failure (12.1%), cardiomyopathy (6.1%), and/or premature 
SCD (SCD<35 years in 4.0% and SCD≥35 years in 5.1%) was reported in 20.2% of cases.  
Routine family screening was not routinely conducted due to resource restraints and familial 
cardiomyopathy, by strict definition of having two or more affected individuals in a family, was 
only confirmed in 7 cases (DCM n=2, HCM n=2, ARVC n=2, LVNC n=1). Specific examples 







Figure 6.2. Familial DCM (Family 35) 
 
Index patient III:5 was diagnosed with PPCM when she presented with heart failure in her third trimester of pregnancy. Her diagnosis changed 
to familial DCM after her son (IV:4) presented with heart failure and dilated cardiomyopathy at age 20 months




Figure 6.3.  Familial cardiomyopathy characterised by LVNC and heart block (Family 28) 
 
Index patient III:3 presented at age 28 years with vague symptoms of palpitations and fatigue.  She reported a family history of heart block 
associated with heart failure and premature death (mother [II:3] and brother [III:2] died at ages 32 and 39, respectively).  On evaluation, index 
patient III:3 had an atrial rhythm and nonspecified conduction abnormalities on ECG.  Her echocardiogram showed diastolic dysfunction but 
normal cardiac dimensions and preserved systolic function. CMR confirmed features of LVNC with linear mid-wall LGE. Shortly after her initial 
presentation, she developed 2.1 heart block requiring permanent pacing. 




Figure 6.4. Family pedigree for family with HCM and a previously identified sarcomeric mutation MYH7 c.2282C>A (p.T761N)  
(Family 16) 
 
Index patient IV:2 was recruited to IMHOTEP when he presented with HCM at age 42. On further exploration of the family history, it was 
discovered that his mother (III:2) had participated in a research study and was reported to have a pathogenic sarcomeric mutation, MYH7 
c.2282C>A (p.T761N).60 Genetic screening for the MYH7 c.2282C>A (p.T761N) in our index case and other family members is still pending.




The mean age of diagnosis was 36.8 ± 12.5 years and differed significantly between 
cardiomyopathies (p=0.002); highest in patients with HCM (49.5 ± 13.6 years) and lowest in 
patients with ARVC (30.5 ± 16.7 years). A large distribution of age was observed in ARVC 
and RCM but the numbers were very small in both these groups and the distribution of age 
was considered normal overall. (Figure. 6.5.). Just over half of the total number of patients 
recruited were female (n=53, 53.5%). The majority of patients were mixed race (n=45, 45.5%) 




Figure 6.5. Histogram showing distribution of age of presentation 
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6.3.4. Symptoms, treatment and events at the time of enrolment 
Most patients (96.0%) were symptomatic at presentation and there were significant 
differences between the diagnostic groups for NYHA class, syncope, orthopnoea, paroxysmal 
nocturnal dyspnoea (PND) and oedema.  Syncope was more common in patients with ARVC 
(50.0%) and HCM (23.1%), whereas moderate to severe effort intolerance (NYHA Class III/IV) 
was more frequently seen in DCM (61.1%), RCM (50.0%) and LVNC (63.6%). Signs of 
congestive heart failure (orthopnoea, PND, oedema) were more common in patients with 
DCM, RCM and LVNC. Clinical features of HF correlated with a significant difference in diuretic 
use between the groups (DCM 91.0%, RCM 75.0%, LVNC 72.7% compared to HCM 23.1%; 
and ARVC 0%).  Palpitations were frequently reported in all cardiomyopathies and there was 
no significant difference between the groups. The onset of symptoms in the peripartum period 
was observed in 25/53 (47.2%) of women, with a final diagnosis of PPCM being made in 
almost a third of the women enrolled (n=17/53, 32.1%).  It should be noted that all cases in 
the LVNC category, where the onset of symptoms occurred in the peripartum period, the 
diagnosis of LVNC was made on CMR at least 6 months post-delivery. There were significant 
differences in baseline heart rate and systolic blood pressure between the different types of 
cardiomyopathy, with a higher mean heart rate (89 ± 22 beats per minute) and lower mean 
systolic blood pressure (108 ± 13 mmHg) in DCM patients. 
 
Beta-blockers and ACE-inhibitors (or ARBs) were prescribed in 76.8% and 77.8% of cases 
respectively, however at the time of recruitment, optimal dosing of these drugs was only 
achieved 13.2% (beta-blockers) and 14.3% (ACE-inhibitors/ARBs). Mineralocorticoid receptor 
antagonists (MRA) were most frequently prescribed in DCM (49.3%) and LVNC (63.6%) 
although the difference between all groups was not considered significant. Calcium channel 
blockers (verapamil) were only prescribed in 2 patients with HCM.  Few patients (7.1%) were 
on digoxin.  
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Three (3.0%) patients (ARVC n=2, DCM n=1) had a history of survived cardiac arrest, and 7 
(7%) patients had documented ventricular tachyarrhythmia’s at the time of enrolment (DCM 
n=2, ARVC n=4, LVNC n=1). All 4 ARVC patients had implantable cardioverter defibrillators 
inserted prior to enrolment, however, none of the DCM or LVNC patients had devices at the 
time of recruitment. One patient (as described in Figure 6.3.) developed 2:1 heart block shortly 
after recruitment and subsequently had a pacemaker inserted. Atrial fibrillation/flutter was 
documented in 4 (6%) patients with DCM and 1 patient with RCM (25%).  A history of a prior 
embolic event was observed in 7.5% and 18.2% of patients with DCM and LVNC, respectively.  
Oral anticoagulation was prescribed in 19.2% of patients in total at enrolment.     
 
6.3.5. Baseline investigations 
Investigations performed are represented in Table 6.3. Electrocardiograms and 
echocardiograms were available for all 99 recruited patients and additional investigations were 
done according to clinical indications at the attending physicians’ discretion. (Table 6.4. and 
Table 6.5.) Apart from heart rate, there were no significant differences in the ECG findings for 
the different cardiomyopathies. Most patients (90.9%) were in sinus rhythm (SR) at enrolment 
(SR with normal PR interval, 81.8%; SR with first degree heart block 9.1%). T- wave inversion 
was reported in the 67.7% of patients overall. QRS morphology was considered normal in 
74.7% of cases. Left bundle branch block was the most frequently occurring conduction 
abnormality overall but was only observed in DCM and LVNC patients (DCM n=6; 9.0%; LVNC 
n=2, 18.2%).  
 
As expected, there were differences observed in echocardiographic findings between the 
different subtypes, specifically for left atrial and ventricular dimensions, LV ejection fraction 
(LVEF), septal and LV wall thickness, RV systolic pressures and the presence of moderate or 
severe mitral regurgitation. LV dimensions were increased in both DCM (LVEDD 64.9 ±8.7) 
and LVNC (LVEDD 63.9 ±8.1). Severely impaired systolic function (mean LVEF 28%) and 
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diastolic dysfunction was observed in both DCM and LVNC groups. Diastolic dysfunction with 
preserved mean ejection fraction was seen in patients with HCM and RCM.  Mean left atrial 
size was increased for all subtypes except ARVC. Moderate to severe functional mitral 
regurgitation was reported in half of the patients with DCM (55.2%) and RCM (50.0%), and 
over a third of patients with HCM (38.5%) and LVNC (36.4%). RV systolic pressures were 
significantly higher in RCM, DCM and LVNC subtypes (p 0.012). Intracardiac thrombus was 
reported in 10.5% of the DCM subtype.  
 
 




(n = 67) 
n (%) 
HCM 
(n = 13) 
n (%) 
ARVC 
(n = 4) 
n (%) 
RCM 
(n = 4) 
n (%) 
LVNC 









Invasive coronary angiography 
Endomyocardial biopsy 



















































CMR, cardiovascular magnetic resonance; CTA, computed tomographic angiography; ECG, 
electrocardiogram; SAECG, signal average electrocardiogram.  
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Table 6.4. Electrocardiogram  
 DCM 
(n = 67) 
n (%) 
HCM 
(n = 13) 
n (%) 
ARVC 
(n = 4) 
n (%) 
RCM 
(n = 4) 
n (%) 
LVNC 
(n = 11) 
n (%) 
P value 
Rate (beats per minute), mean±SD 
Rhythm, n (%) 
Sinus rhythm (normal PR interval) 
Sinus rhythm with 1
st
 degree HB  
Atrial fibrillation 
Atrial flutter 
Atrial ectopic rhythm 
QRS duration (ms), mean±SD 
QRS fractionation, n (%) 






Non-specific conduction abnormality 
T-wave inversion, n (%) 
QTc, mean±SD 
Chamber hypertrophy, n (%) 
Left atrial hypertrophy 
Right atrial hypertrophy 
Left ventricular hypertrophy 












































































































































Table 6.5. Echocardiogram 
 DCM (n = 67) 
n (%) 
HCM (n = 13) 
n (%) 
ARVC (n = 4) 
n (%) 
RCM (n = 4) 
n (%) 
LVNC (n = 11) 
n (%) 
P value 
Left heart study 
LV end-diastolic dimension (mm), mean±SD 
Left ventricular ejection fraction (LVEF) 
LVEF (m-mode), mean (n = 98) 
LVEF (volumetric) mean (n = 24) 
Left ventricular hypertrophy reported, n (%) 
IVS thickness (mm), mean±SD (n=98) 
LVPW thickness (mm), mean±SD (n=98)  
E/A ratio, mean±SD (n=82) 
E/E’ ratio, mean±SD (n=58) 
Deceleration time, mean±SD (n=73) 
Left atrial size 
LA dimension (mm), mean±SD (n=96) 
LA area (cm
2
), mean±SD (n=33) 
LV wall thinning reported, n (%) 
LV regional wall motion abnormalities, n (%) 
LVNC reported, n (%) 













































































































Right heart study 
RA dilatation reported, n (%) 
RV dilatation reported, n (%) 
TAPSE (mm), mean ±SD (n=62) 
Tricuspid regurgitation (mod – severe) 






































LA thrombus, n (%) 
LV thrombus, n (%) 
























Pericardial effusion (≤18mm), n (%) 13 (19.4) 1 (7.7) 0 (0.0) 2 (50.0) 2 (18.2) 0.634 
IVS, intraventricular septum; LA, left atrium; LV, left ventricle; LVNC, left ventricular non-compaction; LVPW, left ventricular posterior wall; RA, right atrium; 
RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion. 
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6.3.6. CMR findings 
CMR studies were conducted in 71/103 patients initially recruited. Four patients were 
subsequently excluded with alternative diagnoses. The CMR findings for the remaining 67 
cases are represented in Table 6.6. Table 6.7. includes the details of selected cases where 
CMR contributed to confirming or altering the clinical diagnosis. The data showed significant 
differences in the means for LV and RV ejection fractions, ventricular volumes and myocardial 
wall thickness consistent with the different morpho-functional definitions of each subtype. 
There was no significant difference in LV mass between the groups. Moderate to severe 
functional mitral and tricuspid regurgitation was observed in 50.7% and 22.4% of cases 
respectively overall. T1 mapping was only available to those patients (30/67) that were imaged 
on the 3 Tesla research scanner. Mean T1 times were increased in all subtypes where 
mapping was performed. Late gadolinium enhancement (LGE) was present in 60/65 (92.3%). 
Two patients (DCM n=1, ARVC n=1) did not have LGE imaging performed. Linear mid-wall 
enhancement was frequently observed in the DCM (94.6%) and LVNC (63.6%) subgroup. 
Three patients (DCM n=2, LVNC n=1) had small sub-endocardial or transmural enhancement 
patterns consistent with embolic infarcts. Inferolateral epicardial enhancement associated with 
a corresponding regional wall motion abnormality was reported in one patient with myocarditis. 
All HCM patients scanned had mid-wall patchy diffuse LGE. Failure to null and markedly 
increased T1 times consistent with amyloidosis were reported in one case of restrictive 
cardiomyopathy. One patient initially referred to IMHOTEP with suspected ARVC (definite 
criteria based on repolarization, depolarization, arrhythmia and structural TFC) had multiple 
patterns (mid-wall, subepicardial, subendocardial, transmural) of LGE consistent with 
sarcoidosis, which was subsequently confirmed on histology. A diagnosis of hypereosinophilic 
endomyocarditis with apical thrombus was made using CMR in a young man who presented 
with chest pain, a troponin leak and unobstructed coronaries. Images of the above described 
examples are illustrated in Figure 6.6.     
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Table 6.6. CMR findings in 67 incident cases 
 DCM 
n = 38 
HCM 
n = 11 
ARVC 
n = 3 
RCM 
n = 4 
LVNC 
n = 11 
P value 




LVEDV (ml), mean±SD 
LVEDV/BSA (ml/m2), mean±SD 
LV mass (g), mean±SD 
LV mass/BSA (g/m2), mean±SD 
Septal thickness (mm), mean±SD 
LV minimum wall thickness (mm), mean±SD 
LV maximum wall thickness (mm), mean±SD 
LV regional wall motion abnormalities, n(%) 
LV trabeculation (NC/C ratio), mean±SD 
LA dimension (mm), mean±SD 
LA area (cm2), mean±SD 
Mitral regurgitation (moderate-severe), n (%) 








































































































RVEF (%), mean±SD 
RVEDV (ml), mean±SD 
RVEDV/BSA (ml/m2), mean±SD 
RV regional wall motion abnormalities, n (%) 
RA area (cm2), mean±SD 













































Table 6.6. CMR findings in 67 incident cases (continued) 
 DCM 
n = 38 
HCM 
n = 11 
ARVC 
n = 3 
RCM 
n = 4 
LVNC 
n = 11 
P value 
Increased T2-weighted SI (ms), mean±SD 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0)e 0 (0.0) 0.001 
Pericardial effusion <20mm, n (%) 19 (50) 7 (63.6) 2 (66.7) 3 (75.0) 6 (54.5) 0.957 
Intra-cardiac thrombus, n (%)  3 (7.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.663 
T1 times (ms) (native T1 time 1100±60ms) 
 
























Presence of late gadolinium enhancement,* n (%) 36/37 (97.3) 11 (100.0) 2/2 (100.0) 4 (100.0) 7 (63.6) 0.004 
Pattern of LGE, n (%) 
Sub-epicardial 




Failure to null 

















































aMyocarditis – localised inferolateral subepicardial enhancement (n=1), bSarcoidosis (n=1), cDCM/HCM overlap (n=1); dSmall embolic infarct (n=2), 
eHypereosinophilic endomyocarditis - diffuse subendocardial, fAmyloidosis, *LGE not done in 2 patients (DCM n=1, ARVC n=1) 
BSA, body surface area; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; LVEDV, left ventricular 
end-diastolic volume; RA, right atrium; RV, right ventricle; RVEF, right ventricular ejection fraction; SAM, systolic anterior motion  
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Table 6.7. Specific cases demonstrating the diagnostic utility of CMR  
Patient 
Diagnostic 
category Referral diagnosis CMR features Specific final diagnosis 
1 LVNC PPCM (LVNC suspected) NC/C ratio 3.1, LVEDV/BSA 148ml/m2, LVEF 44%, LGE+ LVNC/DCM overlap 
15 LVNC Idiopathic DCM NC/C ratio 3.0, LVEDV/BSA 221ml/m2, LVEF 8%, LGE+ LVNC/DCM overlap 
25 LVNC PPCM  NC/C ratio 3.0, LVEDV/BSA 148ml/m2, LVEF 20%, LGE+ LVNC/DCM overlap 
51 LVNC PPCM (LVNC suspected) NC/C ratio 2.5, LVEDV/BSA 150ml/m2, LVEF 29%, LGE+ LVNC/DCM overlap 
58 LVNC DCM - possible PVC-related 
cardiomyopathy 
NC/C ratio 4.0, LVEDV/BSA 104 ml/m2, LVEF 46%, LGE- LVNC/DCM overlap 
59 LVNC Idiopathic DCM NC/C ratio 4.0, LVEDV/BSA 231 ml/m2, LVEF 19%, LGE+ LVNC/DCM overlap 
69 LVNC Unspecified familial 
cardiomyopathy   
NC/C ratio 3.4, LVEDV/BSA 64 ml/m2, LVEF 57%, LGE+ Familial LVNC with heart block 
75 LVNC Idiopathic DCM NC/C ratio 5.0, LVEDV/BSA 139ml/m2, LVEF 37%, LGE- LVNC/DCM overlap 
93 LVNC Idiopathic DCM NC/C ratio 4.0, LVEDV/BSA 210ml/m2, LVEF 10%, LGE- LVNC/DCM overlap 
700 LVNC Idiopathic DCM NC/C ratio 4.6, LVEDV/BSA 181ml/m2, LVEF 30%, LGE+ LVNC/DCM overlap 
702 LVNC Idiopathic DCM  NC/C ratio 2.4, LVEDV/BSA 112ml/m2, LVEF 51%, LGE- LVNC/DCM overlap 
18 ARVC ARVC – presented with VT RV RWMA, RVEDV/BSA 204ml/m2, RVEF 13%, LV and RV 
LGE+, (LVEDV/BSA 101ml/m2, LVEF 57%) 
Definite ARVC – Major criteria for 
structural abnormalities, arrhythmia, 
repolarization. Minor criteria for late 
potentials 
50 ARVC ARVC – presented with 
syncope, cardiac arrest 
RV RWMA and micro-aneurysms, RVEDV/BSA 158ml/m2, 
RVEF 39%, LV and RV LGE+ (LVEDV/BSA 85ml/m2, LVEF 
59%) 
Definite ARVC – Major criteria for 
structural abnormalities, repolarization. 
Minor criteria for late potentials. 
Cardiac arrest, VT present but not 
characterized. 
91 ARVC ARVC – presented with 
cardiac arrest 
RV RWMA and micro-aneurysms, RVEDV/BSA 205ml/m2, 
RVEF 14%, LGE not done, (LVEDV/BSA 108 ml/m2, LVEF 
50%) 
Definite ARVC – Major criteria for 
structural abnormalities, repolarization. 
Minor criteria for late potentials (VF 
arrest)  
49 RCM Idiopathic RCM Normal sized LV and RV (LVEDV/BSA 47 ml/m2, LVEF 60%, 
RVEDV/BSA 59 ml/m2, RVEF 66%), dilated atria (LA area 
39cm2, RA area 41cm2), patchy mid-wall LGE+, T1 time 1340. 
Pericardial effusion 34mm  
RCM – idiopathic 
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Table 6.7. Specific cases demonstrating the diagnostic utility of CMR (continued) 
Patient 
Diagnostic 
category Referral diagnosis CMR features Specific final diagnosis 
94 RCM  RCM - suspected 
amyloidosis 
LVEDV/BSA 68 ml/m2, LVEF 45%, RVEDV/BSA 66 ml/m2, 
RVEF 30%, dilated atria (LA area 38cm2, RA area 26cm2), 
septum 19mm, increased T1 time 1501ms. Atrial LGE+, LV 
failure to null and patchy mid-wall LGE+ consistent with 
amyloid infiltration. Pericardial effusion 6mm  
RCM - amyloidosis 
97 RCM PPCM  LVEDV/BSA 48 ml/m2, LVEF 53%, RVEDV/BSA 47 ml/m2, 
RVEF 36%, dilated atria (LA area 31cm2, RA area 39cm2). T1 
time 1375ms. Diffuse patchy mid-wall LGE+. Pericardial 
effusion 21mm  
Idiopathic RCM 
705 RCM Chest pain syndrome with 
troponin leak and 
unobstructed coronaries, 
transient eosinophilia  
LVEDV/BSA 72 ml/m2, LVEF 48%, RVEDV/BSA 53 ml/m2, 
RVEF 62%, LA area 16cm2, RA area 21 cm2, LV 
endomyocardial enhancement in T2 imaging, endocardial 
enhancement (apical and mid-cavity) on LGE, LV apical 
thrombus, apical endomyocardial LGE+  
Hypereosinophilic endomyocarditis 
(necrotic and thromboembolic phase of 
endomyocardial fibrosis) 
24 DCM Heart failure with severe 
mitral regurgitation (possible 
RHD) 
LVEDV/BSA 123ml/m2, LVEF 42%, RVEDV/BSA 78ml/m2, 
RVEF 48%, normal mitral valve morphology, severe mitral 
regurgitation, circumferential linear mid-wall LGE+ 
Familial dilated cardiomyopathy with 
severe functional mitral regurgitation  
52 DCM PPCM  LVEDV/BSA 141ml/m2, LVEF 39%, LV mass/BSA 69g/m2, 
septum 13mm, LV walls 6-8mm, increased T1 time 1329ms, 
patchy diffuse (septum) and circumferential linear mid-wall 
LGE+ 
Peripartum presentation with 
DCM/HCM overlap 
90 DCM Chest pain syndrome with 
troponin leak and 
unobstructed coronaries  
LVEDV/BSA 100ml/m2, LVEF 45%, RVEDV/BSA 109ml/m2, 
RVEF 42%, RWMA inferolateral wall of the LV with 
corresponding inferolateral epicardial LGE+ 
Myocarditis - likely viral aetiology (no 
EMB) 
704 DCM ARVC – definite diagnosis 
according to 2010 TFC  
Increased RV volumes and RV RWMA, multiple patterns of 
LGE+ (patchy and linear mid-wall, transmural, epicardial and 
endocardial) consistent with sarcoidosis  
Cardiac sarcoidosis - confirmed 
histologically 
703 EXCLUDED Idiopathic DCM LAD territory transmural infarction involving the lateral wall, 
inferior wall and apex 
Ischaemic heart disease with LV 
dysfunction 
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; BSA, body surface area; EMB, endomyocardial biopsy; LGE, late 
gadolinium enhancement; LV, left ventricle; EDV, end-diastolic volume; LA, left atrium; LVNC, left ventricular non-compaction; NC/C, non-compact/compact; PPCM, 
peripartum cardiomyopathy; RA, right atrium; RCM, restrictive cardiomyopathy; RHD, rheumatic heart disease; RV, right ventricle; RWMA, regional wall motion 
abnormalities; TFC, task force criteria; VT, ventricular tachycardia 
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Figure 6.6. Diagnostic CMR images of patients with (A) Myocarditis; (B) Amyloidosis;  
(C) Sarcoidosis; and (D) Hypereosinophilic Myocarditis  
 
A. Myocarditis – arrows indicate inferolateral regional wall motion abnormality on CINE short 
axis view with corresponding epicardial LGE 
B. Amyloidosis – LV wall thickness 19mm on CINE short axis view with failure to null on LGE 
imaging 
C. Sarcoidosis – increased RV volumes with RV regional wall motion abnormalities on CINE 
imaging and multiple patterns of LGE 
D. Hypereosinophilic myocarditis – apical subendocardial enhancement with thrombus on 
LGE images and subendocardial oedema on T2 weighted images 
 












6.4.  DISCUSSION 
IMHOTEP is the first prospective multi-centred cardiomyopathy registry from the African 
continent. This report includes the first 99 adult incident cases recruited as part of the pilot 
phase of the study at the initiating centre, Groote Schuur Hospital in Cape Town, and 
represents real-world contemporary data on the clinical characteristics of patients with 
different forms of cardiomyopathies referred to a tertiary centre in South Africa.   
 
Contrary to what has been reported by the European registry where HCM is considered the 
commonest form of cardiomyopathy,
193,200
 DCM is by far the most frequent type of 
cardiomyopathy seen at our institution (accounting for two thirds of the cohort) followed by 
HCM, LVNC, ARVC and RCM. While we cannot use this data to estimate population 
prevalence, our findings suggest that DCM is the predominant form of cardiomyopathy 
presenting to hospital in South Africa. This observation is further supported by a number of 
HF studies from the African continent where DCM is reported as the third most common cause 




Idiopathic DCM (22.2%) and PPCM (18.1%) accounted for the majority of cases recruited. 
The increased number of PPCM cases may, in part, reflect referral bias due to clinical and 
research interest in cardiac disease in pregnancy at our centre. The spectrum of secondary 
causes of dilated (and restrictive) cardiomyopathy was broad but on an individual level, the 
delineation of specific causes provided the opportunity to address the underlying cause in 
more than a third of patients recruited. Examples of potential interventions include, addiction 
counselling and management in cases of alcohol and drug abuse, antiretroviral therapy in 
HIV-associated cardiomyopathy, anti-thyroid therapies in thyrotoxicosis-related 
cardiomyopathy, and immunosuppression for cases of cardiomyopathy due to sarcoidosis, 
Hypereosinophilic syndromes, and autoimmune connective tissue disorders. Furthermore, 
bromocriptine has recently been shown be associated with a higher rate of full LV-recovery 
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and lower morbidity and mortality in PPCM patients.
43
 Bromocriptine is easily accessible and 
its utility in the context of PPCM is highly relevant in our cohort. 
 
A family history of heart failure, cardiomyopathy or sudden cardiac death was reported in 
20.2% of patients, however, confirmed familial disease by strict definition, was only diagnosed 
in 7.1% patients. These figures are likely an underrepresentation of the true prevalence of 
genetic disease as routine family screening was not conducted in this study and genetic testing 
has not yet been performed. A previous study conducted in the same institution reported that 
familial disease was present in 26.6% of patients with DCM,
4
 the predominant phenotype in 
our cohort. Michels et al. demonstrated that 20% of patients with a negative family history 
were found to have familial DCM when family screening was conducted,
24
 and with follow-up, 
the number of cases diagnosed with familial disease increased by 10% as additional relatives 
developed the condition.
27
  The value of follow-up has already been observed in our study by 
way of 2 examples; an index patient initially recruited as PPCM, was subsequently diagnosed 
with familial DCM after her son presented with DCM at 20 months of age, and an index case 
of HCM was found to be the son of a patient reported to have a sarcomeric mutation in a 
previous study. These examples highlight the usefulness of recruiting both adults and children 
with cardiomyopathy into the same registry, as well as the inclusion of previous smaller studies 
on cardiomyopathy from the same institutions.  Detailed phenotyping will be important in future 
genetic analysis, as we intend to test for known mutations in all index patients where DNA has 
been collected (91/99).  A clear understanding of the morpho-functional phenotype and 
contributing secondary factors (if present), will be essential in determining the significance of 
any genetic variants identified and may broaden our understanding of the interplay between 
genetic and environmental factors. While we have not been able to demonstrate familial 
disease in the two cases presenting with the triad of cardiomyopathy, conduction 
abnormalities and elevated CK levels, it would be important to exclude Lamin A/C mutations 
in these patients.       
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The age at presentation was significantly younger in our cohort than what has been reported 
in European populations (median age 36.0 years versus 49 years). While the age of 
presentation of HCM patients was similar to European patients, the mean age of presentation 
in DCM, ARVC, RCM and LVNC was ≤ 35 years in our cohort. When we excluded PPCM 
patients from the analysis, the mean age of patients presenting with DCM was 37.5 ± 10.8 
years and overall, the mean age of presentation was 38.5 ±12.8 years, therefore the increased 
numbers of PPCM cases does not solely account for the younger age of presentation in our 
cohort. This younger age of onset has great social and economic relevance as these 
conditions are affecting mothers with young children and individuals in the prime of their 
working life.  At the time of recruitment, 43.4 % were employed, 40.4% of patients were 
unemployed, 6.1% of patients were receiving government disability grants, and 5.1% were 
students. Of those patients who were unemployed, 60.0% had NYHA class III/IV symptoms. 
Importantly, more than half of the patients still working had blue collar jobs, which often 
involves some form of physical labour but only 17.4% of these employed individuals reported 
normal effort tolerance (NYHA class 1). These observations reflect the social burden 
cardiomyopathy has on the state, and very few patients with significant symptoms were 
receiving financially support. The reasons for this are likely multifactorial and further 
exploration into the social implications of cardiomyopathy in South Africa may be helpful in 
improving holistic patient care.          
 
Unlike the European registry, IMHOTEP has included LVNC as a separate subtype in 
accordance with the ESC classification. The only published prevalence data on LVNC from 
South Africa comes from another tertiary centre, where the estimated prevalence was 6.9%.
100
 
Although LVNC can be diagnosed on echocardiogram, we only included cases into this 
category where CMR had been performed confirming the diagnosis of LVNC.  While our 
numbers were small, it is worth noting that the majority of LVNC patients were enrolled as 
DCM cases initially and presented in a similar manner to those with DCM – with congestive 
heart failure symptoms, chamber dilatation (mean LVEDD 63.9mm ± 8.1) and reduced systolic 
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function (mean LVEF 28.1 ± 12.6%). In addition, echocardiographic features of 
noncompaction were only reported in 2/11 (18.2%) cases with a final diagnosis of LVNC.  This 
would suggest that LVNC may be underdiagnosed in patients presenting with the classical 
‘DCM phenotype’ and CMR is an important investigative modality in this context. While the 
classification of LVNC as a distinct cardiomyopathy remains unclear, LVNC has been 
associated with increased risk of embolic events and ventricular arrhythmias,
98
 therefore, the 
finding of LVNC has clinical relevance and may impact decisions regarding primary prevention 
for stroke and risk assessment for VT/SCD. Of note, the mean ejection fraction was 28% on 
echocardiogram in this group, however, less than a third of patients were on anticoagulation 
at the time of enrolment. Although not demonstrated in this study, the confirmation of a 
diagnosis of LVNC on CMR has the potential to influence clinical decision making with regards 
prophylactic anticoagulation in patients with LVEF < 40%.
102
         
 
In a clinical context where CMR is not readily available, understanding the diagnostic utility of 
this modality is important. By conducting CMR studies on as many patients as possible, we 
were able to make some key inferences. Firstly, the core investigations (history, examination, 
CXR, basic bloods investigations, ECG, echocardiogram, and family history) are sufficiently 
reliable in making a diagnosis of cardiomyopathy. This is particularly relevant in IMHOTEP, as 
majority of recruitment sites do not have access to extended investigations. The exclusion of 
ischaemic heart disease (IHD) has always been a caveat in studies conducted in resource 
restricted settings. We found only one case of ischaemic LV dysfunction (misdiagnosed as 
DCM) after recruitment where an extensive left anterior descending artery territory infarct was 
found on CMR. While coronary artery disease is not definitively excluded using this imaging 
modality, CMR was useful in excluding the presence of myocardial infarction as the cause of 
LV dysfunction in the DCM subgroup. The 3-stage diagnostic approach was developed in an 
attempt to guide clinicians in resource-restricted environments on how to utilise the 
cardiomyopathy diagnostic guidelines within the constraints of their clinical service to make 
the most accurate diagnosis possible.  We set out to demonstrate that reliable diagnoses of 
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cardiomyopathy can be made if the core investigations are done consistently well. In addition, 
the usefulness of CMR in detailed phenotyping and specific aetiological diagnoses has also 
been shown, demonstrating that while this is an expensive test, there is both clinical and 
research value in building a CMR service in Africa.   
 
Secondly, LGE was observed is 92.3 % of patients.  In the case of DCM, linear mid-wall and 
subendocardial patterns of enhancement were seen in 94.6% and 8.1% of patients 
respectively. These findings differ from what has been reported elsewhere, with linear mid-
wall and subendocardial LGE reported in 28% and 13% of DCM, respectively.
127
 The 
mechanisms of mid-wall fibrosis are thought to be multifactorial – genetic predisposition, toxin 
or pathogen exposure, microvascular ischaemia, abnormal immune or metabolic modulation 
including the over-activity of the renin-angiotensin aldosterone system.
129
 We speculate that 
the explanation for the higher incidence of LGE in our cohort may be, in part, related to later 
presentations and suboptimal treatment in our patients. On review of the baseline 
characteristics in DCM in our cohort compared to the European cohort,
193
 although a higher 
percentage of patients presented with NYHA class III/IV symptoms (61.1% versus 38.4%), LV 
dimensions and LVEF were similar on echocardiogram (LVEDD 64.9mm versus 64.2mm; 
LVEF 28.4-29.5% versus 32.5%). When we analysed the time from onset of symptoms to date 
of recruitment in DCM, a median time of 5.4 months (163 days, IQR 93-310) was calculated. 
Although 92.5% of patients with DCM had already been started on an ACE-inhibitor (or ARB) 
therapy at the time of recruitment, only 11.3% (7/62) of those patients were prescribed optimal 
drug doses.  Pathogen exposure and genetic predisposition may also be important factors to 
consider although currently there is insufficient data available to draw any meaningful 
conclusions. LGE in DCM has been associated with higher all-cause mortality/hospitalisation 
and SCD/VT.
129
  It would therefore be important to correlate these findings with future 
outcomes.   
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Thirdly, CMR is an important tool in detailed phenotyping, and is particularly useful in the 
context of infiltrative and inflammatory conditions.  One of the key aims of IMHOTEP was to 
establish the contribution of myocarditis to the development of cardiomyopathy in our setting 
where infectious diseases are more prevalent. We had hypothesised that by conducting CMR 
studies in patients with new onset heart failure, we would be able to diagnose myocarditis if 
present. However, we only found acute inflammation in two individuals. As patients were 
recruited from an outpatient tertiary centre, the delay in referral to us (median 163 days [IQR 
93-310] from onset of symptoms to recruitment into IMHOTEP overall) likely accounts for 
paucity of active myocarditis in our patients. This pilot data indicates that the current study 
design of IMHOTEP cannot facilitate further understanding of the burden of myocarditis in this 
context. Inpatient recruitment and earlier imaging would be required to address questions 
pertaining to myocarditis as a cause of cardiomyopathy and heart failure in our population.      
 
6.5.  LIMITATIONS 
As this study was conducted at a tertiary centre, these findings reflect the more severe end of 
the disease spectrum and we are unable to make inferences regarding the prevalence of the 
different cardiomyopathies at a population level.  As patients were recruited from a specialist 
clinic, the time period from initial symptoms varied, and therefore the baseline data obtained 
reflects different time points in the natural history of disease.  The implications of this limitation 
mainly relate to our ability to exclude acute myocarditis as a cause of dilated cardiomyopathy, 
as majority of patients did not have CMR imaging at the time of initial presentation with heart 
failure. Generalisability of our findings is limited due to the small number of patients in our 
cohort, however, despite these limitations, we have been able to make some meaningful 
inferences about the manifestations of heart muscle disease within our local context.  
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6.6.  CONCLUSION 
Although this is pilot data with relatively small numbers of patients, we have demonstrated 
that cardiomyopathy is caused by both familial and non-familial factors in the African 
population, and that secondary treatable aetiologies are present in a significant proportion of 
cases. The low rate of acute myocarditis in patients with DCM, is likely related to study design 
and the delay in clinical presentation and referral to our centre. The utility of CMR in this study 
demonstrated that the core investigations are reliable in making a diagnosis of 
cardiomyopathy, and the lack of availability of extended investigations should not limit our 
ability to conduct meaningful research in this field. The predominant type of cardiomyopathy 
presenting to hospital in South Africa is dilated cardiomyopathy, most commonly idiopathic 
DCM and peripartum cardiomyopathy. Most striking, this study shows that the age of onset of 
cardiomyopathy is significantly younger in South African patients. This has far reaching social 
and economic consequences, making cardiomyopathy an important public health problem.  
 
6.7.  CONTRIBUTIONS AND ACKNOWLEDGEMENTS  
The design and implementation of the study was conducted by S. Kraus in consultation with 
B. Mayosi and N. Ntusi.  Patient recruitment, data collection, and data analysis was done by 
S. Kraus.  CMR analysis was done by S. Kraus, under the supervision of N. Ntusi and S. 
Moosa.  P. Samuels and S. Jeremy should be acknowledged for their contributions in CMR 
image acquisition. N. Laing, U. September and M. Van der Wall assisted in the recruitment of 





CHAPTER 7: A clinical genetics overview of families with 
different morpho-functional types of cardiomyopathy in 
Africa 
7.1.  INTRODUCTION 
Familial cardiomyopathies are defined by the occurrence, in more than one family member, of 
either the same disorder, or a phenotype that is (or could be) caused by the same genetic 
mutation and cannot be accounted for by another acquired cardiac or systemic disease.
13
 
Familial (genetic) cardiomyopathies merit close study as they provide a unique opportunity for 
early diagnosis and intervention through clinical family screening, and predictive genetic 




There are two widely adopted approaches for family screening: clinical screening in the 
absence of a genetic diagnosis in the proband, and predictive molecular genetic testing. 
Cascade (step-wise) screening using simple non-invasive cardiac screening techniques, is 
adopted in scenarios where genetic data are not available, either because diagnostic genetic 
testing is not accessible or where genetic testing has failed to identify a causal mutation.  The 
primary goal of clinical family screening in cardiomyopathy is to identify relatives who may 
have the same disease as the proband.  This approach is justified by the high probability of 
disease (50%) in first-degree relatives with autosomal dominant inherited cardiomyopathies, 
and the potential benefit of early diagnosis, risk stratification and treatment implementation.  
In addition to early diagnosis and risk stratification in relatives, clinical family screening also 
provides an opportunity to refine the clinical diagnosis in the proband. This can be particularly 
useful in families with mixed phenotypes, and variable penetrance and expressivity.
58
   
 
The assessment of familial cardiomyopathies requires expertise in clinical phenotyping and a 
good understanding of inheritance patterns, transmission risk, natural history of disease, and 
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the implications of a genetic diagnosis for individuals and families.
58
 The recognition of 
mendelian inheritance patterns requires the construction of a multi-generation pedigree 
through the ascertainment of a reliable and thorough family history. This task requires time 
and specific expertise as several nuances of genetic cardiomyopathies may potentially 
confound the interpretation of pedigree data.
132
 Confounding factors include incomplete 
penetrance, variable disease expression, mixed/overlapping phenotypes, phenotypic and 
genetic heterogeneity, and the influence of environmental factors.
58,64
 Furthermore, the 





In many parts of the world, clinical family screening and genetic testing in inherited heart 
disease has become standard of care
58
 and several inherited cardiovascular disease units 
and registries have been established worldwide. On the African continent, neither family 
screening nor genetic testing for cardiovascular diseases are readily available to the general 
population. Apart from a few case reports and small cohort studies,
4,26,59,60,75,96
 there is a 
substantial gap in knowledge on the clinical and molecular genetics of the different forms of 
cardiomyopathy in African populations.  
 
The advent of advanced methods of genotyping provides opportunities for research in the field 
of cardio genetics. The adoption of first world diagnostic approaches and guidelines into low-
to-middle-income settings remains a challenge, and locally generated research is necessary 
for determination of the cost-effectiveness of family screening and molecular testing in the 
diagnosis and management of patients with inherited cardiomyopathies in Africa. 
 
The principal aims of this study were: (1) to establish a standardised approach for identifying 
and confirming familial cardiomyopathies through family screening and genotyping, applicable 
to the African research and clinical practice setting; (2) to describe an overview of the clinical 
genetics, specifically the inheritance patterns and phenotypic variation, in families affected by 
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different forms of familial cardiomyopathy that have been included into the African 
Cardiomyopathy and Myocarditis Registry Program (IMHOTEP); and (3) explore the feasibility 
of family screening and genetic testing in the South African setting.  
 
7.2.  METHODS 
7.2.1. Study design 
The standardised approach used for the clinical genetics component of IMHOTEP (Figure. 
7.1.) is an adaptation of published guidelines,
58,135,165
 and aims to identify and confirm families 
affected by different forms of familial cardiomyopathy for future molecular genetics research. 
It includes a basic guide for baseline clinical screening and follow-up for both genotype positive 
and genotype unknown families.     
 
7.2.2. Study population 
Affected families were identified using the following methods; (1) Existing families were 
identified from established studies incorporated into IMHOTEP, namely, the Clinical and 
Genetic Study of Familial Dilated Cardiomyopathy in South Africa (HREC 197/96) initiated in 
1996
26
 and the Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Registry of South 
Africa (HREC 047/2003)  initiated in 2003;95,96 (2) new families were identified by reviewing 
the diagnosis and family history of both prevalent and incident index cases of cardiomyopathy 
enrolled into IMHOTEP between 1 February 2015 and March 2018. 
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Figure 7.1. Approach to the study of familial cardiomyopathies 
 
Diagnosis of cardiomyopathy in an index case (proband) based on published criteria
Definitions of specific cardiomyopathies fulfilled:
• DCM defined by LVEF < 45% (and/or FS < 25%), and LVEDD > 117% of the predicted value corrected for 
age and BSA
• HCM defined by septal or LV wall thickness ≥ 15mm on echocardiogram or CMR, in the absence of loading 
conditions (hypertension, valve disease)
• Definite (or borderline) ARVC according to 2010 Task Force Criteria
• RCM based on the confirmation of restrictive physiology (echocardiography, CMR and/or haemodynamics)
• LVNC confirmed by echocardiographic criteria or on CMR with NC/C ratio ≥ 2.3
Exclusion of hypertensive heart disease, ischaemic heart disease, valvular heart disease, congenital heart 
disease, pericardial disease. 
Minimum requirements for diagnostic evaluation include (refer to 3 stage diagnostic approach): 
• History, examination, ECG, echocardiogram, ±CXR, ±blood investigations
• In ARVC, additional investigations including ±SAECG, ±24 hour holter, ±CMR usually required
• Family history and basic pedigree
Selection of cases for family screening
In resource limited settings, the selection of families for family screening can be based on: 
• Positive family history of cardiomyopathy, heart failure and/or unexplained SCD, or likely genetic cause 
for cardiomyopathy (e.g. ARVC, HCM) in the absence of a positive family history
• Younger age of onset
• Family member availability for screening (prioritize families with living relatives that are reported to have 
cardiac symptoms and families with a history of SCD)
• No identifiable secondary cause of cardiomyopathy




Diagnosis of familial 
cardiomyopathy defined by 
the presence of at least two 
affected family members
Molecular genetic studies
(dependent on resource 
availability/research funding)
Clinical family screening
• Family pedigree (minimum 3 generation pedigree)
• Genetics counselling
• Evaluation of relatives: history, examination, ECG, 
echocardiogram (±holter, ±CMR in selected cases 
where resources allow)
• Review of medical records in cases of deceased 
individuals
• Consent for DNA collection, storage and analysis 
• DNA sample collection
Family follow-up
Relatives at risk should have 
clinical screening every 2-5 years
Extension of the pedigree





genetic testing of 
relatives if pathogenic 
genetic mutation 
confirmed
(dependent on resource 
availability/research funding)
Study	of	familial	cardiomyopathies










The following criteria were required for inclusion: (1) confirmation of a diagnosis of 
cardiomyopathy by standard definitions in the proband;
13,73,196
 (2) informed consent for 
participation in genetics research from the proband (and family members if enrolled); (3) 
confirmation of a diagnosis of cardiomyopathy in one or more relatives using published 
criteria
73,165,196
 through clinical evaluation or medical record review, and/or confirmation of a 
causal genetic mutation in the proband. Genotype positive probands were included, even in 
the absence of comprehensive family screening for completeness sake.     
 
7.2.4. Clinical genetics 
A retrospective review was conducted for existing families identified by the Clinical and 
Genetic Study of Familial Dilated Cardiomyopathy in South Africa and the Arrhythmogenic 
Right Ventricular Cardiomyopathy (ARVC) Registry of South Africa.  Pedigree information was 
confirmed by reviewing existing hospital records and previously collected research data. 
Extension of existing families and repeat screening (as described below) was conducted in 
families that were available.   
 
For new families, a basic pedigree was constructed for index cases with cardiomyopathy at 
the time of enrolment into IMHOTEP.  In cases where a positive family history was identified, 
or where the cause for underlying cardiomyopathy was considered most likely genetic (e.g. 
ARVC, HCM),
58
 first degree relatives were invited to come for family screening.  A family 
screening research unit was established, including a physician, genetics counsellor, nursing 
sister and technologist.  At the time of family screening, detailed three to five generation 
pedigrees were constructed according to standardised human pedigree nomenclature,
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 and 
genetic counselling was provided.  Clinical evaluation of relatives included personal medical 
history, examination, electrocardiogram and echocardiogram.  Extended non-invasive 
investigations such as SAECG, 24-hour ECG and/or CMR imaging, were done for relatives of 
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probands affected by ARVC where indicated, or in cases where there was diagnostic 
uncertainty. Families affected by ARVC were reviewed by the ARVC diagnostic panel, with 
experts in clinical cardiology, electrophysiology, cardiac imaging, pathology, and genetics.   
 
Existing and new families were included if one or more relatives had a confirmed diagnosis 
cardiomyopathy according to published criteria.
13,73,165,196
 Genotype positive individuals were 
included if a 2-3 generation pedigree was available for analysis, even in the absence of any 
affected relatives. Pedigree analysis was performed to determine likely patterns of inheritance 
and phenotypic expression.  Family pedigrees were drawn using Invitae Family History Tool, 
Version 2.15.14. Invitae Corporation, US.  
 
7.2.5. Molecular genetics 
The molecular genetics results included in this study have been reported on previously in 
referenced journals or UCT Masters or PhD dissertations (Table 7.2.). Predictive genetic 
screening for 1st degree relatives, using previously reported methods,
75,96,155
 was performed 
for genotype positive families if family members were available and willing to submit a blood 
sample. Classification of variants as disease-causing was evaluated according to definitions 
outlined by recent guidelines for assigning causality
177,178
 and public archive, ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar).  
 
7.2.6. Statistical analysis 
Descriptive statistics were used to describe family pedigree analysis. Categorical variables 
are represented as number and percentage. Continuous variables were reported as mean 
and standard deviation, or median and IQR depending on distribution of data.     
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7.2.7. Ethical considerations 
Approval from the University of Cape Town Human Ethics committee was obtained for this 
study (HREC Ref 766/2014).   Informed consent for participation in cardiovascular genetics 
research was required from all probands, and included a request for permission to invite first-
degree relatives for screening.  All relatives participating in this research study were asked to 
sign consent prior to evaluation. Genetics counselling was provided to individuals and families 
by a genetics counsellor where possible. Information sheets explaining genetics research and 
cardiomyopathy were provided to patients (Appendix F).  Existing families that were enrolled 
from previously approved studies (HREC 197/93, HREC 147/2003), were only included if 
consent for genetics studies had previously been obtained. A waver of consent for deceased 
individuals was granted by the UCT HREC on the premise that the clinical information would 
be useful in understanding the phenotypic expression of genetic cardiomyopathies within 
families. All investigations performed were non-invasive and in accordance with standard of 
care guidelines.  Where a diagnosis of cardiomyopathy was confirmed in a family member, 
with the permission of the participant, the findings were shared with their attending clinicians 
or an appropriate referral to a cardiologist was arranged for ongoing clinical care.   
 
7.3.  RESULTS 
7.3.1. Clinical genetics 
Pedigree analysis was conducted for 35 families that fulfilled inclusion criteria (Table 7.1.), 
including 17 families with ARVC, 11 families with DCM, 1 family with DCM associated with 
atypical muscular dystrophy, 2 families with DCM-LVNC mixed phenotype, 1 family with LVNC 
and conduction disease, 2 families with hypertrophic cardiomyopathy (HCM), and 1 family with 
HCM/DCM mixed phenotype.  Families were divided into genotype positive and genotype 
unknown subgroups. Table 7.2. lists the genotype positive families with previously reported 
172 
mutations and Table 7.3. lists the genotype unknown families included in this study.  Family 
pedigrees are included in the appendices (Appendix K).  
 









n = 35 n = 16 n = 19 
Phenotype 
Arrhythmogenic right ventricular cardiomyopathy 
Dilated cardiomyopathy (DCM) 
Dilated cardiomyopathy with muscular dystrophy 
DCM-LVNC (left ventricular noncompaction) overlap 
Left ventricular noncompaction with conduction abnormalities 
Hypertrophic cardiomyopathy (HCM) 

























Mode of inheritance 
Autosomal dominant 
Inherited (pedigree analysis or founder mutation) 
De Novo  
Uncertain (negative family history/family screening)  
Uncertain inheritance (possible autosomal recessive)** 


















































Proband age of onset < 20 years, n(%) 13 (37.1) 7 (43.8) 6 (31.6) 
Families with a family history of SCD ≤ 35 years, n(%) 4 (11.4) 4 (25.0) 0 (0.0) 
Families with a family history of SCD > 35 years, n(%) 2 (5.7) 0 (0.0) 2 (10.5) 
Clinically affected relatives per family, n(%) 
0 affected relatives  
1 affected relative  
2 affected relatives  
3 affected relatives 
4 affected relatives  
5 affected relatives 

























*Genotype reported previously, **Unable to extend family screening beyond parents,  




Nineteen (54.3%) of the families were of European descent, 11 (31.4%) were of mixed 
ethnicity and 5 (14.3%) were black African families. The median age of presentation of the 
proband was 28.0 years (IQR 15-43) and there was no significant difference in age of onset 
between genotype positive and genotype unknown probands. Thirteen (37.1%) probands (7 
genotype positive, 6 genotype unknown) presented with severe disease under the age of 20. 
A family history of SCD was reported in 6 (17.1%) families but was only observed in families 
with ARVC; SCD under the age of 35 was observed in 4 genotype-positive ARVC families, 
and SCD ≥ 35 years was observed in 2 genotype unknown ARVC families.  
 
The mode of inheritance was considered autosomal dominant (AD) in 33 (94.3%) of the 
families. Families with autosomal dominant cardiomyopathies were further subdivided into 
inherited, de novo and uncertain modes of inheritance based on clinical and molecular genetic 
findings. Inherited autosomal dominant cardiomyopathy was demonstrated through pedigree 
analysis (and/or the presence of a known founder mutation) in 30 families (86.7%). One 
individual had a confirmed de novo mutation (described below). Two genotype positive 
probands were classified as uncertain as it was not possible to determine whether the mutation 
had occurred de novo or had been inherited based on available family data.  Autosomal 
recessive inheritance was considered likely but not confirmed in 1 (2.9%) family (Figure 7.2.). 
In this family, two affected siblings (III:6, III:7) presented with DCM under the age of 2, both 
parents (II:6, II:7) were asymptomatic with normal cardiac findings on clinical screening. As 
this family originated from central Africa, insufficient pedigree information was available to 
confidently exclude AD inheritance with incomplete penetrance or X-linked recessive 
inheritance.  X-linked recessive inheritance was observed in one family (2.9%) with DCM and 
associated muscular dystrophy (described below). The number of clinically affected 
individuals was based on clinical information obtained from medical records or screening 
conducted in our unit. We did not include relatives with reported ‘heart problems’ on family 
history where medical records were not available.
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Figure 7.2. Family 29. Dilated cardiomyopathy with probable autosomal recessive inheritance.  
A&W, alive and well (clinically unaffected) 
 
Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Feb. 9, 2019, 9:43 p.m. GMT
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Registry ARVC AD 
PKP2  
c.C1132T (Q378X) 
Watkins et al.  




Registry ARVC AD 
CDH2  
c.A686C (Q229P) 
Mayosi et al.  




Registry ARVC AD 
PKP2  
c.C1162T (R388W) 
Watkins et al.  








c.C1162T (R388W)  
PKP2  
c.C1162T (R388W) 
Machipisa, T. 2016. 









Mayosi et al.  




Registry ARVC AD 
PKP2 
c.C1162T (R388W) 
Watkins et al.  












Watkins et al.  




Registry ARVC AD 
PKP2  
c.T2540C (L847P) (VUS)* 
Watkins et al.  
Heart Rhythm 2009 
Mixed 




Registry ARVC AD 
PKP2  
c.C1162T (R388W) 
Watkins et al.  




Registry ARVC AD 
PKP2  
c.G1465A (G489R) 
Watkins et al.  
Heart Rhythm 2009 
Black 




Registry ARVC AD 
PKP2  
c.C1162T (R388W) 
Machipisa, T. 2016. 
Ph.D. Thesis, UCT 
Mixed 




Registry ARVC AD 
PKP2  
c.C1162T (R388W) 
Machipisa, T. 2016. 
Ph.D. Thesis, UCT 
Mixed 




Registry ARVC AD 
PKP2  
c.C1237T (R413X) Chapter 4 
Mixed 




Study DCM AD Troponin T 
Mayosi et al.  
CJSA 2004;15:237 
Black 




Study DCM AD 
PNL  
c.25C > T (p.R9C) 
Fish et al.  




family HCM AD 
MYH7  
c.2282C>A (p.T761N)* 
Ntusi et al.  
Cardiovasc J Afr 2016 
Mixed 
ancestry 40s - - 1 
ARVC; arrhythmogenic right ventricular cardiomyopathy, AD; autosomal dominant, CDH2; Cadherin 2, DCM; dilated cardiomyopathy, HCM; hypertrophic cardiomyopathy, JUP; plakoglobin, 
LVNC; left ventricular noncompaction, PKP2; plakophilin, PNL; phospholamban, SCD; sudden cardiac death. *Probable variant of unknown significance (VUS) although reported as 
pathogenic in Watkins et al.  
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ARVC, arrhythmogenic right ventricular cardiomyopathy; AD, autosomal dominant; AR, autosomal recessive; X-LR, X-linked recessive; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; LVNC, left ventricular noncompaction; SCD; sudden cardiac death.  
Table 7.3. Genotype unknown families 
Family Study Type of CMO 
Mode of 






SCD < 35 y 
Family 
history 





ACM 6 ARVC Registry ARVC AD Unknown Mixed ancestry 37 - + 1 
Family 18 
ACM 142 New family ARVC AD Unknown Caucasian 50 - + 3 
Family 19 
ACM 145 New family ARVC AD Unknown Caucasian 19 - - 1 
Family 20 
HCM 50 New family HCM AD Unknown Caucasian 53 - - 1 
Family 21 
DCM 343 FDCM Study DCM/LVNC AD Unknown Caucasian 28 - - 4 
Family 22 
DCM 389 New family DCM AD Unknown Caucasian 44 - - 3 
Family 23 
DCM 141 FDCM Study DCM AD Unknown Mixed ancestry 11 - - 1 
Family 24 
DCM 464 New family DCM AD Unknown Caucasian 71 - - 1 
Family 25 
DCM 390 FDCM Study DCM AD Unknown Mixed ancestry 42 - - 1 
Family 26 
DCM 236 FDCM Study DCM AD Unknown Mixed ancestry 18 months - - 2 
Family 27 
DCM 437 New family DCM/muscular dystrophy X-LR Unknown Caucasian 15 - - 2 
Family 28 
RCM 15 New family LVNC/conduction disease AD Unknown Mixed ancestry 28 - - 2 
Family 29 
DCM 435 New family DCM Uncertain (AR) Unknown Black African 16 months - - 1 
Family 30 
DCM 3 FDCM Study DCM AD Unknown Mixed ancestry 25 - - 3 
Family 31 
DCM 334 FDCM Study DCM AD Unknown Caucasian 13 - - 1 
Family 32 
DCM 24 FDCM Study DCM AD Unknown Black African 38 - - 1 
Family 33 
DCM 303 FDCM Study DCM/LVNC AD Unknown Black African 20 - - 3 
Family 34 
ACM 149 New Family ARVC AD Unknown Caucasian 26 - - 2 
Family 35 
DCM 458 New Family DCM AD Unknown Mixed ancestry 31 - - 1 
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7.3.2. Phenotypic description in selected families 
 
Family 21 (Figure 7.3.) – Genotype unknown, AD inheritance 
A multi-generation pedigree was constructed for Family 21 (Figure 7.3.). Evidence available 
supports the diagnosis of dilated cardiomyopathy in 7 individuals over 6 generations, based 
on information gathered from hospital records dating back to the 1960s and death certificates 
from as far back as 1920s.  The proband (V:8), a 28-year-old Caucasian female, presented 
for the first time in 2010 with signs and symptoms of advanced heart failure. Investigations, 
including an electrocardiogram, echocardiography, CMR, haemodynamic study and 
endomyocardial biopsy, confirmed a diagnosis of dilated cardiomyopathy with severely 
impaired systolic function (LVEF 20%) complicated by atrial fibrillation. While prominent 
trabeculations of the left ventricular wall were noted on CMR, the ratio of non-compact to 
compact myocardium was less than 2.3 and therefore did not fulfil criteria for a diagnosis of 
LVNC at the time of diagnosis.  Although she reported a preceding severe flu-like illness, a 
familial cardiomyopathy was suspected based on a family history of heart failure in her 
paternal grandfather (III:3) and his uncle (II:3). Original hospital records confirmed that the 
proband’s paternal grandfather (III:3) died in 1965 of heart failure due to a dilated 
cardiomyopathy at the age of 29. In addition, individual II:3 underwent orthotopic heart 
transplantation in 1971 at the age of 59 for dilated cardiomyopathy, confirmed by the pathology 
report of the explanted heart.  He died of organ rejection in the weeks following the procedure. 
Death certificates were obtained for individuals I:2 and II:5 reporting the causes of death as 
‘heart failure due to myocardial degeneration’ at age 52, and ‘pneumonia and heart failure’ at 
age 4, respectively. Family screening was initially conducted in 2010 for individuals IV:3, IV:4, 
IV:5, IV:6 and V:9 with no positive findings. The proband (V:8) responded to medical therapy 
and follow-up investigations showed sinus rhythm and near normal LV size and function in 
2015. In 2017, the proband’s daughter (VI:4), age 9 years, presented with acute heart failure 
and despite maximal supportive therapy, died of multi-organ failure a month after diagnosis. 
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The echocardiogram at presentation for VI:4 reported a dilated heart with LVEF 15% and 
features of left ventricular non-compaction which was subsequently confirmed at autopsy. First 
and second degree relatives (IV:3, IV:4, IV:5, IV:6, V:9, VI:5) and individual V:7 (father of VI:4) 
were screened for cardiomyopathy in 2017 following the death of VI:4. At repeat screening, 
the proband’s sibling (V:9) was found to have mildly reduced systolic function on 
echocardiogram and CMR confirmed a reduced left ventricular ejection fraction of 41% with 
features of LVNC. Individual VI:5 was carefully screened as the pedigree suggests he would 
be a mutation carrier. His cardiac function and size remained normal, with no features of LVNC 
on CMR. It should be noted that he was on ACE-inhibitor and beta-blocker therapy for primary 




Figure 7.3: Family 21. Dilated cardiomyopathy with left ventricular noncompaction (LVNC) overlap 
A&W, alive and well (clinically unaffected)
Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Feb. 9, 2019, 7:52 p.m. GMT
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Family 18 (Figure 7.4.) – Genotype unknown, AD inheritance  
A four-generation family pedigree was constructed for Family 18 (Figure 7.4.). The proband 
(IV:3) was diagnosed with definite ARVC at age 50 following a syncopal episode.  The 
diagnosis of ARVC in the proband was based on significant structural abnormalities of the RV 
(with LV involvement) on CMR, major repolarisation changes on ECG, late potentials and 
recurrent ventricular arrhythmias, one episode requiring cardiopulmonary resuscitation.  No 
causal genetic mutation was identified through screened for known pathogenic mutations for 
cardiomyopathy.  On review of the maternal family pedigree, a prominent history of sudden 
death of family members in the 5th and 6th decade of life was noted. Individual I:5 died suddenly 
while travelling on a train. Individual II:6 died in his sleep at age 49, with reported chest pain 
and shortness of breath during the preceding two weeks prior to his death. Individual II:8 
reportedly died in her sleep while in hospital for a presumed “heart attack” (pre-ECG era).  
Individual III:7 suffered a SCD while running but his death was attributed to a myocardial 
infarction confirmed at autopsy. The proband’s younger female sibling (IV:6) subsequently 
suffered a SCD (age 43) a few months after his initial diagnosis.  The autopsy (IV:6) showed 
some RV dilatation with minimal fatty infiltration, and diffuse mid-wall fibrosis in the LV wall, 
consistent with early ARVC. Clinical screening was conducted for first degree relatives (III:4, 
III:5, IV:1, IV:3, V:2, and V:3) of the proband, and available second (III:8) and third (IV:10, 
IV:11, IV:12, V:12) degree relatives.  The mother (III:5) and surviving sister (IV:5) of the 
proband both had sufficient clinical abnormalities to be considered affected.  In addition to 
earning major criteria for family history of ARVC, both III:5 and IV:5 had minor criteria for late 
potentials on SAECG, and > 500 PVC’s on Holter, as well as evidence of diffuse mid-wall 
fibrosis within the septum and LV walls on CMR despite normal chamber size and function.  
Individual III:8 was thoroughly investigated; he had evidence of a previous myocardial 
infarction (on CMR) with confirmed coronary artery disease requiring previous coronary artery 
bypass surgery, and interstitial lung disease, but he did not have any findings diagnostic of 




Figure 7.4. Family 18. Arrhythmogenic right ventricular cardiomyopathy 
Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Feb. 9, 2019, 4:35 p.m. GMT
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Family DCM 27 (Figure 7.5.) – Genotype unknown, X-linked recessive inheritance 
A 3-generation pedigree was constructed for Family 27 (Figure 7.5.).  The male proband (III:8) 
presented at age 15 with weakness and wasting of the bicep, triceps and peroneal muscles 
and markedly elevated creatinine kinase (CK) levels (CK 3173 IU/L, normal < 172 IU/L). In 
addition, he was found to have a dilated cardiomyopathy (LVEF 25-30%) on echocardiogram. 
A number of diagnoses were considered, including Emery-Dreifuss, Duchenne and Becker’s 
Muscular Dystrophy, but no definitive diagnosis has been confirmed in this patient. Molecular 
genetic testing for mutations in LMNA/C and exonic deletion and duplication mutations within 
the dystrophin gene were negative, as was the cardiomyopathy gene panel screening done 
at an international diagnostic genetic screening facility. Subsequent to the proband’s 
diagnosis, his 21-year-old male sibling (III:5) developed acute heart failure following a viral 
gastrointestinal illness, and required cardiac transplantation within a few months of 
presentation. The presumed aetiology of “viral myocarditis” was never confirmed as the 
explanted heart was not sent for histological examination. No neuromuscular abnormalities 
were documented in his clinical records. At subsequent family screening in our unit, it was 
noted that this individual had subtle wasting and mild weakness of the peroneal muscles 
bilaterally and a markedly elevated CK level (CK 2279 IU/L, normal <172 IU/L). Furthermore, 
the proband’s twin sister (III:7), who was 19 years old and 23 weeks pregnant at the time of 
screening, was found to have a mildly dilated heart with mildly reduced systolic function (LVEF 
45%). Although her neuromuscular examination was considered normal, her CK level was 
mildly elevated (CK 412 IU/L, normal < 146 IU/L). These findings were considered consistent 
with that of a carrier of an X-linked muscular dystrophy. Both parents (II:3 and II:4) had normal 
neurological and cardiac examinations, normal cardiac dimensions and systolic function on 





Figure 7.5. Family 27. Dilated cardiomyopathy with associated muscular dystrophy
Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Feb. 9, 2019, 9:36 p.m. GMT
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Family 5 (Figure 7.6) – Genotype positive, de novo 
Our group (Mayosi et al.) recently reported that a genetic mutation in the cadherin-2 (CDH2) 
as a novel genetic cause of arrhythmogenic right ventricular cardiomyopathy (ARVC) in family 
ACM 2 (Family 2). In addition to the CDH2 c.686A>C, p.Q229P mutation described in ACM 2 
family (Family 2), a second rare mutation in CDH2 (i.e., CDH2 c.1219G>A, p.Asp407Asn) was 
found in another unrelated subject with ARVC, ACM 11.2 (Family 5, III:4).75 At the time of the 
original publication, the full clinical and genetic information about the Family 5 was missing. 
Subsequent additional genetic screening on the Family 5 has demonstrated the absence of 
this mutation in both asymptomatic parents (II:3 and II:4). Paternity was confirmed with high 
confidence by means of typing the standard polymorphic microsatellite markers in the father 
and son. This result confirms that the CDH2 c.1219G>A, p.Asp407Asn mutation in III:4, which 
was associated with ARVC, had arisen de novo (unpublished results provided by Shaboodien, 
G. CVG Laboratory, Hatter Institute, UCT).  
 
 
Figure 7.6. Family 5. Arrhythmogenic right ventricular cardiomyopathy
Patient Name: De-Identified MRN: De-Identified DOB: De-Identified Created By: s.kraus@uct.ac.za Last Updated: Feb. 8, 2019, 5:03 p.m. GMT
7.4.  DISCUSSION 
In this study, we describe the inheritance patterns of 35 families recruited to the IMHOTEP 
study; 16 genotype positive families and 19 genotype unknown families.  Autosomal dominant 
inheritance was found in the vast majority of cases, in keeping with what has been reported in 
the literature.4,148,202 Uncertain, although suspected autosomal recessive inheritance was 
observed in one family, as was X-linked inheritance.  The average age of onset of disease in 
the proband was 28.0 years (ranging from 7 months to 71 years), with 37.1% of probands 
presenting under the age of 20. More than half the families were Caucasian, with 31.4% and 
14.3% represented by mixed ancestry and black African families respectively.  The 
underrepresentation of black African families likely reflects referral bias and societal 
inequalities related to access to health care that are still in existence as a consequence of the 
apartheid era in South Africa. Furthermore, the migrant labour system is still observed in South 
Africa, where individuals move to urban cities such as Cape Town for work opportunities, 
leaving their families to reside in rural homelands. This social phenomenon greatly impacts 
the study of families in this ethnic group.  In addition, there are a number of foreign nationals 
from other African countries residing in South Africa, where extended family members have 
remained behind in their country of origin, limiting our ability to screen these families. 
Confirmation of cardiomyopathy in relatives from LMICs can be difficult, even when reported 
by family members, because of variable access to health care, limited availability of 
sophisticated cardiac investigations and suboptimal record keeping. 
 
The detailed description of selected families illustrates the complexity of phenotyping in 
cardiomyopathy and the time period required to build multiplex families.  In Family 21, clinical 
evidence of disease only manifested in living relatives 7 years after the initial presentation of 
the proband. In Families 21, 18 and 27, numerous confounding variables are illustrated – 
incomplete penetrance; variable age of onset and severity of disease; the uncertainty of the 
role of environmental influences as precipitating (e.g. viral infections) or protective (e.g. 
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medications) factors; and variable, overlapping or atypical phenotypes amongst individuals 
within the same family.  Family 21 demonstrates the necessity for tailored serial screening 
protocols.  Family screening in first degree relatives is recommended starting at age 10-12 
years,58 but after the death of the proband’s daughter at age 9, clinical screening was advised 
in all children considered at risk regardless of age.  In light of the early age of onset of disease 
in the daughter and the possibility of compound heterozygosity or homozygosity, her father 
was also clinically screened (normal findings). CMR was also included in the screening 
protocol in light of the overlapping phenotype of DCM and LVNC.   
 
A family history of premature SCD was observed in 17.1% of families, with 5.7% occurring 
under the age of 35 years. The association of premature SCD and cardiomyopathy is well 
established. Ranthe et al. demonstrated that in the general population, a family history of 
premature death and the risk of cardiomyopathy were most dramatic for familial 
cardiomyopathy deaths and were much weaker for ischaemic or other cardiac related causes. 
In that population-based study, the rate of cardiomyopathy increased 100-fold if there was a 
history of premature death (aged <35 years) in first degree relatives, and increased to more 
than 400-fold where there were ≥2 premature deaths in first degree relatives within a family.203   
As illustrated in Family 18, SCD can be multifactorial, accounted for by both ARVC and 
ischaemic heart disease within the same family. Delineation between these two conditions is 
imperative in determining risk, interpretation of molecular data and the clinical management 
of the individuals within a family. The observed increases in risk of clinically diagnosed 
cardiomyopathy in individuals with a family history of premature cardiomyopathy death 
strongly supports the recommendations of pre-symptomatic family screening.203   
 
There are no prospective randomised control trials on the cost-benefit ratio and clinical 
efficacy of family screening, but the potential benefit for early diagnosis and intervention is 
well recognised.58 While we are unable to comment on the outcomes benefit of family 
screening in this study, the impact of screening can be demonstrated on an individual level in 
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the families studied. Medical management was initiated and tailored according to the specific 
findings in each family.  By way of examples, in addition to amended screening protocols for 
relatives and children in Family 21, guideline-based therapy was initiated in the newly 
diagnosed individual (V:9) prior to the onset of heart failure symptoms, and preconception 
counselling on the risk of pregnancy and genetic inheritance was provided, altering the 
decision to go ahead with a planned pregnancy.  In Family 18, due to the prominent family 
history of SCD, in addition to starting beta-blocker therapy in the mildly affected sibling (IV:5), 
an electrophysiological study was performed (negative) and a loop recorder inserted for this 
patient. In Family 27, antenatal genetic counselling was provided to the affected pregnant 
sibling (III:7) regarding the inheritance risk in the foetus (female). In accordance with ESC 
recommendations,58,204 she was referred to the combined cardiac-obstetrics clinic, beta-
blocker therapy was initiated and she was followed closely throughout her pregnancy, delivery 
and postpartum. Her cardiac function subsequently normalized on therapy. A number of 
individuals in the families described required referral for additional psychological support. All 
families have been enrolled into the molecular genetics research programme.       
 
With complex psychological and genetic underpinning, variable phenotypic expression and 
rapidly evolving knowledge on disease concepts and management, the need for specialised 
multidisciplinary services dedicated to the study and management of cardiomyopathies is well 
recognised.14,136 When considering genetic testing in cardiomyopathies, the indications may 
vary according to the complexity and cost of the molecular analysis, the yield of molecular 
testing, and the impact genetic testing will have on the medical management of individuals 
and families.58 Available data from South African cohorts on ARVC and HCM have shown 
relatively low yield with genetic screening compared to European and Western series.59,60,96 
and very little is known about the genetics of dilated and restrictive cardiomyopathies in African 
patients.  The low yield of genetic screening and paucity of data in the African population 
supports the necessity for further study on the full spectrum of causal mutations, the search 
for novel pathogenic variants and investigation into impact of genetic testing on outcomes in 
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the African context. The potential cost implications of cascade clinical and/or genetic family 
screening and clinical surveillance as part of standard of care, are considerable. Genetic 
diagnostic strategies are more likely to be cost-effective than clinical tests alone. Even 
although the initial costs of genetic testing may be higher, there are potential cost-saving 
implications of being able to discharge patients without disease-causing mutations from further 
clinical follow-up.205 Importantly, the economic decision model utilised to validate the cost-
effectiveness of genetic testing in HCM in the UK for example, assumes that the probability of 
identifying a HCM mutation within a proband is 63%,205 a significantly higher yield than has 
been demonstrated in the South African HCM population (29%).59,60 The cost-effectiveness 
and the impact of clinical, and/or genetic screening, and clinical surveillance in inherited 
cardiac conditions in the LMIC setting is yet to be determined.  
 
The challenge faced, beyond the cost and yield of genetic testing, is the correct interpretation 
of genetic variants – the separation of disease-causing mutations and background variant 
noise in the genome. The impact of misclassification of benign variant as pathogenic in 
patients of African descent has been demonstrated in hypertrophic cardiomyopathy.  Manrai 
et al. showed that mutations that were most common in the general population were 
significantly more common among black Americans than white Americans, illustrating the 
need for sequencing of symptomatic controls and affected patients from diverse populations.  
In that study, the authors identified multiple persons of African or unspecified ancestry who 
received positive results based on misclassification of benign variants. Such misclassifications 
invalidate risk assessments in relatives.142  In the majority of patients with a definite clinical 
diagnosis of cardiomyopathy, there is no confirmatory role for routine genetic testing and there 
are no studies documenting the impact on genetic testing in individuals.  The main reason for 
considering genetic testing is to provide predictive diagnosis in relatives, therefore certainty of 
pathogenicity of variants is crucial.58   Routine diagnostic genetic testing in cardiomyopathies 
in African patients without scrutiny against ethnicity-matched population controls, may yield 
false positive or negative reports which may in turn have far reaching adverse consequences 
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for families. Relatives with non-causal variants may be subject to unnecessary repeated 
clinical evaluations, lifestyle modification (e.g. cessation of sporting activities), therapeutic 
interventions (e.g. ICD implantation), and the economical and psychological stress associated 
with an incorrect diagnosis. Relatives without the variant may be falsely reassured that neither 
they, nor their children, require follow-up screening.  
 
To illustrate the complexity around interpretation further, Watkins et al. previously reported the 
variant PKP2 c.T2540C L847P in an individual with ARVC from Family 8 (ACM 34).  This 
variant was considered pathogenic as it was not observed in the general population (n=482 
local population controls), occurred in positions that were conserved across species and is 
predicted to be damaging by 4/4 bioinformatics tools.96 Furthermore, this variant has not been 
observed in other large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et 
al., 2015; Exome Variant Server as reported by ClinVar). While the PKP2 c.T2540C L847P 
variant is rare, segregation with disease has not been demonstrated in the Family 8 due to a 
lack of sufficient clinical information in relatives, nor is there functional data available on this 
variant. In addition, the PKP2 c.T2540C L847P variant was subsequently found in another 
family (Family 30, DCM 3) with familial DCM, and in this family, it did not segregate with 
disease (Mbele, M. 2014. Ph.D. Thesis, UCT). Based on current evidence, the PKP2 
c.T2540C L847P variant has been classified as a variant of unknown significance (VUS) by 
ClinVar and cannot be considered predictive of disease until there is more conclusive 
evidence to support pathogenicity.   
 
Segregation with disease can be difficult to demonstrate in the setting of conditions with low 
penetrance, such as ARVC, and careful clinical phenotyping of extended family members in 
conjunction with molecular testing will be required to establish causality of this genetic variant 
in Family 8. To add to the complexity, a recent study looking at variant non-segregation in 
LMNA-related DCM challenges the traditional view of cardiomyopathies as strictly monogenic 
disorders (in particularly DCM) and that multigene causation may account for non-segregation 
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of variants in families.206 This observation suggests that non-segregation within a family does 
not necessarily exclude a variant as disease-causing, and further supports the study of large 
series of families, deeply phenotyped and genotyped, to better understand clinical variability, 
non-penetrance and nonsegregation.207 
 
The strategy for developing a cardio genetics service in Africa calls for the integration of 
research and clinical care. Based on the current evidence, routine diagnostic genetic testing 
in cardiomyopathy is likely to yield more questions than answers, and there is insufficient 
existing infrastructure to support this kind of service on the continent. This study demonstrates 
the feasibility of an integrated clinical family screening programme as part of IMHOTEP – 
where simple and/or more detailed phenotyping (depending on clinical indications and 
resources) can be done for purposes of risk assessment and initiation of appropriate therapy 
in relatives and for advancing molecular research on the continent. As has been demonstrated 
through the establishment of large collaborative registries in ARVC and HCM, knowledge 
generated from these research programmes influences both clinical and genetic diagnostic 
and management strategies.61,73  
 
In South Africa, we propose the development of an integrated service-delivery and research 
driven cardiomyopathy family screening programme in tertiary centres in each province, with 
the aim of providing early diagnosis and risk stratification for relatives at risk as part of clinical 
care.  This service will provide the platform for collaborative molecular research through 
collective acquisition of clinical data from multiple sites with a centralised molecular genetics 
research laboratory. With the ethnic diversity observed in South Africa, the building of large 
ancestry-matched control cohorts to interpret variants found is essential, and should not be 
limited to one region in South Africa. This approach will not only provide answers to what 
specific mutations should be tested for in our cardiomyopathy patient population, but also 
provide information on the impact of family screening and genetic diagnoses on clinical 
outcomes in our setting. An integrated service-delivery and research programme will facilitate 
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cost-sharing between government and research funding bodies, making it more financially 
viable in a resource restricted setting. Clinical and genetic screening has numerous clinical 
and psychological implications for those diagnosed with disease, and therefore cannot be 
conducted in isolation of the clinical service platform. Standardised protocols for appropriate 
counselling and therapeutic interventions will need to be tailored from international guidelines 
according to resource availability to ensure equity of care in the context of local disease 
burdens. For example, primary preventative ICDs are not currently available as standard of 
care in state funded institutions in South Africa, and the additional cost implications of 
providing (or not providing) this level of care must to be carefully considered.  An integrated 
clinical and research programme ensures collective accountability in both patient care and 
quality of scientific research, where the ethical implications of genetic testing are carefully 
considered for the individual, the family and the broader community.  
 
7.5.  LIMITATIONS 
There are several limitations to this study.  The selection of families for screening has been 
opportunistic and has been largely based on the availability of research funding and clinical 
resources, as well as the geographic locations and availability of family members. As family 
screening has not been routinely conducted on all probands enrolled into IMHOTEP, this study 
does not represent the full spectrum of familial cardiomyopathies in our cohort. The higher 
frequency of DCM and ARVC reflects the incorporation of existing studies on familial DCM 
and ARVC at our institution and does not represent the prevalence of these conditions within 
our population. 
 
7.6.  CONCLUSION 
In comparison to the international work done in clinical genetics in cardiomyopathies, our 
findings are consistent with what has been found elsewhere. The relevance of this study is 
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that it illustrates the feasibility of detailed phenotyping, clinical screening and the potential for 
molecular genetics research in Africa.  It represents the collective efforts of 20 years of work 
within a single centre in a low-to-middle income country, and the foundation on which an 
integrated clinical and research cardio genetics service can be built in Africa. 
 
7.7.  CONTRABUTIONS AND ACKNOWLEDGEMENTS 
The design and implementation of this study was conducted by S. Kraus in consultation with 
B. Mayosi and N. Ntusi. While a number of families were incorporated from existing studies, 
all families were revaluated, followed up and extended by S. Kraus. Phenotyping data was 
collected and analysed by S. Kraus. Pedigrees were constructed and/or updated by S. Kraus, 
N. Laing and A. Ross. We acknowledge the work done by previous study investigators 
(referenced in table 7.2) particularly B. Mayosi and A. Wonkam, in building this cohort of 
families. Recruitment and counselling of families was done by S. Kraus and genetics 
counsellor, N. Laing, assisted by U. September (research nurse), M. Van der Wall (medical 
technologist), and A. Ross (genetics counsellor). We acknowledge G. Shaboodien for 
providing unpublished genetics information for family 5 and family 136. 
CHAPTER 8: The vision for IMHOTEP and future research 
The overall goal of the IMHOTEP study is to improve the outcomes of African patients and 
families affected by heart muscle disease.  The registry was designed with the intention of 
providing a platform for development in three major areas: (1) research, (2) clinical practice 
and (3) education and training, through collaboration and collective expertise (Figure 8.1).   
 
 




8.1.  RESEARCH 
8.1.1. Molecular genetics research 
In addition to the clinical research described in this dissertation, the IMHOTEP registry has 
provided the clinical framework on which to build on African-initiated molecular genetics 
research. One of the principal aims of IMHOTEP is to provide insights into the genetic 
aetiology of cardiomyopathy in African populations and to facilitate the discovery of novel 
variants through:   
 
• Molecular genetics sub-study: phase 1 (as described in chapter 3) - all index cases 
will be screened for known molecular genetic causes of cardiomyopathy using targeted 
Next Generation Sequencing (currently underway). 
 
• Molecular genetics sub-study: phase 2 (as described in chapter 3) – genotype-
negative probands of multiplex families and children with severe early-onset 
cardiomyopathy in family trios will be subjected to whole exome sequencing (WES) to 
identify novel genetic causes of cardiomyopathy. 
- Multiplex families: The study of families with cardiomyopathy that are genotype-
negative for known pathogenic mutations. Molecular genetic studies are underway 
for the families described in Chapter 7 by the Cardiovascular Genetics Laboratory 
at the Hatter Institute for Cardiovascular Research in Africa, University of Cape 
Town.   
- Parent-offspring trios: The study of children presenting under the age of 12 years 
with severe cardiomyopathy phenotypes that are genotype-negative for known 
pathogenic mutations. Parent-offspring trios consist of two clinically unaffected 
parents with a severely affected child. The study of affected children (especially 
affected infants) using the trio is highly informative in terms of genetic yield, with 
far greater power to detect causal genes than in autosomal dominant families with 
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up to 5 affected members. Furthermore, infant and childhood onset 
cardiomyopathy is rare and the children identified by IMHOTEP make this an 
internationally competitive resource that will inform genetic aetiology in Africans. 
Planned postdoctoral work, in collaboration with the University of Oxford, will focus 
on conducting molecular genetic analysis on parent-offspring trios recruited to 
IMHOTEP. The specific objectives will be to conduct WES analysis in parent-
offspring trios, with functional characterisation of novel mutations identified (e.g. 
biochemical and functional studies in CRISPR gene edited iPS-derived 
cardiomyocytes).  In addition, we plan to test the contribution of low penetrance 
rare variants in known genes (and potentially novel genes), and look at modifying 
influences of low-frequency variants of intermediate size – a unique area of 
expertise that exists at Oxford. This work will provide exposure to statistical 
analysis to assign significance to findings and perhaps lead to new ways of 
individualizing risk. Furthermore, we would like to explore the application of our 
findings into local clinical practice, particularly with regards to predictive testing in 
families, evaluating the usefulness of genetic testing in distinguishing early-onset 
familial cardiomyopathies from myocarditis in children, evaluating the impact of 
genetic testing on outcomes and the potential development of a targeted NGS 
diagnostic panel tailored for use in Africa. 
 
• Future studies: 
- Planned studies on clinical features and genetics of endomyocardial fibrosis. 
- Planned studies on novel gene modifiers in local patients with HCM. 
 
8.1.2. Clinical research 
• Outcomes sub-study: IMHOTEP has been created as a clinical registry to facilitate 
data collection on African patients and families with heart muscle disease over an 
extended period of time, in order to evaluate the impact of standard of care on patient 
outcomes.  
• Myocarditis sub-study: Clinical (including CMR) and multiomic approach to 
understanding myocarditis amongst Africans.  
 
8.1.3. Planned expansion of IMHOTEP 
• We hope to secure funding to expand IMHOTEP to include additional sites in 
collaborating countries as listed in Appendix J, using a staggered approach (as in the 
multicentre pilot). 
• We hope that IMHOTEP will become a platform that will provide genetic testing 
opportunities for other African countries.   
 
Candidate’s contributions: S. Kraus intends to continue contributing to the IMHOTEP 
project.  She has a planned postdoctoral fellowship in the Department of Cardiovascular 
Medicine at Oxford University with the Watkins Research Group, where NGS on IMHOTEP 
samples is being conducted, and plans to lead the parent-offspring trio sub-study. In addition, 
she remains involved in the IMHOTEP project and is co-ordinating the outcomes sub-study.  
 
8.2.  CLINICAL PRACTICE 
“The prevalence, complexity, clinical importance, heterogeneity and unpredictability of 
inherited cardiovascular diseases make the development of inherited cardiovascular disease 
centres an inevitability, with the ultimate goal of reducing the morbidity and mortality 
associated with these conditions. An inherited cardiovascular disease centre may be seen as 
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a subunit of a cardiology department, with health professionals specializing in these types of 
disorders, organised to provide excellence in all related areas, including diagnosis, treatment, 
follow-up, prevention, risk stratification and prognosis. Among its objectives are the 
development of action protocols and the creation of databases that enable patients to be 
included in national and international research networks. To achieve these objectives these 
centres should include functional units of clinical and basic sciences, research, training and 
education, acting in harmony in a holistic approach to patients and their families.” 
Nuno Cardim, António Freitas and Dulce Brito208 
 
As described in chapter 7, the goal is to create centres of excellence In Africa that integrate 
clinical care and research (clinical and scientific) with the intention of providing appropriate 
and sustainable health care for patients with familial and acquired cardiomyopathies according 
to resource availability, in addition to the development of expertise in the field of cardio 
genetics on the African continent. Centres of reference or expertise are made up of the 
following components: (1) appropriate capacity to diagnose, follow up and manage patients, 
(2) attractiveness (measured through volume of activity), (3) the ability to provide expert advice 
on diagnosis and management, (4) the ability to produce and adhere to good practice 
guidelines, (5) demonstration of a multidisciplinary approach, (6) a high level of expertise and 
experience demonstrated through publications, grants, honorary positions, (7) teaching and 
training, and (8) a strong contribution to research.208 IMHOTEP hopes to clarify the 
components of what clinical services are required to meet local needs, which may vary across 
different regions.  
  
Candidate’s contributions: The Cardiomyopathy Specialist Clinic at Groote Schuur Hospital 
was established by B. Mayosi and K. Sliwa.  S. Kraus took over the running of this clinical 
service for 5 years while conducting her PhD.  In addition, she developed the research-based 
family screening programme (with support from N. Laing) described in chapter 7. A strategy 
for developing a cardio genetics service in South Africa with potential expansion to other 
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regions on the continent, is described in chapter 7 (discussion). The establishment of a cardio 
genetics service and centres of excellence in cardiomyopathy on the African continent, is the 
candidates personal ambition. N. Ntusi is involved in CMR research and service development 
on the continent.  
 
8.3.  EDUCATION AND TRAINING 
In addition to conducting scientific work that will hopefully broaden our understanding of 
genetics in African patients with cardiomyopathy, a principal vision of IMHOTEP has been to 
provide professional development for African based co-investigators and develop 
collaborative expertise in the field of heart muscle disease on the continent. We have hosted 
three IMHOTEP investigator meetings (October, 2016 – Cape Town; December, 2017 – Cape 
Town; November, 2018 – Maputu, Mozambique) in which collaborators have been able to 
come together and share expertise and experience. Current funding has provided 
opportunities for studentships in molecular genetics, clinical cardiovascular research and 
CMR.  
 
Candidate’s contributions: S. Kraus has conducted all site initiation training and given 
lectures on different aspects of cardiomyopathy at all Investigator Meetings.  In addition, she 
has and will continue to supervise student projects related to IMHOTEP.  
 
The establishment of an African Myocardial Diseases Working Group would be an important 
step in developing research, clinical care, and education/training goals discussed in this 
chapter.   
 
The IMHOTEP Study official logo is shown in Figure 8.2. 
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Figure 8.2. The IMHOTEP Study logo. Designed by Peter Kraus
CHAPTER 9: Conclusion 
Heart failure is an important cause of morbidity and mortality worldwide.  Studies have shown 
that cardiomyopathies contribute significantly to the burden of heart failure in African patients. 
There is a recognised need for large, multi-centred studies to better understand the genetic 
underpinnings of cardiomyopathy and the role of non-genetic and environmental factors in the 
development of heart muscle disease on the continent. The principal aim of this doctorate was 
to create a collaborative registry applicable to centres within LMIC setting, to systematically 
capture clinical, genetic, and outcomes data on both adults and children with heart muscle 
disease from multiple regions on the African continent, over an extended period of time.   
 
We built the foundations for IMHOTEP through the development of study tools and a 
comprehensive database, and have successfully implemented the initiative. To date, 
IMHOTEP has recruited over 600 patients of all ages with various forms of cardiomyopathy 
from 6 different sites in South Africa, and over 35 affected families.  We believe that the series 
of sub-studies presented in this body of work, support our hypotheses that cardiomyopathies 
are caused by familial and non-familial factors, and that a number of secondary factors (e.g. 
pregnancy, chemotherapy, HIV, inflammatory conditions, illicit drug and alcohol use) 
contribute to the development of disease in our population.  We suspect that the absence of 
acute myocarditis in our cohort is a reflection of the study design, specifically the timing of 
recruitment (median time of recruitment was 162 days after onset of symptoms), rather than 
a lack of disease. While further work is still required in the molecular genetic aspects of the 
work, we have described phenotypic overlap between the different morphological types of 
cardiomyopathies and demonstrated the importance of accuracy of diagnosis, aetiology, and 
detailed phenotyping in individuals and families affected by heart muscle disease.   
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One of the key challenges encountered in the creation of this registry has been in the 
standardisation of case definitions. Morphological and functional parameters vary 
substantially between the different types of cardiomyopathies. In addition, specific parameter 
definitions vary according to the age and size of the patient, and whether the patient is a 
proband or a relative. Furthermore, the influence of medical therapies and interventions on 
the natural history of disease is difficult to quantify or define. We, therefore, adopted the 
descriptive definitions provided by the ESC, and developed an adapted 3 stage diagnostic 
approach to facilitate more accurate diagnoses applicable to all centres regardless of resource 
availability. By utilising CMR in a significant proportion of incident cases recruited, we have 
demonstrated that the use of our tailored diagnostic approach in conjunction with the adapted 
inclusion/exclusion criteria, allow for reliable diagnoses of cardiomyopathy using non-invasive 
core investigations. While CMR has proved useful in delineating overlapping phenotypes and 
confirming specific aetiological diagnoses, only 4/103 incident patients recruited were 
excluded based on CMR and/or other extended (e.g. invasive) investigations after enrolment. 
We have demonstrated that LV dysfunction secondary to ischaemia in patients presenting 
with a ‘DCM phenotype’ is infrequent in our population group and routine angiography is not 
necessarily indicated unless a patient has specific risk factors. Importantly, hypertension is 
the leading cause of HF in Africa and therefore hypertensive heart disease with HF with 
reduced ejection fraction (HFrEF) is the most important differential diagnosis to consider. We 
have also been able to demonstrate that echocardiographic parameters collected from 
clinically generated reports correlated with CMR findings fairly accurately (except in the 
assessment of the right ventricle where CMR is significantly superior). We are therefore 
confident that this study is feasible in resource restricted environments provided the core 
investigations (including ECG and echocardiogram) are done well by trained individuals, with 




Although the reclassification of patients referred with suspected ARVC according to the 
updated 2010 diagnostic criteria was labour intensive, the clinical and research implications 
of the diagnostic amendments cannot be underestimated, as 92/162 patients referred did not 
have clinical criteria to support a diagnosis of ARVC.  These diagnostic changes reflect the 
evolution of our understanding of the pathogenesis and genetic aetiology of this condition over 
2 decades, the influence of sophisticated diagnostic modalities (e.g. CMR), and clinical 
expertise in the interpretation of results. The careful review of cases by an experienced 
diagnostic panel with appropriate expertise is particularly important in ARVC and an essential 
component of the registry structure.  Despite the complexity of the diagnosis of ARVC, we did 
find that the combined presence of VT with LBBB morphology and repolarisation changes in 
the precordial leads on ECG were present in 71.2% of patients, therefore, the ECG represents 
an important screening tool in ARVC and can facilitate appropriate referral of patients to 
centres that have sufficient expertise to confirm the diagnosis.   
 
While the observational nature of the study limits generalisability of our findings and translation 
into clinical practice, this work has provided key insights into the demographic and clinical 
profile of patients affected by these conditions in our setting.  Preliminary baseline data on 
both prevalent and incident cases has shown that in contrast to European cohorts, our patients 
are significantly younger, there is a slight female predominance overall, and DCM is the 
predominant form of cardiomyopathy encountered in the hospital setting.  The younger age of 
onset has potentially significant social implications at individual, family, community, and 
population levels, as economically active individuals and women of child-bearing age are at 
risk of developing a condition that carries significant morbidity and mortality. The social 
implications of these conditions have not been explored in this body of work, but the 
observation is an important one and further exploration into the social impact of these 
conditions is considered necessary. South African population statistics released in July 2018, 
estimate that 51% of the population is female and 81% of the population is black African. While 
our cohort is ethnically diverse, it is likely that the black African population is still 
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underrepresented. Importantly, the patients described in this thesis come from the Western 
Cape Province in South Africa, where there is a higher percentage of mixed race individuals, 
therefore the demographics presented in the prospective arm of the study is representative of 
the local population. The predominance of Caucasian participants in the ARVC cohort and 
families study reflects historical referral bias.   
 
CMR has been shown to be diagnostically useful modality in cardiomyopathy. To our 
knowledge, we have reported the first CMR series of cardiomyopathy patients from Africa.  
The most notable observation was the high prevalence of LGE in our DCM patients, compared 
with what has been reported in the literature (linear mid-wall enhancement 94.6% versus 
28%).  This correlated with elevated T1 times in those cases where T1 mapping was available.  
The underlying mechanisms of mid-wall fibrosis are multifactorial and the reason for this 
finding is unclear. LGE has been associated with poorer outcomes and may in part account 
for the poorer outcomes previously observed in African patients, however, this has not been 
verified in this study.  
 
Although the IMHOTEP study is ongoing and we have not yet reached our full complement of 
recruited cases (target n=750), we have made some important observations based on 
outcomes data from the prevalent DCM and ARVC cohorts. There appears to be an 
encouraging trend of improvement in survival in DCM compared to a previous study conducted 
at our institution with transplant-free survival probability of 82.2% at 5 years (compared to 60% 
previously reported).  We have shown that patients with PPCM have a better overall prognosis 
compared to other forms of DCM.  Additionally, pregnancy has been noted to be a precipitating 
factor in patients with underlying DCM, particularly familial DCM. Whether the 
decompensation of patients with underlying DCM in pregnancy is also related to abnormal 
prolactin production remains unclear, and further study is required to establish whether this 
marker could be used to distinguish PPCM from underlying DCM in postpartum women 
presenting with HF. We hope that IMHOTEP will provide further insights into the genetic profile 
 204 
of PPCM, particularly in those that do not recover their LV function on therapy. Our findings 
support previous reports suggesting that digoxin is an independent predictor of mortality in 
DCM; however, the reason for this association remains unclear.  In the ARVC cohort, we found 
that there was no significant difference in survival between genotype positive and 
negative/unknown individuals, nor was there a significant difference in survival between those 
with or without ICDs although SCD was more common in those without devices. As the 
numbers in this study are small and there is notable selection bias, these results should be 
viewed with an appropriate degree of caution.  
 
While the study of families has not provided novel observations in the clinical genetics of 
cardiomyopathy, we have established a research-based family screening programme that has 
proven to be feasible in our setting and has provided a platform for molecular genetics 
research. Each family recruited facilitates novel gene discovery, providing research 
development opportunities for student scientists on the continent, and the potential to fill the 
current knowledge gap on the genetics of cardiomyopathy in African populations. The 
importance of detailed phenotyping in genetics research has been illustrated and while the 
impact of family screening on overall outcomes has not yet been demonstrated, we have been 
able to show that it improves the care of individuals within affected families.  We have also 
demonstrated the role of genetic counselling and the adaptation of clinical screening 
guidelines to the specific needs of families, as well as the necessity for long-term follow-up. 
We have highlighted the complexity of genetic results interpretation and described some of 
the challenges associated with application into the clinical setting. Furthermore, we have 
identified the need for large ethnically diverse African-based population control cohorts, and 
that expertise in variant interpretation and risk prediction specifically applicable to our 
population is currently lacking.  With the low yield of genotype positive results in patients with 
ARVC and HCM reported in this dissertation and previous studies conducted in South Africa, 
and the current deficiencies in knowledge and expertise, we conclude that further research 
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and capacity building is required prior to initiating a diagnostic genetic service for inherited 
cardiac conditions on the continent.  
 
While there are a number of study limitations described in the preceding chapters, including 
notable selection bias particularly in the retrospective cohorts, IMHOTEP does represent a 
new frontier in cardio-genetics research in Africa. To the best of our knowledge, IMHOTEP is 
the largest African-based study on heart muscle disease to be conducted to date, and the 
molecular genetics analysis currently underway will provide vital and novel data on the genetic 
underpinning of heart muscle disease in Africans. IMHOTEP has provided important insights 
into the manifestation of these conditions within our population and the feasibility of research 
comparable to international registries, despite the resource restraints that exist on the 
continent. It has also highlighted the complexity of these conditions and the requirement for 
specific expertise, careful investigation and individualized care, in addition to exposing gaps 
in existing health care practices (e.g. delayed referral to specialist care). By including both 
adults and children, and building capacity for long-term follow-up, we hope to provide further 
understanding on how these conditions affect individuals and families over a complete 
lifespan. We have every expectation that IMHOTEP will continue to expand to include centres 
across the African continent and develop into network of collective expertise in all forms of 
heart muscle disease.    
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A. Human Ethics Research Committee (HREC) approval for the IMHOTEP study 
B. IMHOTEP informed consent for participation in the registry (adults and minors) 
C. IMHOTEP assent for participation in the registry 
D. Illustrated consent for children 
E. Consent for collection, storage and analysis of DNA samples 
F. Information sheets/booklets for patients 
I. Cardiovascular genetics research 
II. Cardiomyopathies in children (Z-pamphlet) 
III. Dilated cardiomyopathy in adults (Z-pamphlet) 
IV. Information booklet on ARVC 
V. Information booklet on HCM 
VI. Information booklet on LVNC 
G. Clinical algorithms 
I. Cardiomyopathy - 3 stage diagnostic approach 
II. Myocarditis 
H. Standard operating procedures for recruitment 
I. Algorithm for recruitment of prevalent cases from existing studies at Groote Schuur 
Hospital 
II. Algorithm for recruitment of incident and newly identified prevalent cases to IMHOTEP 
I. Case Report Form for baseline core data (adults)  
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Mayosi Research Group, University of Cape Town 
UCT Clinical Research Unit J52 
Old Main Building, Groote Schuur Hospital 
Cape Town, 7925, South Africa 












about	my	medical	history,	 family	history	and	medications,	and	 I	will	be	examined.	 I	understand	that	 I	may	
undergo	further	investigations	as	per	standard	of	care	guidelines	for	my	condition.		These	investigations	will	












my	 symptoms,	 medication,	 or	 whether	 I	 have	 required	 any	 additional	 investigations,	 suffered	 from	 any	
complications	 of	 the	 disease	 or	 required	 any	 procedural	 interventions.	 I	 give	 permission	 for	 the	 study	
investigators	to	contact	my	attending	doctor(s)	to	access	all	medical	information	regarding	my	condition.	
	
As	 cardiomyopathy	 is	 a	 familial	 (genetic)	 disease	 in	 30-50%	 of	 people,	 I	 agree	 to	 have	 my	 first-degree	
relatives	 contacted	 for	 clinical	 screening	 and	 participation	 in	 this	 study.	 	 	 Each	 family	 member	 will	 be	
counseled	about	cardiomyopathy	and	will	have	to	sign	a	consent	form	prior	to	being	included	in	the	study.	
	












Participant	name	 	 	 	 Participant	signature	 	 	 Date	
	
______________________________	 ________________________________	 _______________________	
Witness	name	 	 	 	 	 Witness	signature	 	 	 Date	
	
______________________________	 ________________________________	 _______________________	
Investigator	name	 	 	 	 Investigator	signature	 	 	 Date	
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cardiomyopathy.	 I	 understand	 that	my	 child/ward	 and	 I	will	 be	 interviewed	 about	 his/her	medical	 history,	 family	














After	 my	 child’s/ward’s	 initial	 assessment,	 I	 agree	 to	 be	 followed	 up	 annually	 to	 access	 if	 there	 have	 been	 any	
changes	 in	his/her	 symptoms,	medication,	or	whether	he/she	has	 required	any	additional	 investigations,	 suffered	







I	 understand	 that	 my	 child’s/ward’s	 participation	 in	 this	 study	 is	 entirely	 voluntary.	 	 All	 information	 gathered	 is	
strictly	confidential,	and	will	only	be	used	for	research	relating	to	the	study	of	cardiomyopathy	and/or	myocarditis.		
This	 information	(including	the	genetic	material)	will	not	be	used	to	generate	profit.	 	 I	will	not	be	identified	in	any	
published	report.		I	am	free	to	refuse	to	participate	or	withdraw	my	child/ward	from	the	study	at	any	time,	without	
jeopardizing	his/her	future	care.		All	results	that	are	relevant	to	the	medical	management	of	his/her	condition	will	be	
made	 available	 to	 my	 attending	 doctor	 and	 myself.	 	 If	 I	 have	 any	 questions,	 I	 may	 contact	
_________________________________	at	____________________________.	
	
I	 agree	 to	 allow	my	 child/ward	 to	 participate	 in	 the	African	Cardiomyopathy	 and	Myocarditis	 Registry	 and	 I	 have	




_______________________________	 	 _________________________	 	 ____________	
Parent/Guardian’s	name	 	 	 Participant	signature	 	 	 Date	
	
_______________________________	 	 _________________________	 	 ____________	
Witness	name	 	 	 	 	 Witness	signature	 	 	 Date	
	
_______________________________	 	 _________________________	 	 ____________	
Investigator	name	 	 	 	 Investigator	signature	 	 	 Date	
APPENDIX B – Informed Consent 
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We	 are	 doctors	 and	 nurses	 from	 IMHOTEP	 study,	 and	 we	 are	 doing	 a	 study	 of	 the	 hearts	 of	






























Participant	name/fingerprint	 	 	 	 	 	 Date	
	
_______________________________	 _________________________	 _______________________	
Parent/Guardian	name	 	 	 Parent/Guardian	signature	 Date	
	
_______________________________	 _________________________	 _______________________	
Investigator	name	 	 	 Investigator	signature	 	 Date	
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REQUEST FOR MOLECULAR STUDIES (DNA) 
Molecular Laboratory Blood should be drawn in plastic EDTA Tubes (Purple top) 
Division of Cardiovascular Genetics 20ml of blood in total is required in adults (2-4 EDTA tubes) 
4th floor, Chris Barnard Building, Please label blood tubes with the patient's name and DOB. 
UCT Medical School, Observatory 7925 Place blood in fridge at 4°C until able to send to laboratory  
Tel: (021) 406 6615      Fax: (021) 4478789 Please DO NOT send specimens on ice or frozen. 
 
Patient details: (or hospital sticker here) 
 
Surname:________________________________   First Name (S): _____________________________ 
Hospital folder number: ________________________________________________________________ 
Sex:     M  o      F  o  Date of Birth (DD/MM/YYYY): ___________________________________ 
Patient address: ______________________________________________________________________ 
Contact numbers: _____________________________________________________________________ 
Email address: _______________________________________________________________________ 
Referring hospital and doctor: ____________________________________________________________ 
Referring doctor’s contact details: _________________________________________________________ 
 
Clinical information: (PLEASE COMPLETE A FAMILY PEDIGREE OVER THE PAGE)  
New Family:  Yes o   No o    Family name: ______________________________________ 
Ethnic Origin:  Black African o, Mixed race o, Caucasian o, Asian o, Other ___________________ 
Provisional Diagnosis:   
Clinically affected o        At Risk (unaffected clinically) o         Spouse o    Query o       
Morphofunctional phenotype Specific diagnosis 
o   Dilated cardiomyopathy oFamilial    oIdiopathic   oPPCM   oSecondary (specify) 
Specify (e.g. myocarditis)     
o   Hypertrophic cardiomyopathy oHCM        oHCM – phenocopy (specify) 
Specify (e.g. Noonans)   
o   ARVC oDefinite    oBorderline   oPossible    oUnconfirmed 
o  Restrictive cardiomyopathy oFamilial    oIdiopathic    oSpecific aetiology (specify) 
Specify (e.g. EMF) 
o  Unspecified cardiomyopathy oLVNC      oTakusubu     oOther (specify) 
Specify:  
o  Arrhythmia (with no clinical   
evidence of CMO) 
oLQTS       oVT               oVF             oSCD          oOther  
Specify 
oMarfan Syndrome oConfirmed clinically        oSuspected 
                    
Additional disorders (apparent or previously treated):  _______________________________ 
 
Have samples from this patient been sent to a DNA lab before? oYES    o NO    oDon't Know                                





I understand that I have agreed to participate in genetics research that will be 
conducted at the molecular genetics laboratory at the Hatter Insititute for 
Cardiovascular Research in Africa, situated at the University of Cape Town in 
South Africa.  This laboratory, in collaboration with other local and international 
laboratories, is dedicated to doing research related to genetic causes of 
cardiovascular disease in people living in Africa. 
 
I understand that a blood sample (5-25ml or 1-5 teaspoons of blood) will be 
collected from me and my genetic material will be extracted from this sample for 
analysis. In some instances, other samples may be collected depending on the 
circumstances (please specify if collected): _______________________________
  
I understand that a portion of my genetic material will be stored at the Hatter 
Institute for additional research projects approved by the University of Cape Town 
Human Research Ethics Committee (HREC).  My genetic material/information, 
together with other relevent medical information, may be shared with other 
researchers and institutions involved in HREC approved studies but my personal 
identifying information will not be shared. I authorize that my doctors can provide 
relevent clinical information (medical records) to researchers. 
 
I understand that the nature of research means that I may or may not receive a 
result from studies performed on my DNA. Although the laboratory will do its best 
to confirm that the findings relate to my condition, results received from a research 
laboratory should be confirmed diagnostically. If a genetic cause for my condition 
is found, the researchers from the Hatter Insitute will do their best to inform me of 
the results, either via my doctor, a genetics counsellor or in writing, depending on 
the available resources.  If my contact details change, it is my responsibility to 
inform the laboratory.  In the event that I am unavailable or incapacitated, I do / do 
not (please delete where not applicable) want my immediate family members to be 
informed of the results.  
	
I understand that the genetics molecular laboratory is under obligation to respect 
my confidentiality. I understand that my participation in genetics research is 
entirely voluntary and that I may withdraw my consent at any time without it 
affecting my future medical care.     
 
_______________________ _______________________ ______________ 
Particpant name    Signature    Date 
 
_______________________ _______________________ ______________ 
Doctor/nurse/genetics counsellor  Signature   Date 
 
Study: ____________________ HREC REF: _______________ _______________ 
        (Study number)  
For Laboratory use only: 
DNA number: ________________ Vol.Blood: ________________(ml)     Other: _________________ 
Date Received (DD/MM/YYYY): ___________________________ 














In	many	 cases,	 cardiomyopathy	 can	 be	 caused	 by	 a	 change	 (mutation)	 in	 a	 gene	within	 our	 DNA,	which	means	 that	 this	
condition	can	be	inherited.	In	other	words,	it	can	affect	multiple	individuals	within	a	family.			
DNA	is	the	code	that	instructs	our	bodies	how	to	work	and	it	is	organised	into	sections	called	genes.	Each	gene	encodes	an	
instruction	 that	 tells	 the	 body	 how	 to	make	 a	 specific	 protein	 that	will	 have	 a	 specific	 function	 in	 our	 bodies.	 Genes	 are	
packaged	into	bigger	structures	called	chromosomes	that	are	arranged	in	23	pairs	within	every	cell	(see	picture	below).		One	
member	of	each	pair	of	 chromosomes	 is	 inherited	 from	our	mother	and	 from	our	 father.	 If	 there	 is	a	 spelling	mistake,	or	
change,	within	the	DNA	code	within	a	gene,	this	means	that	the	instruction	will	be	made	incorrectly.	A	genetic	change	can	be	
inherited	from	a	parent	or	it	can	occur	by	chance,	in	an	individual,	as	a	new	mutation.		There	could	be	many	different	types	

























to	access	 your	medical	 records	 so	 that	we	can	 review	your	medical	history	and	 the	 specific	 investigations	 that	have	been	
done.			 	
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The	 African	 Cardiomyopathy	 and	 Myocarditis	 Registry	
Program	 (IMHOTEP)	 is	 a	 collaborative	 effort	 by	 medical	
professionals	 from	 different	 African	 countries	 to	 collect	
information	 from	 individuals	 and	 families	 affected	 by	
cardiomyopathy,	in	an	attempt	to	enrich	our	understanding	
of	the	causes	of	heart	muscle	disease,	and	positively	impact	




‘Cardiomyopathy’	 is	 a	 term	 that	 describes	 a	 group	 of	
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word	 "cardiomyopathy”	 is	 used	 to	 describe	 a	 disease	 that	
affects	 the	 heart	 muscle,	 resulting	 in	 damage	 and	
impairment	of	 the	heart’s	 ability	 to	pump	blood	normally.	
There	 are	 many	 different	 types	 of	 cardiomyopathies,	 but	
the	most	common	form	is	dilated	cardiomyopathy	(DCM).	
Dilated	 cardiomyopathy	 (DCM)	 is	 a	 condition	 where	 the	
heart	muscle	becomes	thinned	and	stretched	(dilated).	As	a	
result	 the	 heart	muscle	 is	weakened	 and	 unable	 to	 pump	
blood	 normally.	 	 DCM	 can	 be	 caused	 by	 a	 genetic	










• Nutritional	 –	 deficiencies	 in	 thiamine	 (B1),	 carnitine,	
phosphate,	selenium	
• Other	 (less	 common	 causes	 in	 children):	 Iron	
overload,	 drugs	 (e.g.	 certain	 chemotherapy	 agents),	
alcohol,	 tachymyopathy	 (due	 to	 a	 persistent	 fast	
arrhythmia)		
Your	 doctor	 will	 do	 specific	 tests	 to	 exclude	 these	 causes	
depending	on	your	child’s	clinical	presentation.			
	
Genetic	 cardiomyopathies	 are	 caused	 by	 mutations	
(mistakes)	 in	 the	 genes	 that	 code	 for	 a	 variety	 of	 heart	
muscle	proteins	that	make	up	the	heart	muscle	cells.	 	As	a	




instruction	 that	 tells	 the	 body	 how	 to	 make	 a	 specific	




and	 one	 from	 your	 father.	 	 Therefore,	 you	 can	 inherit	 a	
genetic	 mutation	 from	 a	 parent.	 This	 is	 why	 multiple	
members	 of	 a	 family	 can	 have	 cardiomyopathy	 as	 they	
share	 similar	DNA.	 	Most	 cardiomyopathies	are	autosomal	
dominantly	 inherited,	 which	 means	 that	 if	 one	 of	 your	
parents	carries	a	genetic	mutation	for	cardiomyopathy,	you	
have	a	50%	chance	of	inheriting	it	from	them.		Importantly,	
because	 you	 have	 2	 copies	 of	 each	 gene	 (one	 from	 your	
mother	 and	 one	 from	 your	 father)	 not	 everyone	 who	
carries	a	genetic	mutation	will	develop	cardiomyopathy	but	
you	may	become	more	 susceptible	 to	muscle	 cell	 damage	
from	other	factors	listed	previously.				
Genetic	 dilated	 cardiomyopathy	 can	occur	 in	 isolation,	or	
occasionally	 can	 occur	 as	 part	 of	 other	 genetic	 conditions	
(e.g.	 Duchenne	 Muscular	 Dystrophy,	 mitochondrial	
myopathies,	other	genetic	muscle	disorders).			
Another	type	of	cardiomyopathy	that	can	occur	in	children	
is	hypertrophic	 cardiomyopathy	 (HCM).	 HCM	 is	 a	 genetic	
cardiomyopathy	 where	 the	 heart	 muscle	 becomes	
thickened	 (“hypertrophied”)	 due	 to	 an	 increase	 in	 the	
muscle	 bulk	 resulting	 from	 excessive	 contraction	 of	 the	
heart	muscle.	A	thickened	heart	muscle	can	also	be	caused	
by	infiltration	of	the	heart	muscle	by	substances	such	as	fat	
or	 glycogen.	 	 This	 occurs	 if	 there	 is	 a	 problem	 with	 the	
metabolism	 of	 these	 substances	 in	 the	 body	 and	 many	
organs	 may	 be	 affected.	 In	 some	 cases,	 hypertrophic	
cardiomyopathy	is	associated	with	other	genetic	syndromes	
(e.g.	Noonan’s	syndrome,	Friederich’s	ataxia)			
Your	 doctor	 will	 explain	 to	 you	 exactly	 which	 kind	 of	
cardiomyopathy	your	child	has.		
	












































The	 African	 Cardiomyopathy	 and	 Myocarditis	
Registry	 Program	 (IMHOTEP)	 is	a	collaborative	effort	
by	 medical	 professionals	 from	 different	 African	
countries	 to	 collect	 information	 from	 individuals	 and	
families	affected	by	cardiomyopathy,	in	an	attempt	to	
enrich	 our	 understanding	 of	 the	 causes	 of	 heart	
muscle	 disease,	 and	 positively	 impact	 and	 improve	
lives	of	those	living	with	cardiomyopathy	in	Africa.	By	
participating	in	IMHOTEP,	you	are	actively	helping	the	
international	 medical	 community	 learn	 more	 about	
this	condition	
‘Cardiomyopathy’	 is	a	 term	that	describes	a	group	of	









that	 affects	 you	 (or	 your	 family	member/friend),	 the	
special	investigations	that	may	be	required	to	assist	us	
in	confirming	the	diagnosis,	and	the	specific	treatment	
options	 available	 for	 this	 condition.	 You	 have	 been	
diagnosed	with	Dilated	Cardiomyopathy	(DCM)	
CONTACT	INFORMATION	FOR	IMHOTEP	
Mayosi Research Group, University of Cape Town 
UCT Clinical Research Unit J52, Old Main Building 
Groote Schuur Hospital, Cape Town, 7925, South Africa 





The	 word	 "cardiomyopathy”	 is	 used	 to	 describe	 a	





result	 the	 heart	 muscle	 is	 weakened	 and	 unable	 to	





• Myocarditis	 –	 inflammation	 of	 the	 heart	muscle	
due	to	an	infection	(virus,	HIV,	bacteria,	TB,	fungi,	
parasites),	 toxin,	 autoimmune	 condition	
(rheumatoid	arthritis,	Lupus),	or	sarcoidosis	
• Drugs	 –	 e.g.	 certain	 chemotherapy	 agents,	
cocaine,	methamphetamines	(tik)	
• Pregnancy	 –	 also	 known	 as	 Peripartum	
Cardiomyopathy,	 usually	 develops	 in	 the	 last	
trimester	 of	 pregnancy	 or	 in	 the	 first	 5	 months	
after	pregnancy.		It	is	thought	to	be	related	to	the	
effects	 of	 pregnancy-related	 hormones	 on	 the	
heart	muscle	 and	 the	 increased	workload	of	 the	
heart	in	pregnancy	
• Iron	overload	
• Endocrine	 (hormones)	 conditions	 –	 e.g.	 thyroid	
disease	




to	 an	 electrical	 abnormality	 (arrhythmia)	 in	 the	
heart	
Your	 doctor	 will	 do	 specific	 tests	 to	 exclude	 these	
causes	depending	on	your	clinical	presentation.			
Genetic	or	 familial	dilated	cardiomyopathy	 is	caused	
by	mutations	 (mistakes)	 in	 the	 genes	 that	 code	 for	 a	
variety	 of	 heart	 muscle	 proteins	 that	 make	 up	 the	





Our	 DNA	 is	 made	 up	 of	 multiple	 genes.	 	 Each	 gene	
codes	an	instruction	that	tells	the	body	how	to	make	a	
specific	 protein	 that	 will	 have	 a	 specific	 function.		
Genes	 are	 packaged	 together	 on	 chromosomes	 and	
each	 human	 being	 has	 23	 chromosome	 pairs	 (46	
chromosomes	 in	 total).	 	One	 chromosome	 from	each	
pair	is	inherited	from	your	mother,	and	one	from	your	
father.	 	Therefore,	you	can	inherit	a	genetic	mutation	
from	 a	 parent.	 This	 is	 why	 multiple	 members	 of	 a	
family	can	have	cardiomyopathy	as	they	share	similar	
DNA.	 	 Most	 cardiomyopathies	 are	 autosomal	
dominantly	inherited,	which	means	that	if	one	of	your	
parents	 carries	 a	 genetic	 mutation	 for	
cardiomyopathy,	you	have	a	50%	chance	of	 inheriting	
it	from	them.		Importantly,	because	you	have	2	copies	
of	 each	 gene	 (one	 from	 your	 mother	 and	 one	 from	
your	 father)	 not	 everyone	 who	 carries	 a	 genetic	
mutation	 will	 develop	 cardiomyopathy	 but	 you	 may	
become	more	susceptible	to	muscle	cell	damage	from	
other	factors	listed	previously.				
Occasionally,	 dilated	 cardiomyopathy	 can	 occur	 as	
part	 of	 other	 genetic	 conditions	 (e.g.	 Duchenne	
Muscular	 Dystrophy).	 	 If	 you	 have	 such	 a	 condition	
your	doctor	will	have	counseled	you.			
Common	symptoms	in	DCM	
Heart	 failure	 is	 the	 most	 common	 presentation	 in	
patients	with	DCM.		The	term	“heart	failure”	is	used	to	
describe	 what	 happens	 when	 the	 heart	 is	 unable	 to	
pump	 blood	 effectively,	 and	 patients	 develop	
shortness	 of	 breath	 and	 body	 swelling	 due	 to	
accumulation	of	fluid	in	the	lungs	and	tissues.			
Patients	with	heart	 failure	 suffer	 from	breathlessness	
on	exertion	(e.g.	climbing	stairs,	walking)	because	the	
heart	 is	 not	 strong	 enough	 to	 keep	 up	 with	 the	
demands	of	the	activity.		Due	to	accumulation	of	fluid	
in	the	lungs,	patients	may	develop	shortness	of	breath	
or	 a	 heavy	 feeling	 over	 the	 chest	 when	 lying	 down,	
and	 often	 have	 to	 sleep	 upright.	 In	 some	 cases,	
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Possible subclinical acute myocarditis (asymptomatic)!
OR!
Probable acute or fulminant myocarditis (symptomatic)!
i 
i 
Diagnostic and management approach for myocarditis!
l    m 






One or more of the following:!
Elevated biomarkers !
! Troponin, CK, CRP/ESR, WCC, BNP!
ECG changes !
! Non-specific T wave or ST changes!
Atrial or ventricular conduction delays or 
arrhythmias!
Echocardiogram (any of the following)!
! Impaired systolic function!
Regional wall motion abnormalities!




! History and clinical examination!
! ! Drug and toxin exposure!
! ! Recent viral illness!




Biomarkers (Troponin, CK, CRP/ESR, BNP)!
Blood investigations    *At physicians discretion !
! HIV (Human Immunodeficiency Virus) !
*Autoimmune screen, *SACE & calcium!
Cardiovascular magnetic resonance (CMR) Imaging       
! **Should be done within 3 weeks of onset of symptoms 
 T1&T2-weighted images - myocardial oedema!
LGE - Linear mid-wall enhancement!
STAGE 2: INVASIVE!!
Indications for ENDOMYOCARDIAL BIOPSY (EMB)!
Patients with heart failure and either of the following:!
1. a normal sized or dilated LV, < 2 weeks symptoms, 
and haemodynamic compromise, OR!
2. a dilated ventricle, 2 weeks - 3 months of symptoms, 
new ventricular arrhythmias or Mobitz type 2 second-
degree HB or third-degree HB, or who fail to respond 
to usual care within 1-2 weeks!
Cardiac Catheterisation (see cardiomyopathy diagnostic algorithm)
STAGE 3: GENETIC!!
Family history of cardiomyopathy or SCD!
i 
If positive, consider myocarditis as a secondary insult in 
addition to an underlying cardiomyopathy and proceed to 









Biomarkers -! Biomarkers +!
CMR - ! ! CMR +!
i  i 
Myocarditis ! Myocarditis!
unlikely! ! suspected!
i  i 
HF ! ! HF!
Treatment! Treatment!
! ! i 
  No recovery 
! !  despite!
! ! treatment!
! ! for 2-3 months!
! ! i 
  Stage 2: !
! ! Invasive !
! ! investigations!




Biomarkers -! Biomarkers + 
CMR -! ! CMR +!









No recovery despite treatment in 2-3 
months!
i 




Myocarditis        No myocarditis!
i    i 
Viral      ! !      HF ! !







Refer urgently to 
cardiology for urgent EMB 






Syncope (due to arrhythmia or heart block)!
Fatigue!
Cardiogenic shock!
Averted sudden cardiac death!
Asymptomatic!!
With or without a history of a recent flu-like illness
Exclusion of acute coronary syndrome!
Coronary angiography (gold standard) or clinical assessment
ECG=electrocardiogram, EMB=endomyocardial biopsy, ESR=Erythrocyte sedimentation rate,  
CK=creatinine kinase, CMR=cardiac Magnetic resonance imaging, CRP=C-reactive protein, CXR=chest X-
ray,  
LVEF=left ventricular ejection fraction, HB=heart block, HF=heart failure, HIV=human immunodeficiency virus,  © IMHOTEP
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Sites Staff  
Data and study co-ordinating 
centre, University of Cape Town 
S. Kraus, V. Francis, S. Bhovula, M. De Vries, S. 
Pandie, L. Mhlathi 
Cardiovascular Genetics 
Laboratory, Hatter Institute of 
Cardiovascular Research in 
Africa, University of Cape Town 
G. Shaboodien, T. Spracklen, S. Khumali, P. 
Ndibangwi, L. Pearce, K. Brooks 
Groote Schuur Hospital, Cape 
Town 
S. Kraus (prevalent and incident cohorts, February 
2015 - date), Z. Kerbelker (incident cohort August 2017 
– July 2018), J. Cirota (incident cohort, October 2018 - 
date) and the Mayosi Research Group study team (U. 
September, M. Van Der Wall, N. Laing, N. Jamieson-
Luff) 
Red Cross War Memorial 
Children’s Hospital, Cape Town 
J. Lawrenson, G. Comitis, T. Aldersley, L. Zulkhe 
Tygerberg Hospital, Cape Town J. Lawrenson, B. Fourie 
Mthatha M. Thomas, K. Thomas, K. Moekestsi, P. Mdlatu, Y. 
Luzipo 
Port Elizabeth L. Pepeta, N. Makubalo, S. Jiyana, G. Nyengane-
Menziwa 
Bloemfontein M. Makotoko, F. Smith, S. Brown, J. Fontein, Y. Tiga, 
M. Karstens, A. Page, L. Greyling, M. Kautjunga 
Mozambique A. Damasceno, A. Mocumbi, V. Govo, C. Novela, J. 
Chemane 
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List of current and future participating sites and investigators by country 
Country Investigators Institution 
Botswana Dr. Julius Mwita University of Botswana, Gaborone 
Egypt Dr. Ahmed El-Guindy, Prof. Sir Magdi 
Yacoub 
Aswan Heart Centre, Aswan 
Guinea Dr. Tolno Sandy Kola Hospital De L'amitie Sino-
Guineenne, Conakry, Guinea 
Kenya Dr. F Ayub Barasa Moi University, Eldoret 
Mozambique Prof. Albertino Damasceno Eduardo Mondlane University, 
Maputo 
Dr. Ana Olga Mocumbi Instituto Nacional de Saúde, 
Ministério da Saúde, Maputo 
Nigeria Dr. Okechukwu Ogah University College Hospital, Ibadan 
Saudi Arabia Prof. Motasim Badri King Saud Bin Abdalaziz University 
for Health Sciences, Riyadh 
Sierra Leone Dr. James Russell Connaught Hospital, Freetown 
South Africa Dr. Ashley Chin, Dr. Sarah Kraus, Prof. 
Bongani Mayosi, Prof. Mpiko Ntsekhe, 
Prof. Ntobeko Ntusi, Prof. Karen Sliwa, 
Prof Ambroise Wonkam, Ms. Nakita 
Laing, Dr Shaheen Pandie, Dr Blanche 
Cupido 
Groote Schuur Hospital, Cape Town 
Dr. George Comitis, Dr. John 
Lawrenson, Assoc Prof Rik De Decker, 
Assoc Prof Liesl Zühlke 
Red Cross War Memorial Children’s 
Hospital, Cape Town 
Prof. Paul Brink, Dr. Barend Fourie, Dr. 
Marshall Heradien 
Tygerberg Hospital, Cape Town 
Prof. Lungile Pepeta, Dr. Nomlindo 
Makubalo, Dr. Mahlubandile Nxele 
Dora Nginza Hospital, Port Elizabeth 
Prof. Benjamin Longo-Mbenza, Dr. 
Khulile Moeketsi, Prof. Baby Thomas, 
Dr. Kandithalal Thomas 
Nelson Mandela Academic Hospital, 
Mthatha 
Prof. Antoinette Cilliers, Prof. Richard 
Nethononda, Dr. Hopewell Ntsinjana, Dr. 
Ferande Peters 
Chris Hani Baragwanath Hospital, 
Soweto 
Prof. Makoali Makotoko, Prof. Stephen 
Brown 
University of the Free State, 
Bloemfontein 
Sudan Dr. Ahmed Suliman University of Khartoum, Khartoum 
Dr. Sulafa Ali Sudan Heart Centre, Khartoum 
Tanzania Dr. Kemilembe Tibazarwa Muhimbili National Hospital, Dar es 
Salaam 
Uganda Dr. Charles Mondo St. Francis Hospital Nsambya, 
Kampala 
Dr Michael Mungoma Mulago Hospital, Kampala 
United Kingdom Prof. Bernard Keavney University of Manchester, 
Manchester 
Prof. Heather Cordell University of Newcastle-upon-Tyne, 
Newcastle 
Dr Vanessa Ferreira, Dr Masliza 
Mahmod, Prof Stefan Neubauer, Prof 
Hugh Watkins 
University of Oxford, Oxford 
United States of 
America  
Prof. Leslie T Cooper Mayo Clinic, Jacksonville 
Zimbabwe Dr. Ellise Tapiwa Gambahaya Parirenyatwa Hospital, Harare 
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1. Family ACM 1 – Genotype positive ARVC 
2. Family ACM 2 – Genotype positive ARVC 
3. Family ACM 5 – Genotype positive ARVC 
4. Family ACM 8 – Genotype positive ARVC 
5. Family ACM 11 – Genotype positive ARVC 
6. Family ACM 12 – Genotype positive ARVC 
7. Family ACM 19 – Genotype positive ARVC 
8. Family ACM 34 – Genotype positive ARVC 
9. Family ACM 38 – Genotype positive ARVC 
10. Family ACM 39 – Genotype positive ARVC 
11. Family ACM 57 – Genotype positive ARVC 
12. Family ACM 71 – Genotype positive ARVC 
13. Family ACM 136 – Genotype positive ARVC 
14. Family DCM 4 – Genotype positive DCM 
15. Family DCM 320 – Genotype positive DCM 
16. Family HCM 4 – Genotype positive HCM 
17. Family ACM 6 – Genotype unknown ARVC 
18. Family ACM 142 – Genotype unknown ARVC 
19. Family ACM 145 – Genotype unknown ARVC 
20. Family HCM 50 – Genotype unknown HCM 
21. Family DCM 343 – Genotype unknown DCM/LVNC overlap 
22. Family DCM 389 – Genotype unknown DCM 
23. Family DCM 141 – Genotype unknown DCM/HCM overlap 
24. Family DCM 464 – Genotype unknown DCM 
25. Family DCM 390 – Genotype unknown DCM 
26. Family DCM 236 – Genotype unknown DCM 
27. Family DCM 437 – Genotype unknown DCM/muscular dystrophy 
28. Family RCM 15 – Genotype unknown LVNC/heart block 
29. Family DCM 435 – Genotype unknown DCM 
30. Family DCM 3 – Genotype unknown DCM 
31. Family DCM 334 – Genotype unknown DCM 
32. Family DCM 24 – Genotype unknown DCM 
33. Family DCM 303 – Genotype unknown DCM/LVNC overlap 
34. Family ACM 149 – Genotype unknown ARVC 
35. Family DCM 458 – Genotype unknown DCM  
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4. Family ACM 8 [+PKP2 c.C1162T] 
 
Individuals IV:3 and IV:4 - homozygous 
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7. Family ACM 19 [+PKP2 c.C1162T; *PKP2 c.2197-2202del CACACCinsG] 
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21. Family DCM 343 
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30. Family DCM 3 
 
Variant of unknown significance (VUS), +PKP2 c.2540T>C, does not segregate with disease (Mbele,	M.	2014.	Ph.D.	Thesis,	UCT) 
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